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Executive summary
Assessment of cardiovascular disease (CVD) risk on the basis of the combined
effect of multiple risk factors (absolute CVD risk) is more accurate than the use
of individual risk factors, because the cumulative effects of multiple risk factors
may be additive or synergistic.1-3
In Australia, 64% of the adult population have three or more
modifiable risk factors. As CVD is largely preventable, an
approach focusing on comprehensive risk assessment
will enable effective management of identified modifiable
risk factors through lifestyle changes and, where needed,
pharmacological therapy.
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Absolute CVD risk in the context of these guidelines refers
to the likelihood of a person experiencing a cardiovascular
event within the next five years. These guidelines
incorporate the previous Guidelines for the Assessment
of Absolute Cardiovascular Disease Risk10 and provide
additional guidance on the management of CVD risk in a
primary prevention setting in all adults over 45 years of age
(35 years for people of Aboriginal or Torres Strait Islander
[A&TSI] decent)
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Although the goal for management of absolute CVD risk is
to reduce the level of absolute risk (AR) in the person, this is
achieved by management of multiple individual risk factors.
Individual risk factors such as high blood pressure (BP) and
raised lipid levels have been shown to have a continuous
association with the risk of CVD events; therefore, moderate
reductions in several risk factors may be more effective
in reducing overall CVD risk than a major reduction in
one factor.5 Decisions regarding management of risk are
therefore made according to the individual’s AR level, while
response to treatment is monitored by measurement of
individual risk factors.
The algorithms and table on pages 7-9 provide a summary
of the recommended assessment pathway, interventions,
targets and follow-up.

Risk Assessment and Management Algorithm:
Adults aged 45 years and over without known history of CVD
Already known to be at increased risk?
Adults with any of the following conditions do not require absolute CVD risk
assessment using the Framingham Risk Equation because they are already
known to be at clinically determined high risk of CVD: (EBR: Grade D)
• Diabetes and age >60 years
• Diabetes with microalbuminuria (> 20 mcg/min or urinary
	albumin:creatinine ratio >2.5 mg/mmol for males, >3.5 mg/			
mmol for females)
• Moderate or severe chronic kidney disease (persistent proteinuria or
estimated glomerular filtration raterate [eGFR] <45 mL/min//1.73 m2)
• A previous diagnosis of familial hypercholesterolaemia
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure
≥110 mmHg
• Serum total cholesterol >7.5 mmol/L

NO

Conduct formal absolute
risk assessment

Calculate risk level using Framingham Risk
Equation (EBR: Grade B):
• Australian cardiovascular risk charts
• Web calculator www.cvdcheck.org.au
• Enter age 74 for adults aged 74+ (CBR)

YES

High: greater than 15%
risk of CVD within the next
5 years (includes clinically
determined high risk) (PP)

• Provide frequent and     
sustained lifestyle advice,
support and follow-up (CBR)
• Commence BP + lipid
lowering therapy
unless contraindicated or
clinically inappropriate
(EBR: Grade B)

Moderate: 10-15% risk of CVD within the next
5 years (PP)
Provide lifestyle advice and support (CBR)
Is one of the following present?
• BP persistently ≥160/100 mmHg
• Family history of premature CVD
• South Asian, Middle Eastern, Maori or Pacific
Islander peoples

Monitor individual risk factor
response to treatment (PP)
Monitor response (PP)

Provide lifestyle advice (CBR)
Is BP persistently
≥160/100 mmHg?

YES

NO

NO

YES
• Identify all other risk
factors
• Continue with
lifestyle
intervention (CBR)
• Treat for BP and/or
lipid lowering (CBR)

Low: less than 10% risk of CVD
within the next 5 years (PP)

Monitor and review risk
at 3-6 months (CBR)
Has risk improved?
YES

• Treat BP
(CBR)
• Continue
with
lifestyle
advice (CBR)

NO

Consider
Continue
with lifestyle treating for
BP and/or
intervention lipid-lowering
(CBR)
(CBR)

Monitor
response
(PP)

Monitor
response (PP)

Review absolute risk
according to clinical
context (PP)

Review absolute risk in
6-12 months (PP)

Review absolute risk in
6-12 months (PP)

Review absolute risk in
2 years (PP)

EBR: Evidence-based recommendation (Graded A-D) CBR: Consensus-based recommendation PP: Practice point
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Risk Assessment and Management Algorithm:
Aboriginal and Torres Strait Islander adults aged 35 years and over without
known history of CVD
Already known to be at increased risk?
Adults with any of the following conditions do not require absolute CVD risk
assessment using the Framingham Risk Equation because they are already
known to be at clinically determined high risk of CVD: (EBR: Grade D)
• Diabetes and age >60 years
• Diabetes with microalbuminuria (>20 mcg/min or urinary
	albumin:creatinine ratio >2.5 mg/mmol for males, >3.5 mg/			
mmol for females)
• Moderate or severe chronic kidney disease (persistent proteinuria or
estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m2)
• A previous diagnosis of familial hypercholesterolaemia
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure
≥110 mmHg
• Serum total cholesterol >7.5 mmol/L

NO

Conduct formal absolute
risk assessment

• Aboriginal and Torres Strait Islander adults aged over 74 (CBR)
Calculate risk level using Framingham
Risk Equation (EBR: Grade B):
• Australian cardiovascular risk charts
• Web calculator www.cvdcheck.org.au

YES

High: greater than 15%
risk of CVD within the next
5 years (includes clinically
determined high risk) (PP)

Moderate: 10-15% risk of CVD within the next 5
years (PP)

Provide lifestyle advice (CBR)
Provide lifestyle advice and support (CBR)

• Provide frequent and
sustained lifestyle advice,
support and follow-up
(CBR)
• Commence BP +
lipid-lowering therapy
unless contraindicated or
clinically inappropriate 		
(EBR: Grade B)

Monitor individual risk factor
response to treatment (PP)

Review absolute risk
according to clinical
context (PP)
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Low: less than 10% risk of CVD
within the next 5 years (PP)

• Identify all other risk factors
• Continue with lifestyle intervention (CBR)
• Treat for BP and/or lipid lowering (CBR)

Monitor individual risk
factor response to treatment
(PP)

Review absolute risk in
6-12 months (PP)

Is BP persistently ≥160/100 mmHg?

YES

NO

• Treat BP
(CBR)
• Continue		
with lifestyle 		
advice (CBR)

Monitor
response
(PP)

Review absolute risk in
2 years (PP)

EBR: Evidence-based recommendation (Graded A-D), CBR: Consensus-based recommendation, PP: Practice point

Risk Management Summary
CVD risk

High risk
Clinically
determined
or calculated
using FRE as
>15% absolute
risk of CVD
events over 5
years

Lifestyle

Pharmacotherapy

Targets

Monitoring

Frequent and
sustained specific
advice and support
regarding diet and
physical activity.

Treat simultaneously with lipid
lowering and BP lowering unless
contraindicated or clinically
inappropriate.

BP:
≤140/90 mmHg in
general or people with
CKD;
≤130/80 mmHg in all
people with diabetes;
≤130/80 mmHg
if micro or macro
albuminuria (UACR
>2.5 mg/mmol in men
and >3.5 mg/mmol in
women).

Adjust medication as
required.

Appropriate advice,
support and
pharmacotherapy
for smoking
cessation.
Advice given
simultaneously
with BP and lipid
lowering drug
treatment.

Moderate
risk
Calculated using
FRE as 10-15%
absolute risk of
CVD events over
5 years

Appropriate,
specific advice and
support regarding
diet and physical
activity.
Appropriate advice,
support and
pharmacotherapy
for smoking
cessation.
Lifestyle advice
given in preference
to drug therapy.

Aspirin not routinely
recommended.
Consider withdrawal of therapy
for people who make profound
lifestyle changes.

Lipids:
TC <4.0 mmol/L;
Not routinely recommended.
HDL-C ≥1.0 mmol/L;
Consider BP lowering and/or lipid LDL-C <2.0 mmol/L;
Non HDL-C <2.5
lowering in addition to lifestyle
mmol/L;
advice if 3-6 months of lifestyle
intervention does not reduce risk TG <2.0 mmol/L.
or:
• BP persistently ≥160/100
mmHg
• Family history of premature
CVD
•	Specific population where the
FRE underestimates risk e.g.
A&TSI peoples, South Asian,
Maori and Pacific Islander,
Middle Eastern.
Consider withdrawal of therapy
for people who make profound
lifestyle changes.

Low risk
Calculated using
FRE as <10%
absolute risk of
CVD events over
5 years

Brief, general
lifestyle advice
regarding diet and
physical activity.
Appropriate advice,
support and
pharmacotherapy
for smoking
cessation.

Not routinely recommended.
Consider BP lowering therapy
in addition to specific lifestyle
advice if BP persistently
≥160/100 mmHg.
Consider withdrawal of therapy
for people who make profound
lifestyle changes.

Review of absolute
risk according to
clinical context.

Adjust medication as
required.
Review absolute risk
every 6–12 months.

Lifestyle:
Smoking cessation
(if smoker); consume
diet rich in vegetables
and fruit, low in salt
and saturated and
trans fats; at least
30 mins moderate
intensity physical
activity on most or
preferably every day
of the week; limit
alcohol intake.
Adjust medication as
required.
Review absolute risk
every 2 years.
Blood test results
within 5 years can be
used.

A&TSI: Aboriginal and Torres Strait Islander peoples; BP: blood pressure; CKD: Chronic Kidney Disease; DBP: diastolic blood pressure; FRE:
Framingham Risk Equation; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; SBP: systolic blood pressure;
TC: total cholesterol; TG: Triglycerides; UACR: urinary albumin:creatinine ratio
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Summary of Recommendations
This section lists the recommendations presented in the
guidelines together with the relevant section where the
supporting evidence is discussed. Each recommendation
is given an overall grading based on National Health and
Medical Research Council (NHMRC) Levels of Evidence and
Grades for Recommendations for Developers of Guidelines
(2009).6 Where no robust evidence was available but
there was sufficient consensus within the Expert Working
Group (EWG), consensus-based recommendations
(CBR) have been provided. Practice points (PP) were
added where necessary, to provide practical guidance
to facilitate the implementation of the guidelines. Where
recommendations were developed in an AR paradigm,
but based on relative risk (single risk factor) evidence,
the expert panel carefully examined the literature before

making and grading the recommendations. Consideration
included any heterogeneity found between subgroups
and the generalisability of the findings. The final grading
of these recommendations was downgraded to account
for the uncertainty of applying evidence from a relative risk
approach to an AR paradigm. Some recommendations
have been drawn from the Guidelines for the Assessment
of Absolute Cardiovascular Disease Risk and have been
included to provide context and a complete set of absolute
CVD risk recommendations. These recommendations
are dated (2009) to indicate that they were developed
in a separate process. (See Scope for further details on
recommendations from the Guidelines for the Assessment
of Absolute Cardiovascular Disease Risk).

Grading of evidence-based recommendations (EBR)6
Grade of
recommendation

Description

A

Body of evidence can be trusted to guide practice

B

Body of evidence can be trusted to guide practice in most situations

C

Body of evidence provides some support for recommendation but care should be taken in its
application

D

Body of evidence is weak and recommendation must be applied with caution

Additional guidance
CBR
PP
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Consensus-based recommendations: developed by the guidelines expert working group when
a systematic review of the evidence found either an absence of direct evidence which answered
the clinical question or poor quality evidence, which was deemed not to be strong enough to
formulate an evidence-based recommendation.
Practice points: developed by the guidelines expert working group where a systematic review
had not been conducted but there was a need to provide practical guidance to support the
implementation of the evidence-based and/or consensus-based recommendations.

Evidence-based recommendations
Assessment of CVD risk

Grade

Clinically determined high risk
EBR 1: Adults with any of the following conditions do not require absolute cardiovascular risk
assessment using the Framingham Risk Equation because they are already known to be at clinically
determined high risk of CVD:
i.
Diabetes and age >60 years
ii.
Diabetes with microalbuminuria (>20 mcg/min or UACR >2.5 mg/mmol for males,
>3.5 mg/mmol for females)
iii.
Moderate or severe CKD (persistent proteinuria or eGFR <45 mL/min/1.73 m2)
iv.
A previous diagnosis of familial hypercholesterolaemia
v.
SBP ≥180 mmHg or DBP ≥110 mmHg
vi.
Serum TC >7.5 mmol/L.

D10 (2009)

General population aged 45–74 years
EBR 2: Absolute CVD risk assessment, using the Framingham Risk Equation to predict risk of a
cardiovascular event over the next five years, should be performed for all adults aged 45–74 years who
are not known to have CVD or to be at clinically determined high risk.

B10 (2009)

Aboriginal and Torres Strait Islander adults aged 35–74 years
EBR 3: In Aboriginal and Torres Strait Islander adults aged 35–74 years who are not known to have CVD
or to be at clinically determined high risk, absolute cardiovascular risk over the next five years should
be calculated using the Framingham Risk Equation. Although the Framingham Risk Equation might
underestimate risk in this population, available evidence suggests that this approach will provide an
estimate of minimum cardiovascular risk.

D65 (2009)

Adults with diabetes
EBR 4: In adults with diabetes aged 60 years or less who are not known to have CVD or to be at
clinically determined high risk, absolute cardiovascular risk over the next five years should be assessed
using the Framingham Risk Equation. Although the Framingham Risk Equation might underestimate risk
in this population, available evidence suggests that this approach will provide an estimate of minimum
cardiovascular risk.

C10 (2009)

Adults who are overweight or obese
EBR 5: In adults who are overweight or obese and who are not known to have CVD or to be at clinically
determined high risk, absolute cardiovascular risk over the next five years should be assessed using the
Framingham Risk Equation. The results should be interpreted with the awareness that its predictive value
has not been specifically assessed in this population.

D10 (2009)

Treatment
Lifestyle modification
EBR 6: Weight loss should be recommended for people who are overweight or obese.

B124-127

EBR 7: All adults should be advised to participate in at least 30 minutes of moderate intensity activity on
most days or preferably every day of the week.

B135-139

EBR 8: All smokers should be advised to stop smoking.

A14,148

Pharmacotherapy
EBR 9: Aspirin or other antiplatelet therapy is not routinely recommended for primary prevention of CVD.

B234, 237, 238, 242, 243
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Assessment of CVD risk

Grade

For adults at high risk of CVD
EBR 10: Adults at high absolute risk of CVD should be simultaneously treated with lipid and blood
pressure-lowering pharmacotherapy in addition to lifestyle intervention unless contraindicated or
clinically inappropriate.

B 192, 195, 204, 206, 207

Blood pressure-lowering therapy
EBR 11: Treatment should begin with any one of the following agents:
• ACE inhibitor
• Angiotensin receptor blocker
• Calcium channel blocker
• Low dose thiazide or thiazide-like diuretic.
EBR 12: If monotherapy does not sufficiently reduce blood pressure add a second agent from a
different pharmacological class.

A192, 199

A192

Lipid-lowering therapy
EBR 13: Statins should be used as first-line therapy.

A206, 208, 209

EBR 14: If LDL-C levels are not sufficiently reduced on maximally tolerated dose of statin, one or more
of the following may be added:
• ezetimibe
• bile acid binding resin
• nicotinic acid.

C224-226
D219, 223
D218, 227

EBR 15: Where statins cannot be tolerated at all, one or more of the following can be used:
• ezetimibe
• bile acid binding resin
• nicotinic acid.

D225
D223
D227-229

EBR 16: If triglyceride levels remain elevated, treatment with one of the following may be considered:
• fenofibrate (especially if HDL is below target)
• nicotinic acid
• fish oil.

C200-222
C218, 227
C230-232

Populations requiring special consideration
People with diabetes
EBR 17: Blood pressure-lowering therapy in people with diabetes should preferentially include an ACE
inhibitor or angiotensin receptor blocker.
EBR 18: If monotherapy does not sufficiently reduce blood pressure add one of the following:
• Calcium channel blocker
• Low-dose thiazide or thiazide-like diuretic.

A297, 298, 302, 303

B299, 300
C273, 299

People with chronic kidney disease (CKD)
EBR 19: Blood pressure-lowering therapy in people with CKD should begin with an ACE inhibitor or
angiotensin receptor blocker.
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A302, 303

Consensus-based recommendations
Assessment of CVD risk
General population aged over 74 years
CBR 1: In adults aged over 74, who are not known to have CVD or to be at clinically determined high risk, absolute
cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Calculation should be
performed using the age of 74 years. Although the Framingham Risk Equation might underestimate risk in this population,
available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.
Aboriginal and Torres Strait Islander adults aged over 74 years
CBR 2: Aboriginal and Torres Strait Islander adults aged over 74 years should be considered as being at high CVD risk.

Treatment
For adults at moderate risk of CVD
CBR 3: Adults at moderate absolute risk of CVD should have their risk factors initially managed by lifestyle interventions.
Pharmacotherapy for blood pressure and/or lipid lowering is not routinely recommended but may be considered if 3–6
months of lifestyle intervention does not reduce the individual’s risk factors.
CBR 4: Adults at moderate absolute risk of CVD may be treated with pharmacotherapy for blood pressure and/or lipid
lowering in addition to lifestyle intervention if one or more of the following applies:
• Persistent blood pressure ≥160/100 mmHg
• Family history of premature CVD
• Aboriginal and Torres Strait Islander peoples
• Other populations where Framingham Risk Equation is known to underestimate risk (South Asians, Maori and Pacific
Islanders, people from the Middle East).
For adults at low risk of CVD
CBR 5: Pharmacotherapy for blood pressure and lipid lowering is not routinely recommended for adults at low absolute risk
of CVD.
CBR 6: Adults at low absolute risk of CVD who have persistent blood pressure ≥160/100 mmHg may be treated with
blood pressure-lowering pharmacotherapy in addition to lifestyle intervention.
Maximising the benefits of pharmacotherapy
CBR 7: Pharmacotherapy for blood pressure-lowering should aim towards the following targets while balancing the risks/
benefits:
• ≤140/90 mmHg for adults without CVD (including those with CKD)
• ≤130/80 mmHg for adults with micro or macro albuminuria (UACR >2.5 mg/mmol in males and >3.5 mg/mmol in
females)
• ≤130/80 mmHg for all adults with diabetes.
CBR 8: Pharmacotherapy for lipid lowering should aim towards the following targets while balancing the risks/benefits:
• TC <4.0 mmol/L
• HDL-C ≥1.0 mmol/L
• LDL-C <2.0 mmol/L
• Non HDL-C <2.5 mmol/L
• TG <2.0 mmol/L.
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Practice point
Assessment of CVD risk
Conducting a comprehensive risk assessment
PP 1 (2009): In adults without known CVD, a comprehensive assessment of cardiovascular risk includes
consideration of the following:
Modifiable risk factors
• Smoking status
• Blood pressure
• Serum lipids
• Waist circumference and Body Mass Index (BMI)
• Nutrition
• Physical activity level
• Alcohol intake.
Non-modifiable risk factors
• Age and sex
• Family history of premature CVD
• Social history including cultural identity, ethnicity and socioeconomic status.
Related conditions
• Diabetes
• Chronic Kidney Disease (albuminuria ± urine protein, eGFR)
• Familial hypercholesterolaemia
• Evidence of atrial fibrillation (history, examination, electrocardiogram).
Absolute CVD risk categories
PP 2 (2009): The following qualitative risk categories can be used to describe calculated absolute cardiovascular risk:
• low risk corresponds to <10% probability of CVD within the next five years
• moderate risk corresponds to 10–15% probability of CVD within the next five years
• high risk corresponds to >15% probability of CVD within the next five years.
All adults aged over 74 years
PP 3: In adults aged over 74 years, the decision to initiate therapy should be based on clinical judgement which takes into
account:
• Likely benefits and risks of treatment
• Life expectancy, co-morbidities and quality of life
• Personal values.
Adults with depression
PP 4: Adults being assessed for CVD risk should also be assessed for depression (and other psychosocial factors).
Cardiovascular risk assessment using the Framingham Risk Equation may underestimate risk in adults with depression.
Socioeconomic status
PP 5 (2009): A comprehensive assessment of cardiovascular risk involves consideration of socioeconomic deprivation,
because it is an independent risk factor for CVD. Absolute risk of CVD calculated using the Framingham Risk Equation is
likely to underestimate CVD risk in socioeconomically disadvantaged groups.
Atrial fibrillation (AF)
PP 6 (2009): In adults with AF (particularly those aged over 65 years), the increased risk of cardiovascular events and
all-cause mortality, in addition to thromboembolic disease including stroke, should be taken into account when assessing
cardiovascular risk.
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Review of CVD risk
PP 7 (2009): Regular review of absolute cardiovascular risk is recommended at intervals according to the initial assessed
risk level:
• Low – review every 2 years
• Moderate – review every 6–12 months
• High – review according to clinical context
PP 8: In adults at low absolute risk of CVD, blood test results within five years may be used for review of absolute
cardiovascular risk unless there are reasons to the contrary.

Treatment
Lifestyle modification
PP 9: All adults should be supported to follow the current Dietary Guidelines for Australian Adults.
PP 10: All smokers should be offered advice about methods to aid smoking cessation, including counselling services, and
if assessed as nicotine dependent, nicotine replacement therapy or other appropriate pharmacotherapy should be used.
PP 11: All adults should be advised to follow the current Australian guidelines to reduce health risks from drinking alcohol
(2009)171.
PP 12: Adults at higher absolute risk of CVD should be given more frequent and sustained lifestyle advice, support and
follow-up to achieve behavioural change.
Blood pressure-lowering therapy
PP 13: If blood pressure is not responding to pharmacotherapy, reassess for:
• non-adherence
• undiagnosed secondary causes for raised blood pressure
• hypertensive effects of other drugs
• treatment resistance due to sleep apnoea
• undisclosed use of alcohol or recreational drugs
• unrecognised high salt intake (particularly in patients taking ACE inhibitors or angiotensin receptor blockers)
• ‘white coat’ raised blood pressure
• technical factors affecting measurement
• volume overload, especially with CKD.
PP 14: If dual therapy at higher doses does not sufficiently reduce blood pressure, add an additional agent.
PP 15: If combination therapy does not sufficiently reduce blood pressure, consider specialist advice.
PP 16: Treatable secondary causes for raised blood pressure should be considered before commencing blood pressure
drug therapy.
PP 17: The following combinations should generally be avoided:
• potassium-sparing diuretic plus either ACE inhibitor or angiotensin receptor blocker
• beta-blocker plus verapamil.
Lipid-lowering therapy
PP 18: Treatable secondary causes of dyslipidaemia should be considered before commencing lipid-lowering
pharmacotherapy.
Maximising the benefits of pharmacotherapy
PP 19: Adults who commence pharmacotherapy should have their medication adjusted as required and response
assessed regularly (approximately 6-12 weekly) until sufficient improvement has been achieved or maximum tolerated dose
has been reached.
PP 20: Reduction or withdrawal of pharmacotherapy may be considered in adults who make sustained lifestyle changes
which significantly reduce their risk (e.g. smoking cessation, significant weight loss).
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Introduction
Cardiovascular disease (CVD), defined collectively in these
guidelines as coronary heart disease (CHD), stroke and
other vascular disease including peripheral arterial disease
(PAD) and renovascular disease, is a leading cause of
death and disability in Australia7 and in 2003 accounted
for approximately 18% of the total burden of disease in
Australia.8 In 2008, CVD accounted for over one-third (nearly
50,000) of deaths in Australia.9 It has a strong relationship
with diabetes and chronic kidney disease (CKD) as these
conditions share many risk factors and often co-exist.

Scope

In Australia, 90% of the adult population has at least
one modifiable risk factor, while 64% have three or more

These guidelines build on the existing Guidelines for
the Assessment of Absolute Cardiovascular Disease
Risk10 by expanding the age range for absolute CVD risk

modifiable risk factors.4 Although the rate of death due to
CVD continues to decline in Australia, the total CVD burden
is expected to increase over the next few decades due to
the ageing population.4 The Guidelines for the Management
of Absolute CVD Risk have been developed by the National
Vascular Disease Prevention Alliance (NVDPA) in response
to the burden of CVD in the Australian community. They
recommend strategies for management of CVD risk in the
primary prevention setting, in addition to providing guidance
on assessment of CVD risk in all adults over 45 years of age
(35 years for A&TSI peoples).

Purpose
CVD remains the leading cause of mortality in Australia.
These guidelines have been developed to consolidate a
number of evidence-based guidelines for conditions with
similar risk factors and management approaches, and
provide clear guidance to prevent first-ever CVD events.
They build on the NHMRC approved NVDPA Guidelines
for the Assessment of Absolute Cardiovascular Disease
Risk 200910, which introduced the concept of AR in the
assessment of CVD risk.
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The Guidelines for the Management of Absolute
Cardiovascular Disease Risk make recommendations
regarding the management of cardiovascular risk in
Australian adults aged 45 years and over (35 years for
A&TSI peoples) who have no previous history of CVD.

Correlation with the Guidelines for the Assessment of
Absolute Cardiovascular Disease Risk (2009)

assessment from 45 to 74 years (35 to 74 for A&TSI
peoples) to include all adults aged 75 years and over in
addition to providing guidance for the management of risk.
All of the recommendations have been replicated in the
new guidelines (dated 2009) to ensure completeness and
provide context. Some minor wording changes have been
made to ensure that the recommendations make sense
within the context of the new guidelines e.g. replacement of
the term ‘high risk’ with the term ‘clinically determined high
risk’ to clarify how this risk was determined, and the addition
of an upper age limit in some recommendations to clarify
the age range.
Correlation with other guidelines
The Guidelines for the Management of Absolute
Cardiovascular Disease Risk update evidence covered in
existing Australian guidelines regarding elevated BP,11 lipids,5
and prevention and detection of macrovascular disease in
people with type 2 diabetes.12
These guidelines do not apply to people with existing CVD,
because they are already known to be at high risk of further
CVD events. However, they should be considered in parallel
with other existing Australian guidelines (some of which are
noted within these guidelines and some of which were being
updated as this document was being finalised) including:

• Clinical practice guidelines for the management of
overweight and obesity in adults. Canberra: NHMRC
2003.
• Dietary Guidelines for Australian Adults. NHMRC 2003.
• Guidelines for preventive activities in general practice
(7th edition). The Royal Australian College of General
Practitioners 2009.
• National Evidence-based Guideline for Diagnosis,
Prevention and Management of Chronic Kidney Disease
in Type 2 Diabetes. Diabetes Australia 2009.
• Australian Guidelines to Reduce Health Risks from
Drinking Alcohol. NHMRC, Canberra 2009.
• Clinical Guidelines for Stroke Management 2010. National
Stroke Foundation, Melbourne 2010.
• Guidelines for the management of acute coronary
syndromes. National Heart Foundation 2006. (And
addendum 2011 jointly published with Cardiac Society of
Australia and New Zealand).
• Prevention of progression of kidney disease. Caring for
Australasians with Renal Impairment 2006.
• National Evidence-Based Guideline on Secondary
Prevention of Vascular Disease in Type 2 Diabetes.
(Currently being drafted - see Appendix 2 Section 6.1 for
details of consultation between guideline development
groups.)
• Guidelines for the prevention, detection and management
of chronic heart failure in Australia. National Heart
Foundation of Australia and the Cardiac Society of
Australia and New Zealand. Updated 2011.
• Nutrient Reference Values for Australia and New Zealand
Including Recommended Dietary Intakes. Australian
Government (NHMRC approved), Canberra 2006.
• Non-valvular atrial fibrillation and stroke prevention.
National Heart Foundation MJA 2001; 174: 234-239.

Correlation with Pharmaceutical Benefits Scheme (PBS)
The timing of releasing a new clinical guideline and review
and update of related items in the PBS is not currently
aligned in Australia. Therefore in regard to pharmacotherapy
recommendations within this guideline doctors should be
mindful of current regulations that may apply where the cost
of the medicine is subsidised by the Government (Schedule
of Pharmaceutical Benefits).

Target audience
The Guidelines for the Management of Absolute CVD Risk
are intended for use by general practitioners, Aboriginal
health workers, other primary care health professionals and
physicians. They are intended to provide health system
policy makers with the best available evidence as a basis for
population health policy.

Development
The Guidelines for the Management of Absolute CVD Risk
build on the Guidelines for the Assessment of Absolute
CVD Risk 200910 and incorporate information previously
provided by specific risk factor guidelines. The guidelines
have been developed according to the processes outlined
in the document NHMRC Standards and Procedures for
Externally Developed Guidelines (2007) under the direction
of a multidisciplinary EWG (see Appendix 1). Details of the
development methodology and consultation process are
outlined in Appendix 2.

Revision of the guidelines
To maintain currency these guidelines will be reviewed and
updated by 2016/7.

Funding body
The National Stroke Foundation received funding from
the Australian Government Department of Health and
Ageing (DoHA) to develop guidelines for the management
of absolute cardiovascular disease risk on behalf of the
NVDPA.

• Ambulatory blood pressure monitoring in Australia: 2011
consensus position statement. Head et al. J Hypertens.
2012;30(2):253-66.
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Chapter 1:

Assessment and review of CVD risk

Multiple causal factors contribute to CVD. It has been
estimated that 64% of Australians have three or more
modifiable risk factors.4 Approximately 90% of the risk of
myocardial infarction (MI) observed worldwide can be
attributed to blood lipid abnormalities, smoking, raised BP,
diabetes, abdominal obesity, psychosocial factors, physical
inactivity and inadequate intake of fruits and vegetables.13
Given that CVD is largely preventable, Australian and
overseas primary care guidelines emphasise comprehensive
risk assessment to enable effective management of identified
modifiable risk factors through lifestyle changes (e.g. weight
management, smoking cessation and increased physical
activity) and pharmacological therapy (e.g. BP-lowering
agents and lipid-modifying agents).5, 11, 14-18
Absolute CVD risk in the context of these guidelines refers to
the likelihood of a person experiencing a cardiovascular event
within the next five years. The Guidelines for the Assessment
of Absolute Cardiovascular Disease Risk 200910 focused on
the assessment of absolute risk in those aged 45–74 years
(35–74 years for A&TSI peoples) because many risk factors
included in the FRE (e.g. high BP, high total cholesterol [TC])
become more prevalent with increasing age. In addition to
providing guidance in the management of CVD risk, these
new guidelines build on the assessment guidelines to include
a discussion of AR assessment in the population aged
greater than 74 years.
This chapter covers methods for assessment and review
of CVD risk for adults aged 45 (35 for A&TSI peoples)
and over. It incorporates the recommendations from the
assessment guidelines and new recommendations for
those aged 75 years and over. Evidence relating to the new
recommendations is presented in detail in these guidelines.
Evidence for the existing recommendations for assessment
of CVD risk for people aged 45–74 years (or 35–74 years for
A&TSI peoples) is summarised in this document to provide
context for the recommendations. Further details on evidence
relating to these recommendations can be found in the
Guidelines for the Assessment of Absolute CVD Risk 2009.10
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1.1 Potential benefits of absolute
CVD risk assessment
Individuals tend to develop clusters of risk factors.1
Assessment of CVD risk on the basis of the combined
effect of multiple risk factors is more accurate than the use
of individual risk factors, because the cumulative effects of
multiple factors may be additive or synergistic.1-3 Individual
risk factors such as BP and lipid levels have been shown to
have a continuous association with the risk of CVD events,
therefore, moderate reductions in several risk factors may
be more effective in reducing overall CVD risk than a major
reduction in one factor.5 This evidence forms the basis of the
AR approach, where reduction of any of the key risk factors
has an effect on the total risk score, regardless of the
starting level of that risk factor. For example, Person A, who
presents with a BP of 150/95 mmHg, may have a lower AR
score than Person B, who has a BP of 140/90 mmHg but is
a smoker and has an elevated lipid level. Person B is more
likely to benefit from interventions to reduce risk than Person
A because of the potential to reduce the overall absolute
CVD risk.
There is emerging evidence that clinical decisions based
on absolute CVD risk may lead to improved management
of CVD risk. Access to absolute CVD risk assessments has
been shown to increase prescribing of lipid-modifying drugs
for high-risk people with diabetes19 and lead to improvement
in lipid profiles and significant reductions in the risk of
CHD.20, 21 As absolute CVD risk assessment provides a more
accurate assessment of risk than individual risk factors, it is
reasonable to expect that basing management decisions on
this assessment will improve outcomes.
Modelling studies provide the most compelling current
evidence that absolute CVD risk assessment in general
practice is likely to improve CVD outcomes, compared
with assessment of single risk factors. When applied to a
reference population with known risk factors, a strategy
based on targeting those at highest absolute CVD risk is

potentially more than twice as effective in reducing death
from CHD than treating people with single risk factors (e.g.
high TC level).22
At the population level, interventions targeting those
at highest overall CVD risk are likely to achieve the
best balance between preventing death and avoiding
unnecessary treatment in those at lower risk.23, 24 For
example, lipid-lowering treatment in people assessed to
be at high risk on consideration of all risk factors present
will potentially prevent twice as many deaths from CHD in
a given population than treating only those with TC levels
above a given arbitrary cut-point.22, 23 Therefore, accurate
estimation of CVD risk, especially in people without known
CVD, could play a complementary role with other strategies
(e.g. to reduce salt and tobacco consumption) in delivering
effective population preventive health programs. Since the
mid-1990s, major guidelines for the prevention of CVD
have moved from an approach based on identifying and
correcting individual risk factors through the application of
several separate guidelines, to a focus on the individual’s
overall risk through multiple risk factor assessment.

1.2 Taking a clinical history
To ensure a comprehensive risk assessment, a clinical
history should be routinely taken and should cover the
information given in Practice Point 1. This includes the risk
factors to be used for calculation of a risk score and other
modifiable and non-modifiable risk factors to be considered
in making a clinical judgement about the individual’s
total CVD risk. Consideration of related conditions that
could contribute to CVD risk, such as the presence of
AF, should also be made. Readers are referred to an
Australian evidence summary25 and international guidelines
for a discussion of the general evidence related to AF
assessment and management26-29 and current Australian
guidelines for assessment and management of diabetes,12, 30
CKD31 and familial hypercholesterolaemia.32

1.3 Measuring Risk Factors
In order to estimate an individual’s absolute risk of CVD, the
risk factors in Table 1 should be measured.

1.4 Assessing absolute CVD risk
To calculate an individual’s estimated 5-year absolute CVD
risk use the Risk Assessment and Management Algorithm
(Appendix 4) and the risk charts or online calculator at

Practice point
Conducting a comprehensive risk assessment
PP 1 (2009): In adults without known CVD, a comprehensive assessment of CVD risk includes consideration of the
following:
Modifiable risk factors
•
•
•
•
•
•
•

Smoking status
Blood pressure
Serum lipids
Waist circumference and BMI
Nutrition
Physical activity level
Alcohol intake

Non-modifiable risk factors
• Age and sex
• Family history of premature CVD
• Social history including cultural identity, ethnicity and socioeconomic status
Related conditions
•
•
•
•

Diabetes
CKD (albuminuria ± urine protein, eGFR)
Familial hypercholesterolaemia
Evidence of AF (history, examination, electrocardiogram)
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Table 1: Risk factors that may be considered for absolute CVD risk assessment

Risk factor

Measurement

Blood pressure

Absolute risk calculators have been developed using clinic BP measurements, therefore, if using
ambulatory BP readings for risk assessment, clinicians should convert to the clinic equivalent using
the appropriate tables (see National Heart Foundation and High Blood Pressure Research Council
of Australia consensus statement 2012). For clinic BP measurement, the average of two seated BP
measurements over two separate occasions should be used to calculate risk. The most recently
recorded pre-treatment value can be adopted for individuals taking antihypertensive medication.
Ambulatory BP measurement is a better predictor of outcomes than clinic BP measurements and
therefore should be used to monitor BP lowering therapy.

Serum lipids

Plasma glucose

A fasting lipid profile (TC, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein
cholesterol [HDL-C], non high-density lipoprotein cholesterol [non HDL-C], TC:HDL ratio and
triglycerides) should be taken. A single TC:HDL ratio is used to calculate CVD risk. When a fasting
sample is not possible, a non-fasting TC:HDL ratio may be used for an initial screening assessment
of CVD risk, however treatment decisions should be made on the basis of fasting lipid levels.
In order to screen for diabetes, an assessment of fasting plasma glucose is recommended. A value
of ≤ 5.4 mmol/L indicates a normal level. A result of 5.5–6.0 mmol/L may be normal but some
people will show diabetes or impaired glucose tolerance in an oral glucose tolerance test (OGTT).
A value of ≥ 6.1 mmol/L but ≤ 6.9 mmol/L is diagnostic of impaired fasting glucose and requires an
OGTT to confirm diabetes or impaired glucose tolerance. A value of ≥ 7.0 mmol/L on two separate
occasions is diagnostic of diabetes and does not require an OGTT.
When a fasting sample is not possible non-fasting glucose can be measured with further testing
required if the result is ≥5.5 mmol/L. HbA1c can be used to diagnose diabetes with a level of
≥6.5% being diagnostic.

Waist
circumference
and BMI

Left ventricular
hypertrophy (LVH)
(If assessed)
Renal function

Smoking status

A BMI <25 kg/m2 is desirable. Individuals with a BMI ≥25 kg/m2 are classified as overweight
and those with a BMI ≥30 kg/m2 are obese and at increased risk of diabetes, CHD and stroke
compared with individuals with normal BMI (< 25 kg/m2).33-35
Waist circumference, as a measure of central obesity, is a better predictor of CVD risk than BMI.34,
36
A waist circumference of ≥94 cm in men (≥90 cm in Asian men) and ≥80 cm in women (≥80 cm
in Asian women) is suggestive of central obesity.37
Echocardiography, if available, should be the test of choice to assess for LVH as it is more sensitive
than electrocardiography. In the absence of echocardiography, electrocardiograms can be used.

Renal function should be estimated from GFR. An eGFR <60 ml/min/1.73m2 is indicative of stage 3
CKD.
Proteinuria is defined as urinary albumin:creatinine ratio (UACR) > 35 mg/mmol in females and >25
mg/mmol in males. Persistent proteinuria is defined as 2 positive measurements, 3 months apart.
The preferred method for assessment of proteinuria in both diabetic and non-diabetic patients
is UACR in a first void spot specimen. Where a first void specimen is not possible or practical, a
random spot urine specimen for UACR is acceptable. A positive UACR test should be repeated to
confirm persistence of albuminuria. CKD is present if two out of three tests (including the initial test)
are positive. If the first positive UACR is a random spot (as it may be for opportunistic testing), then
repeat test results should ideally be first morning void specimens.
For the purposes of CVD risk assessment, a non-smoker is defined as someone who has never
smoked or has given up smoking and has not smoked for ≥12 months.

BMI: body mass index; CHD: coronary heart disease; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; OGTT: oral glucose tolerance
test.
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www.cvdcheck.org.au which are based on the FRE.
The FRE has been validated to include age, sex, smoking
status, diabetes, SBP, TC:HDL ratio and LVH as part of the
equation. All other risk factors should be factored into the
clinical judgement for decisions regarding the management
of individual patients.
Descriptors of risk categories are arbitrary, with definitions
of ‘moderate’ and ‘high’ risk varying between national and
international guidelines. For the Australian context, the
Guidelines for the Assessment of Absolute Cardiovascular
Disease Risk (2009)10 defined the categories as in Practice

Diabetes with microalbuminuria
The presence of microalbuminuria approximately doubles
CVD risk.38-41 In clinical practice it is both reasonable and
expedient to make the assumption that all adults with
diabetes and microalbuminuria are at high CVD risk.
Numerical calculation of absolute CVD risk is unlikely to
affect clinical management decisions significantly, given that
intensive management of risk factors is generally indicated
in this group.

point 2.

Practice point
Assessing absolute CVD risk
PP 2 (2009): The following qualitative risk categories can be used to describe calculated absolute cardiovascular risk:
• low risk corresponds to <10% probability of CVD within the next five years
• moderate risk corresponds to 10–15% probability of CVD within the next five years
• high risk corresponds to >15% probability of CVD within the next five years

1.5 Assessment of CVD risk in
different populations
1.5.1 Clinically determined high risk
Based on available published evidence and clinical
consensus, certain groups can be assumed to be at high
risk of cardiovascular events because of their clinical
condition, and a calculation of absolute CVD risk is not
considered necessary. This section applies to adults aged
45 and older (35 and older for A&TSI peoples) of any ethnic
background who have been clinically determined to be at
high risk.

Diabetes and age >60 years
In clinical practice it is both reasonable and expedient to
make the assumption that all patients aged over 60 years
with diabetes are at high CVD risk, given that numerical
calculation of absolute CVD risk is unlikely to affect clinical
management decisions significantly because intensive
management of risk factors is generally indicated in this
group. For instance, blood pressure-lowering drugs are
indicated and cholesterol-lowering drugs are likely to be
prescribed regardless of numerical risk.

Moderate or severe CKD
Clinical studies indicate that people with moderate or severe
CKD (defined as persistent proteinuria or eGFR < 45 mL/
min/1.73 m2) have an increased risk of developing CVD.
This effect is independent of the presence of diabetes or
pre-existing CVD.42, 43 The definition of moderate or severe
CKD on which this recommendation is based represents
a threshold midway between stage 3 and stage 4 CKD as
defined by the National Kidney Foundation Kidney Disease
Outcomes Quality Initiative.44 Absolute CVD risk assessment
based on the FRE is not suitable in this population because
traditional risk factors have been shown to underestimate
CVD events in people with CKD.

Familial hypercholesterolaemia
Familial hypercholesterolaemia (FH), a genetic disorder
resulting in impaired cellular uptake of plasma LDL-C, is
strongly associated with premature CHD. Most international
guidelines for CVD risk management recommend that
individuals with FH should be considered to be at high risk
for CVD and receive treatment to reduce risk.14, 45, 46
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Evidence-based recommendation

Grade

Clinically determined high risk
EBR 1: Adults with any of the following conditions do not require absolute cardiovascular risk
assessment using the Framingham Risk Equation because they are already known to be at
clinically determined high risk of CVD:

D10 (2009)

i. Diabetes and age >60 years
ii.	Diabetes with microalbuminuria (>20 mcg/min or UACR >2.5 mg/mmol for males, >3.5 mg/
mmol for females)
iii. Moderate or severe CKD (persistent proteinuria or eGFR < 45 mL/min/1.73m2)
iv. A previous diagnosis of familial hypercholesterolaemia
v. SBP ≥180 mmHg or DBP ≥110 mmHg
vi. Serum total cholesterol >7.5 mmol/L.

SBP ≥180 mmHg or DBP ≥110 mmHg
Extreme levels of risk factors are associated with high
absolute CVD risk, regardless of other factors. Adults with
markedly elevated BP should be assessed as having high
risk for CVD.47

Serum total cholesterol >7.5 mmol/L
The Framingham Heart Study included few people with
TC levels of 7.5 mmol/L or higher. Therefore, the FRE has
not been validated in this group. Markedly elevated TC
levels are commonly associated with FH, which is known to
carry a high risk of CVD. Consistent with other international
guidelines, it is reasonable to assume that markedly
elevated TC indicates high CVD risk.14, 48

1.5.2 General population
There has been a natural evolution in research evaluating
models to assess AR – comparing new and locally
produced models with the original FRE or recalibrations
of the FRE using local data. This section presents a brief
summary of the evidence presented in the Guidelines for
the Assessment of Absolute Cardiovascular Disease Risk,
and a review of the more recent evidence for CVD risk
assessment of adults. For details of the evidence relating
to risk assessment models for people aged 45–74 years
refer to the Guidelines for the Assessment of Absolute
Cardiovascular Disease Risk.10
Fourteen high-quality cohort studies that assessed AR in
a mixed population (>18 years) with no history of CVD or
diabetes49-62 were identified in the current literature review in
addition to the 10 high-quality studies that were indentified
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in the literature review of the assessment guidelines.
These 14 additional studies reported on the applicability
to local populations of recalibrated versions of various
risk calculation models including FRE,53, 54 SCORE,50,
54, 59
UKPDS,62 CLEM,56 QRISK,57 and locally generated
models: 3C (France),51 GP (United Kingdom),60 India,52 and
NIPPON DATA80 (Japan).49 A consistent finding from these
studies is that regardless of the tool used to measure AR,
recalibration using local, country-specific data can produce
more accurate risk estimations. However, one study
using recalibrated versions of FRE showed that although
recalibration of risk calculation models to local data is a
practical approach to estimation of CVD risk, the reliability
and applicability of the data used for recalibration is of key
importance.54
In Australia, one new study was located, the purpose of
which was to develop a parsimonious model to predict
CHD and CVD deaths using individual components of
the FRE plus measures of central obesity.55 Fifteen-year
mortality data were assessed in 8,662 Australian adults
in the National Heart Foundation Risk Factor Prevalence
Survey of 1989, excluding those with a baseline history of
heart disease. Smoking status, HDL-C and the TC:HDL-C
ratio together with SBP were found to be significant
predictors of CVD deaths. The obesity measures of waist
circumference and waist-to-hip ratio were significant
univariate predictors but BMI was not. In multivariable
analyses, smoking status and waist-to-hip ratio were the
only risk factors identified as key independent risk factors
for coronary and cardiovascular-related deaths, although
TC:HDL-C ratio contributed minimally to the prediction of
CHD deaths. However, the FRE was found to have almost
identical accuracy of risk prediction as the use of the waistto-hip ratio plus smoking risk prediction model. These

results suggest that a model for predicting coronary and
cardiovascular deaths that incorporates central obesity plus
smoking would have similar efficacy as the FRE.
One study found that the locally calibrated version of the
SCORE risk prediction tool was more accurate than the
standard tool in populations aged 36–64 years.50 Another
study in people aged 30–74 years validated a sex-specific
multivariable risk factor algorithm that can predict risk based
on traditional risk factors such as age, TC, HDL-C, SBP,
treatment for hypertension, smoking and diabetes status.53
A comparison of the FRE and CLEM models in a population
aged 30–67 years demonstrated reasonable discriminating
ability for both models to predict risk in this age group.56
Another recent study constructed a prediction algorithm
for 30-year risk of cardiovascular events (e.g., coronary
death, MI and stroke) using observational follow-up data
from 4,506 participants from the Framingham Offspring
cohort aged 20–59 years and free of CVD and cancer at
baseline.61 After adjusting for competing risks of death, the
30-year event rates were 7.6% for women and 18.3% for
men. Standard risk factors (male sex, SBP, antihypertensive
treatment, TC and HDL-C, smoking and diabetes mellitus)
measured at baseline, were significantly related to the
incidence of CVD and remained significant when updated
regularly. BMI was also associated positively with 30-year
risk of CVD, but only in models that did not update risk
factors.
Collectively, these results indicate that risk prediction
models can be used to reasonably predict CVD risk in adult
populations. The FRE, when compared to other absolute
CVD risk assessment methods, has shown equivalent
or higher predictive ability in non-diabetic cohorts. It
remains the most thoroughly tested method of assessing
absolute CVD risk in adults without a previous history of
diabetes or CVD. The FRE has been found to overestimate
or underestimate risk in some populations. There is no
current support for the use of ancillary cardiac imaging
such as coronary CT angiography to refine FRE based risk
assessment and decisions to initiate therapy.
Many of the risk factors included in the FRE become more
prevalent with increasing age. An analysis of the risk factors
associated with chronic disease found that in Australia, the
proportion of people with five or more risk factors for chronic
disease (including CVD) was highest in the 45-64 and 65-84
year old age groups.63
The lower and upper age limits presented by the Guidelines
for the Assessment of Absolute CVD Risk were selected
for several reasons. Firstly, the lower age limit of 45 years
was consistent with Australian policy initiatives, such as

the ‘45-year-old health check’ (Medicare Benefits Scheme
item number 717). This program has now been updated to
encourage preventative health checks for people between
the ages of 45 and 49 years who are at risk of developing
chronic disease (Medicare Benefits Scheme items 701, 703,
705 and 707). The lower age limit of 45 years is also aligned
with existing clinical recommendations in Australia, such
as the Royal Australian College of General Practitioners
(RACGP) Guidelines for Preventative Activities in General
Practice,64 which recommends assessment of lipid levels
from 45 years. The upper age limit of 74 years was
proposed because this was the upper age for the original
Framingham Heart Study cohort.65
The literature review found little strong evidence supporting
CVD risk estimation in people aged 30 years or less and
only limited evidence for those 30-45 years. Hence the
original baseline age of 45 years (35 years for A&TSI
peoples) was deemed appropriate. For people aged under
45 years clinicians should examine those with isolated,
elevated single risk factors or a strong family history of CVD
to rule out secondary causes and to determine if they fall
into the clinically determined high risk category.

Aged over 74 years
The upper age limit of 74 years was proposed by the expert
panel for the use of the FRE for routine assessment of
absolute CVD risk because this was the upper age for the
original Framingham Heart Study cohort. In the absence of
robust data for risk estimation in this population, the FRE
can provide an estimate of risk for this age group, which
can be used to guide management decisions. Although
age is a significant risk factor for CVD, age in itself is not a
reason to initiate pharmacotherapy. Age alone should not
be a contraindication to drug therapy, but consideration
should be given to quality of life, co-morbidities and life
expectancy. These issues should be discussed with the
patient before making treatment decisions. Although older
people gain a similar relative benefit from reduction of the
levels of individual risk factors such as BP and lipids, they
are more likely to benefit in absolute terms because of their
much higher pre-treatment cardiovascular risk. Therefore,
when assessing CVD risk in people aged 74 and older, FRE
may be used as a guide to determine the level of risk by
assuming an age of 74 years. While acknowledging that
FRE may underestimate risk in that individual, the resulting
score may be used to inform management decisions by
discriminating between adults at moderate risk and those at
high risk.
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Evidence-based recommendation

Grade

General population aged 45-74 years
EBR 2: Absolute CVD risk assessment, using the Framingham Risk Equation to predict risk of a
cardiovascular event over the next five years, should be performed for all adults aged 45–74 years
who are not known to have CVD or to be at clinically determined high risk.

B10 (2009)

Consensus-based recommendation
General population aged over 74 years
CBR 1: In adults aged over 74, who are not known to have CVD or to be at clinically determined high risk, absolute
cardiovascular risk over the next five years should be assessed using the Framingham Risk Equation. Calculation should be
performed using the age of 74 years. Although the Framingham Risk Equation might underestimate risk in this population,
available evidence suggests that this approach will provide an estimate of minimum cardiovascular risk.

Practice point
All adults aged over 74 years
PP 3: In adults aged over 74 years, the decision to initiate therapy should be based on clinical judgement which takes into
account:
• Likely benefits and risks of treatment
• Life expectancy, co-morbidities and quality of life
• Personal values

1.5.3 Aboriginal and Torres Strait Islander
peoples
Aboriginal and Torres Strait Islander peoples have a
high prevalence of risk factors for heart, stroke and
vascular disease. The presence of these risk factors may
contribute to the overall risk differently from the patterns
observed in reference populations that are reported in the
published evidence. People of Aboriginal and Torres Strait
Islander background may experience more rapid disease

progression than the reference population. They also have
exceedingly high age-standardised mortality that has not
shown the downward trend seen in the rest of the Australian
community over the past 40 years. A literature search
failed to locate any new data on this cohort. Therefore,
the recommendations below are based on one published
study66 from the Guidelines for the Assessment of Absolute
CVD Risk10 and on expert opinion.

Evidence-based recommendation

Grade

Aboriginal and Torres Strait Islander adults aged 35–74 years
EBR 3: In Aboriginal and Torres Strait Islander adults aged 35–74 years who are not known to have
CVD or to be at clinically determined high risk, absolute cardiovascular risk over the next five years
should be calculated using the Framingham Risk Equation. Although the Framingham Risk Equation
might underestimate risk in this population, available evidence suggests that this approach will
provide an estimate of minimum cardiovascular risk.
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D66 (2009)

Consensus-based recommendation
Aboriginal and Torres Strait Islander adults aged over 74 years
CBR 2: Aboriginal and Torres Strait Islander adults aged over 74 years should be considered as being at high CVD risk.

1.5.4 Populations requiring special
consideration
Adults with diabetes
In adults with diabetes without known CVD, most
risk equations developed in the general population
underestimate risk. However, there is little evidence that
risk scores developed in diabetic populations provide better
estimates. Two high-quality studies were identified that each
compared two methods of absolute CVD risk assessment.
The FRE was compared with the UKPDS risk score in
people participating in a small (n=428) UK general practicebased follow-up study conducted among men and women
with diabetes aged 30–64 years.67 For the entire cohort,
no statistically significant difference in predictive ability was
found between the two methods. However, the area under
the curve (AUC) for 10-year risk was numerically higher
for the FRE than the UKPDS risk score for both men and
women when data were analysed separately. The clinical
implications of this finding are unclear.
A US study of 1,237 men and women with diabetes aged
45–64 years compared the predictive ability of traditional
risk factors (e.g. age, race, TC, HDL-C, SBP) with the
predictive ability of a combination of traditional and nontraditional factors (e.g. BMI, waist-to-hip ratio, serum
lipoprotein(a), serum albumin, serum creatinine, white blood
cell count, fibrinogen, factor VIII, physical activity, dietary
lipid, left ventricular hypertrophy, carotid intima-media
thickness).
The score based on a combination of traditional and nontraditional factors was a better predictor of 10-year absolute
CVD risk than traditional factors alone, in both men and
women.68

Other recent cohort studies have reported that the FRE
underestimated risk in people with diabetes,69, 70 consistent
with the findings of the systematic review. Based on these
findings, some investigators argue for the development
of diabetes-specific CVD risk calculators.69 However,
others have concluded that the development of separate
risk prediction models for people with diabetes does not
improve predictive ability and that the presence of diabetes
alone should not be assumed to indicate a common level
of high risk.71 Some investigators have proposed the use of
the FRE with the addition of a constant calibration factor for
diabetes.70
A more recent systematic review compared the FRE with
observed events in people with type 1 diabetes, and found
that, in general, the equation was a poor predictor of
cardiovascular events.72 However, the authors noted that
diabetes-specific risk scores need to be validated in other
populations before they are widely adopted. In another
recent study, the FRE, SCORE and UKPDS tools were
compared in adults with and without diabetes.73 The FRE
appeared to either underestimate or overestimate events,
while the SCORE and UKPDS risk models, with the addition
of non-traditional risk factors, proved more accurate for the
assessment of AR.
Overall, current evidence supports the use of the FRE
for calculation of CVD risk in the general population of
adults with diabetes, despite evidence to show that it
underestimates risk in this population.70, 74 In people with
diabetes aged over 60 years, a high risk of CVD events
(>15% probability of a CVD event within five years) is likely,
therefore numerical calculation of absolute CVD risk is not
necessary in this group.

Evidence-based recommendation

Grade

Populations requiring special consideration: adults with diabetes
EBR 4: In adults with diabetes aged 60 years or less who are not known to have CVD or to be
at clinically determined high risk, absolute cardiovascular risk over the next five years should be
assessed using the Framingham Risk Equation. Although the Framingham Risk Equation might
underestimate risk in this population, available evidence suggests that this approach will provide an
estimate of minimum cardiovascular risk.

C 10(2009)
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Adults who are overweight or obese
No studies were identified that specifically evaluated the
predictive ability of absolute CVD risk assessment in adults
who are overweight or obese and without known CVD. Two
meta-analyses from large observational studies have found
a strong relationship between overweight and obesity and
CVD mortality.75, 76 Australian data are limited. Investigators
in a multivariate analysis concluded that obesity (in this
study, best measured by waist-to-hip ratio) is a dominant
and independent predictive variable for CVD events and
deaths in Australian men and women.77 In line with previous
meta-analyses, a recent meta-analysis found the association
of measures of obesity are generally accounted for by
changes in BP, diabetes and lipid measures.78
The most widely recognised indicator of overweight and
obesity is BMI, measured as weight divided by height
squared (kg/m2). Recently, several authors have proposed
that CVD risk correlates better with other metrics that
quantify abdominal (visceral) obesity, such as waist
circumference or waist-to-hip ratio.79, 80 NHMRC clinical
practice guidelines for the management of overweight and
obesity in adults recommend that waist circumference
should be measured in combination with either BMI or
weight, for those patients who wish to be measured.81
Definitions and targets based on data from European
populations may not be appropriate for all ethno-cultural
groups.
The FRE does not include measures of obesity. Hence,
in the absence of evidence for the predictive ability of an
absolute CVD risk assessment method in adults who are
overweight or obese, it is reasonable to use the FRE in
this group. Further details of assessment of those who are

overweight or obese can be found in the Clinical Practice
Guidelines for the Management of Overweight and Obesity
in Adults.81

Adults with depression
Clinical depression, social isolation and lack of quality
social support have been shown to predict incident CHD
and worsen its prognosis, independent of conventional risk
factors such as smoking, raised lipids and elevated BP.8287
Therefore, adults being assessed for CVD risk should
also be assessed for depression and other psychosocial
factors. This section reviews the evidence to support the
assessment of depression in adults at risk of CVD.
Multiple cohort studies have found a similar strength of
association between depression, social isolation or lack of
quality social support and CHD compared with traditional
risk factors.84, 88 With minor depression, the risk of CHD
increased one-to two-fold. However, with major depression
there was a three-to five-fold increase in CHD risk.84 These
results concur with the results of another meta-analysis
involving 11 cohort studies in initially healthy subjects that
found an overall increase in risk by 64% (RR 1.64, 95%
CI 1.29–2.08, p<0.001).85 Another recent review of the
relationship between depression and anxiety with chronic
diseases found consistent evidence that depression is a risk
factor for heart disease, stroke and diabetes.83 However,
there is no evidence that treatment of depression reduces
the risk of CVD events. Two systematic reviews, both in
patients with established CHD, failed to demonstrate a
link between cardiovascular outcomes and the treatment
of depression.89, 90 Both reviews concluded, however, that
the lack of evidence should not detract from the need to
address depression as a clinical issue in its own right.

Evidence-based recommendation

Grade

Populations requiring special consideration: adults who are overweight or obese
EBR 5: In adults who are overweight or obese and who are not known to have CVD or to be
at clinically determined high risk, absolute cardiovascular risk over the next five years should
be assessed using the Framingham Risk Equation. The results should be interpreted with the
awareness that its predictive value has not been specifically assessed in this population.

D10 (2009)

Practice point
Populations requiring special consideration: adults with depression
PP 4: Adults being assessed for CVD risk should also be assessed for depression (and other psychosocial factors).
Cardiovascular risk assessment using the Framingham Risk Equation may underestimate risk in adults with depression.
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Socioeconomic status
Measures of socioeconomic status are not included in the
FRE, but are included in some more recent absolute CVD
risk assessment methods. Socioeconomic deprivation
should be considered in addition to calculated risk, because
it is an independent risk factor for CVD.
Few data are available to quantify the effect of
socioeconomic status on absolute CVD risk. Data
from a study conducted in Scotland indicate that
the FRE underestimated absolute CVD risk in
socioeconomically deprived groups.91, 92 No Australian
studies have directly addressed this issue.
Socioeconomic deprivation has been associated with
adverse cardiovascular outcomes in Australian adults
(where socioeconomic disadvantage is measured
according to the Index of Relative Socioeconomic
Disadvantage, which takes into account social and
economic characteristics of the geographical area
such as low income, low educational attainment, high
levels of public sector housing, high unemployment
and jobs in relatively unskilled occupations).4, 9 There
is emerging evidence that the incorporation of social
deprivation scores into absolute CVD risk assessment
tools improves their predictive value.92,93 However, this
approach has been tested only in specific populations
and has not been validated in the Australian population.
In the absence of a numerical formula for incorporating

social deprivation into risk assessments for Australian
adults, it is recommended that a subjective assessment
of the effect of social status should be taken into
account when assessing CVD risk.

Atrial fibrillation
Atrial fibrillation (AF) is an important marker (regardless
of causality), not only of thromboembolic disease
and stroke, but also of incident all-cause mortality,
cardiovascular death, heart failure and possibly
coronary events.94, 95 AF is associated with an odds
ratio for death of 1.5 for men and 1.9 in women,
which does not vary by age, but most of the excess
of mortality attributed to AF occurs early after the
diagnosis.94
The prothrombotic state imposed by AF predisposes
individuals to stroke and thromboembolism, with an
approximately five-fold greater risk than that of people
without AF.96 Furthermore, the risk of stroke increases with
increasing age, previous transient ischaemic attack (TIA) or
stroke, raised BP, diabetes, impaired left ventricular function
and a large left atrium.
The presence of AF should prompt a thorough investigation
for other CVD risk factors.25-29 Readers are referred to an
Australian evidence summary25 and international guidelines
for a discussion of the general evidence related to AF
management.26-29

Practice point
Populations requiring special consideration: socioeconomic status
PP 5 (2009): A comprehensive assessment of cardiovascular risk involves consideration of socioeconomic deprivation,
because it is an independent risk factor for CVD. Absolute risk of CVD calculated using the Framingham Risk Equation is
likely to underestimate CVD risk in socioeconomically disadvantaged groups.

Practice point
Populations requiring special consideration: atrial fibrillation
PP 6 (2009): In adults with AF (particularly those aged over 65 years), the increased risk of cardiovascular events and all
cause mortality, in addition to thromboembolic disease including stroke, should be taken into account when assessing
cardiovascular risk.
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Adults already receiving
pharmacotherapy for single risk factors
Use of on-therapy measures for BP and cholesterol will
inaccurately estimate AR for people already receiving
lipid or blood pressure-lowering therapy. Therefore, it
is recommended that the most recently recorded pretreatment measure be used to estimate absolute CVD risk.
Where this is not possible, clinicians should make decisions
on intensification or withdrawal of pharmacotherapy or
lifestyle interventions based on discussions with the patient
and consideration of their individual context.

1.6 Review of CVD risk
Intervals for review of absolute CVD risk
were determined after consideration of the
recommendations of established preventive
guidelines for general practice and of the likelihood
that an individual’s risk status will change over
time. Reassessment of absolute CVD risk status
should be undertaken when there is a reasonable
expectation that it will affect clinical management
decisions. In those at low risk, absolute CVD risk
should be assessed approximately every two years or
if individual risk factor status deteriorates. Another set
of blood tests may not be necessary for assessment
of people at low risk, i.e. assessment may be
conducted with previous cholesterol or blood glucose

levels if they have been taken within five years.97 The
decision to conduct a blood test should be made
by the clinician after taking into consideration the
individual person’s context, e.g. specific populations
known to be at increased risk, or recent changes
such as significant weight gain, uptake of smoking, or
onset of menopause.
In a person assessed to be at moderate absolute
CVD risk (10–15% probability of a cardiovascular
event within five years), closer monitoring of risk
is needed because risk level may become high in
response to worsening status of one or more risk
factors. In a person assessed to be at high absolute
CVD risk (>15% probability of a cardiovascular event
within five years), risk status is unlikely to be revised
downward in the short term, although occasionally
it may be reduced following reversal of modifiable
risk factors (e.g. permanent smoking cessation).
Reassessment of risk status will depend on the
individual’s clinical profile and the purpose of risk
assessment (e.g. to encourage continued adherence
to a treatment plan or to inform the decision to
commence additional treatment).
The following intervals are intended only as a guide.
Appropriate intervals at which an individual’s absolute
CVD risk should be reviewed will depend on clinical
judgement.

Practice point
Review of CVD risk
PP 7 (2009): Regular review of absolute cardiovascular risk is recommended at intervals according to the initial assessed
risk level:
• Low – review every 2 years
• Moderate – review every 6–12 months
• High – review according to clinical context
PP 8: In adults at low absolute risk of CVD, blood test results within five years may be used for review of absolute
cardiovascular risk unless there are reasons to the contrary.
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Chapter 2:
Treatment
2.1 Lifestyle

Dietary advice

This section covers treatment, including targets, for the
management of CVD risk, and applies to all adults aged
over 45 years (35 years for A&TSI peoples), irrespective of
CVD risk level.

Dietary advice appears to be effective in bringing about
modest beneficial changes in diet and CVD risk factors.
In a recent review of 38 trials with a minimum followup period of three months, dietary advice (e.g. advice
to decrease consumption of fat, saturated fatty acids,
cholesterol, salt and/or increase consumption of fruit,
vegetables, polyunsaturated fatty acids, monounsaturated
fatty acids, fish, fibre and potassium) reduced total serum
cholesterol by 0.16 mmol/L (95% CI 0.06–0.25) and LDL-C
by 0.18 mmol/L (95% CI 0.1–0.27).99 Mean HDL-C levels
and triglyceride levels were unchanged, however BP
was reduced, SBP by 2.07 mmHg (95% CI 0.95–3.19)
and DBP by 1.15 mmHg (95% CI 0.48–1.85). Dietary
Guidelines for Australian Adults have been developed by
the NHMRC100 and are currently being updated. Although
the dietary guidelines have been developed for general
health measures and not specifically for CVD prevention,
the recommendations are consistent with the aim of
CVD prevention. Referral for nutritional review and dietary
counselling should be considered, depending on need. A
brief guide to dietary advice is presented, along with other
lifestyle advice, in Table 4.

Lifestyle changes in nutrition, physical activity and smoking
status typically show excellent cost-effectiveness in lowering
the burden of disease, especially with respect to obesity,
future diabetes and heart disease.98 However, there is an
inherent difficulty in undertaking randomised controlled trials
of lifestyle factors. For example, the diet of any individual
is related to other lifestyle factors (e.g. smoking, exercise,
etc.), and although randomised controlled trials are able to
eliminate such bias, they are more difficult to conduct for
lifestyle factors than those for pharmacotherapy. For that
reason, data pertaining to lifestyle interventions is primarily
from cohort and observational studies.

2.1.1 Nutrition, overweight and obesity
A number of behavioural characteristics, including
nutrition, overweight and obesity, play an important role in
the development of CVD. In Australia, the prevalence of
overweight and obesity has been steadily increasing over
the past 20–30 years. Data from 2004–05 indicate that
about 2.5 million Australian adults were obese (19% of
males and 17% of females aged 18 years and over), and a
further 4.9 million adults were estimated to be overweight.9
This section reviews the relationship between nutrition,
overweight, obesity and CVD.

Altering dietary fat: saturated fat
There is a strong, consistent and graded relationship
between saturated fat intake, blood cholesterol and
the occurrence of CVD. A review of 27 trials involving
18,196 participants examined the effect of a reduction
or modification of dietary fats for at least six months on
reducing serum cholesterol levels and on all-cause and
cardiovascular mortality and morbidity.101 The review
included trials of high (n=7), moderate (n=6) and low risk
(n=14) participants. There was a trend towards protection
from cardiovascular mortality (rate ratio 0.91, 95% CI
0.77–1.07), and significant protection from cardiovascular
events (rate ratio 0.84, 95% CI 0.72–0.99). This effect was
non-significant if studies at high risk of bias were removed.
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However, there was stronger evidence of protection against
cardiovascular events when trials with at least two years
of follow-up were assessed (rate ratio 0.76, 95% CI 0.650.90).

Altering dietary fat: n-3 fatty acids
While the evidence for the benefits of fish oil is stronger in
secondary prevention, the benefits also appear to translate
to the primary prevention setting. Several large systematic
reviews have reported lower rates of fatal coronary events
and sudden death among people who regularly consume
fish than among non-consumers.102-104 In a meta-analysis
of observational studies including 222,364 individuals and
an average follow-up period of 11.8 years, individuals with
a higher intake of fish had lower CHD-related mortality
compared with those who never consumed fish or ate fish
less than once per month.103 The relative risks for CHD
were 0.89 (95% CI 0.79–1.01) for fish intake 1–3 times per
month, 0.85 (95% CI 0.76–0.96) for once per week, 0.77
(95% CI 0.66–0.89) for 2–4 times per week, and 0.62 (95%
CI 0.46–0.82) for five or more times per week. Furthermore,
each 20 g/d increase in fish intake was related to a 7% lower
risk of CHD mortality (p for trend = 0.03).
However, conflicting results were reported in a 2006 metaanalysis of 48 randomised controlled trials and 26 cohort
studies.105 In that analysis, the observational studies alone
suggested that omega 3 fats reduced total mortality.
The pooled results from the 48 randomised controlled
trials showed no benefit of omega 3 fats on mortality or
cardiovascular events in patients with existing CHD. Further
high-quality trials are needed to confirm suggestions of a
protective effect of n-3 fatty acids on cardiovascular health
to prevent CVD.

Salt intake
There is now abundant evidence from epidemiological
studies and clinical trials that increased levels of salt intake
increases BP and therefore, the risk of stroke and CHD.
A meta-analysis of 28 trials showed that BP could be
significantly reduced in people with raised or normal BP
levels, by a modest reduction of dietary salt over four or
more weeks.106
A Cochrane review of salt restriction for the prevention
of CHD cited too few cardiovascular events to make a
clear conclusion.107 However, it did report that SBP and
DBP were reduced in those given low sodium advice as
compared with controls (SBP by 1.1 mmHg, 95% CI 1.8–
0.4, DBP by 0.6 mmHg, 95% CI 1.5 to -0.3). Furthermore,
people on anti-hypertensive medications were able to
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stop their medication more often on a reduced sodium
diet as compared with controls, while maintaining similar
BP control. Over 70% of the salt consumed comes from
processed foods and is not related to the discretionary use
of salt, therefore a reduction in the amount of salt in the diet
would require reduction in the amount of salt used in food
production.

Vegetables and fruit
Four systematic reviews examined the benefits of vegetable
and fruit intake for the reduction of CVD risk.108, 111 There
is evidence from these reviews to support the notion that
vegetable and fruit consumption is inversely associated with
the risk of CVD. In one review of eight cohort studies, the
pooled relative risk of stroke was 0.89 (95% CI 0.83–0.97)
for individuals with 3–5 servings per day, and 0.74 (95% CI
0.69–0.79) for those with more than five servings per day,
compared with those who had less than three servings of
vegetables and fruit per day.111 Another report found that the
risk of CHD decreased by 4% (RR 0.96, 95% CI 0.93–0.99,
p=0.0027) for each additional portion of vegetables and fruit
intake per day.109

Dairy products
A detailed meta-analysis of the evidence on milk and
dairy consumption and the incidence of vascular diseases
and diabetes was recently published.112 The results
provide evidence of an overall survival advantage from the
consumption of milk and dairy foods. However, it should be
noted that the meta-analysis did not differentiate between
full fat and reduced fat products. The relative risk of stroke
and/or heart disease in subjects with high milk or dairy
consumption was 0.84 (95% CI 0.76–0.93) and 0.79 (95%
CI 0.75–0.82) respectively, relative to the risk in those with
low consumption.

Wholegrain cereals
Despite the evidence from observational studies that
whole grains can have a beneficial effect on risk factors for
CHD,113-118 a meta-analysis of 10 randomised controlled
trials found no effect of wholegrain diets on CHD mortality or
CHD events or morbidity.119 In eight of the included studies,
the wholegrain component was oats. Pooled analysis of
those studies demonstrated lower TC (-0.20 mmol/L, 95%
CI -0.31 to -0.10, p=0.0001) and LDL-C (0.18 mmol/L, 95%
CI -0.28 to -0.09, p<0.0001) with oatmeal foods. However,
many of the trials were short-term, poor quality and had
insufficient power.

Low glycaemic index diets
The glycaemic index (GI) is a physiological measure of the
ability of a carbohydrate to affect blood glucose. Interest is
growing in the low GI index for the clinical management of
people at risk of or with established CHD. To date, however,
the evidence from randomised controlled trials showing that
low GI diets reduce CHD and CHD risk factors is weak. In
a meta-analysis of 15 trials there was no evidence that low
GI diets have an effect on LDL-C or HDL-C, triglycerides,
fasting glucose or fasting insulin levels.120

Mediterranean diets
The Mediterranean diet is characterised by the traditional
cooking style of countries bordering the Mediterranean Sea.
The principle of the Mediterranean diet includes high levels
of olive oil, legumes, unrefined cereals, fruits, vegetables,
moderate consumption of dairy products (mostly as cheese
and yogurt), moderate to high consumption of fish, low
consumption of meat and meat products, and moderate
wine consumption.

A systematic review of 12 observational studies with a
total of 1,574,299 subjects followed from 3 to 18 years,
demonstrated that adherence to a Mediterranean diet is
associated with a significant improvement in health status,
as seen by a significant reduction in overall mortality (RR
0.91, 95% CI 0.89–0.94), and mortality from CVD (RR 0.91,
95% CI 0.87–0.95).121

Other interventions
Several other interventions, including soya protein,122
phytosterols123 and selenium supplements,124 have been
investigated for their potential benefits on CVD risk factors.
In general, soya protein,122 phytosterols and soluble fibre123
may have modest hypocholesterolaemic effects, while there
is insufficient evidence to determine the effect of selenium
supplements on the prevention of CVD.124 More evidence
is required before clear recommendations can be made
regarding these interventions.

Table 2: Effect of lifestyle and dietary factors on CVD outcomes: summary of key evidence

Reference

Study details

Intervention

Results

Brunner et al (2007)99

Good quality SR (n=38
Dietary advice
RCTs); 17,871 healthy
vs no advice or
adults. Median follow-up 10 minimal advice
months.

TC 0.16 mmol/L,  LDL-C 0.18 mmol/L,
SBP 2.07 mmHg / DBP 1.15 mmHg
after 3-24 months. Mean HDL-C levels and
triglyceride levels unchanged.

Dickinson et al (2006)125

Good quality SR (n=105
RCTs); 6,805 adults with
BP ≥140/85 mmHg. At
least 8 weeks follow-up.

Lifestyle
interventions vs
control

Improved diet SBP 5.0 mmHg;  aerobic
exercise SBP 4.6 mmHg;  alcohol SBP
3.8 mmHg; sodium restriction SBP 3.6
mmHg; and fish oil supplements  2.3
mmHg.

Dauchet et al (2005)108

Good quality SR (n=7
Vegetables and
prospective cohort studies); Fruit
232,049 participants;
90,513 men, 141,536
women.

 risk of stroke (RR 0.89, 95% CI 0.85-0.93)
for each additional portion per day of fruit. 
risk of stroke (RR 0.95, 95% CI 0.92-0.97)
for additional fruit and vegetables per day.
Linear relationship between fruit or fruit and
vegetables and stroke.

Dauchet et al (2006)109

Good quality SR (n=9
Vegetables and
prospective cohort studies); Fruit
221,080; 91,379 men,
129,701 women.

For each additional portion per day of
vegetable and fruit  risk CHD (RR 0.96,
95% CI 0.93-0.99). For each additional
portion per day of fruit intake  risk of CHD
(0.93, 95% CI 0.89-0.96).
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Reference

Study details

Intervention

Results

Elwood et al (2008)112

Fair quality SR (n=15
cohort studies).

Dairy

High vs low milk or dairy consumption
 stroke and/or CHD (RR 0.84, 95% CI
0.76-0.93 and RR 0.79, 95% CI 0.75-0.82
respectively). Limited data on full vs fat
reduced products although the risk of IHD
was halved in one large cohort of women
with reduced fat products.

Flores-Mateo et al
(2006)124

Moderate quality SR (n=31
studies). 14 cohort and
11 CCTs that measured
selenium concentrations
and six RCTs of selenium
supplements.

Selenium
supplements

In the 6 RCTs, there was no difference in
CHD (RR 0.89, 95% CI 0.68-1.17).

Harland et al (2008)122

Good quality SR (n=30
RCTs); 2,913 adults with
normal or mildly elevated
cholesterolaemia.

Soya protein

The inclusion of modest amounts of soya
protein (~25 g) into the diet of adults with
normal-mild raised lipids resulted in small,
but significant reductions in LDL-C, TC and
triglycerides.

He et al (2004)103

Good quality SR (n=11
cohort studies); 222,364
participants. Mean
follow-up 11.8 years.

Fish Intake

Compared with those who never ate fish or
ate fish <once a month, individuals with a
higher intake of fish had lower CHD mortality.
Each 20-g/d increase in fish intake was
related to a 7% lower risk of CHD mortality.

He et al (2006)111

Good quality SR (n=8
cohort studies); 257,551
individuals. Average followup 13 years.

Vegetables and
Fruit

Compared with individuals who had <3
servings/day of vegetables and fruit: >5
servings/day  stroke (RR 0.74, 95% CI
0.69-0.79); 3-5 servings per day  stroke
(RR 0.89, 95% CI 0.83-0.97)

He et al (2007)110

Good quality SR (n=12
cohort studies); 278,459
individuals (9,143 CHD
events). Median follow-up
11 years.

Vegetables and
Fruit

Compared with individuals who had <3
servings/day of vegetables and fruit: >5
servings/day  CHD (RR 0. 0.83, 95% CI
0.77-0.89); 3-5 servings per day did not
change CHD (RR 0.93, 95% CI 0.86-1.00;
p=0.06)

Hooper et al (2001)101

Good quality SR (n=27
Reduction or
RCTs); 18,196 healthy
modification of
adults. Follow-up periods
dietary fats
were grouped into <2 years
and >2 years.

 CVD events (RR 0.84, 95% CI 0.72-0.99).
No difference in all-cause mortality (RR
0.98, 95% CI 0.86-1.12) or CV mortality (RR
0.91, 95% CI 0.77-1.07). Analysis of CVD
events became non-significant on sensitivity
analysis. Stronger results found for trials >2
yrs.

Hooper et al (2004)107

Good quality SR (n=11
Salt reduction diet
RCTs); 3,514 healthy adults
reducing sodium intake
over at least a six month
period.

Dietary salt reduction may lower BP by small
amounts (e.g. ~1 mmHg SBP, <1 mmHg
DBP after one year). However reductions
may be higher in people with higher BP.

Hooper et al (2006)105

Good quality SR (n=48
RCTs and 41 cohort
studies); 36,913
participants in the RCTs.
Mixed primary and
secondary prevention.

Omega-3 fatty
acids

No difference for all-cause mortality or CVD
events.

Kelly et al (2004)120

Good quality SR (n=21
RCTs); 713 adults with
existing CHD or who had
at least one risk factor for
CHD.

Low GI diet

Compared to high GI diets, there is no
evidence that low GI diets have any effect
on CHD outcomes, and only borderline
reduction in LDL-C (-0.16 mmol/L, 95% CI
-0.32-0.00, p=0.05).

Reference

Study details

Intervention

Results

Kelly et al (2007)119

Good quality SR (n=10
RCTs); 738 adults with
existing CHD or who had
at least one risk factor for
CHD. Minimum 4 weeks
diet.

Wholegrain cereal
diet

There is no evidence that wholegrain diets
have an effect on CHD outcomes. In eight
studies wholegrain (oats)  TC (-0.20
mmol/L, p=0.0001) and  LDL-C (0.18
mmol/L, p<0.0001).

Sofi et al (2008)121

Good quality SR (n=12
Mediterranean diet
prospective cohort studies);
1,574,299 subjects with
3-18 years follow up.

Greater adherence to a Mediterranean diet is
associated with a  in overall mortality (RR
0.91, 95% CI 0.89-0.94) and a  in CVD
mortality (RR 0.91, 95% CI 0.87-0.95).

Wang et al (2006)104

Good quality SR (n=33
Fish oils / n-3 fatty
trials). 1,199, 246
acids
participants. Primary
prevention (1 RCT; 25
prospective cohort studies;
7 CCTs). Secondary
prevention (14 RCTs; 1
prospective cohort study).
All studies followed patients
for >1 yr.

Increased consumption of n-3 fatty acids from
fish or fish-oil supplements, but not of alphalinolenic acid,  all-cause mortality, cardiac
and sudden death, and possibly stroke. The
evidence for the benefits of fish oil is stronger
in secondary than in primary-prevention
settings.

BP: blood pressure; CCT: clinical controlled trial; CHD: coronary heart disease; CI: confidence interval; CVD: cardiovascular disease; DBP:
diastolic blood pressure; GI: glycaemic index; HDL: high density lipoprotein; HR: hazard ratio; IHD: ischaemic heart disease; LDL: low
density lipoprotein; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure; SR: systematic review; TC: total
cholesterol.

Practice point
Nutrition, overweight and obesity
PP 9: All adults should be supported to follow the current Dietary Guidelines for Australian Adults.

Weight loss
There is evidence to support the promotion of weight loss
interventions in people who are overweight or obese. Such
interventions can favourably influence CVD risk factors such
as BP and blood lipid levels. There is limited evidence that
directly links weight loss with a reduction in cardiovascular
events.
Four systematic reviews covering a range of weight loss
interventions including, pharmacologic, diet, exercise,
behaviour therapy and surgery were identified.126-129
The most recent assessed the effects of weight loss
interventions versus placebo or no intervention across nine
trials involving almost 2,000 participants.129 At 12 months,
weight loss interventions resulted in significantly greater
weight loss compared with controls (-3.0 kg, 95% CI -5.1
to -0.9, p=0.005). Weight loss interventions were also

associated with significant reductions in TC (-0.36mmol/L;
95% CI -0.75 to 0.04, p=0.008), and favourable (although
not statistically significant) changes in LDL-C, HDL-C and
triglycerides. This study also identified some evidence
to indicate that weight loss could have an independent
effect on cardiovascular events, showing a hazard ratio
for recurrence of hypertension or cardiovascular events of
0.65 (95% CI 0.50–0.85) for weight loss compared with
controls.130
These observations are supported by the results of other
reviews where weight loss resulted in improvements in
BP,126-128, 131, 132 lipid profiles126-128 and glucose.128 In general,
the combination of physical activity and dietary advice
provided the greatest benefit,128 while low carbohydrate and
high protein diets were more effective than low fat diets in
reducing weight and CVD risk factors at 12 months in one
review.127
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Evidence-based recommendation

Grade

Nutrition, overweight and obesity
EBR 6: Weight loss should be recommended for people who are overweight or obese.

In another review of 84 studies, a weight loss of 10 kg
was associated with a fall in TC of 0.25 mmol/L and a
fall in DBP of 3.6 mmHg, while a weight loss of 10% was
associated with a fall in SBP of 6.1 mmHg.126 Low fat diets
were associated with the prevention of type 2 diabetes
and improved control of elevated BP. These diets were
associated with a weight loss after 12 months of 5.31
kg (95% CI -5.86 to -4.77 kg). Furthermore, intentional
weight loss in women with obesity-related illnesses was
associated with a reduced risk of death, CVD death, cancer
and diabetes-related death – a result that was irrespective
of the amount of weight lost. Men with general illness who
lost weight intentionally appeared to have a reduced risk
of diabetes related death, but there was no demonstrable
effect on CVD mortality, and cancer mortality appeared
increased.
In one study, participants randomised to the weight loss
group demonstrated a BP reduction of 4.0/1.1 mmHg
compared with a 0.8/0.8 mmHg change in the control group
(p<0.001).130 The net effect of those reductions resulted in
the discontinuation of antihypertensive medications in 93%
of the weight loss group.

2.1.2 Physical activity
Physical activity is defined as any bodily movement
produced by skeletal muscles that requires energy
expenditure.133 Physical inactivity, including sitting time and
leisure activity, is a growing public health problem and is
associated with an increased risk of ill health and death,
particularly relating to CVD.134, 135 Regular physical activity
reduces CVD risk in its own right, reduces CVD risk factors
such as obesity and elevated blood pressure, improves the
levels of HDL-C and helps protect against type 2 diabetes.9
This section summarises the evidence for physical activity
from systematic reviews and individual trials considered for
the primary prevention of cardiovascular events.

B124-127

Physical activity as an independent risk factor
Several meta-analyses provide evidence for a significant
effect of physical activity on CVD risk, after controlling for
other key risk factors.136-140 In general, these studies confirm
an inverse relationship between physical activity and the risk
of a cardiovascular event or all-cause mortality. Effect sizes
for specific activities range from 30% to 40% relative risk
reductions for CVD137, 138 and 19% to 33% risk reductions
for all-cause mortality.136, 139
One meta-analysis combined the results of 22 observational
studies, involving 977,925 participants, and used a doseresponse meta-regression model to estimate the relationship
between non-vigorous physical activity and mortality.140
The results demonstrated a dose response-relationship for
exercise duration: 2.5 hours/week (equivalent to 30 minutes
daily of moderate intensity activity on five days a week)
compared with no activity, was associated with a reduction
in mortality risk of 19% (95% CI 15–24), while 7 hours/week
of moderate activity compared with no activity reduced the
mortality risk by 24% (95% CI 19–29). Furthermore, the
largest benefit was found when moving from no activity
to low levels of activity. The presence of a dose-response
curve for exercise duration is consistent with results from
other studies.136, 141
The evidence also suggests a dose-response relationship
for exercise intensity. For example, one well conducted
meta-analysis evaluated the results from 38 studies with 3–4
different intensities of regular physical activity.137 For studies
with three activity categories (mildly, moderately and highly
active), highly active men had a 22% lower risk of all-cause
mortality (RR 0.78; 95% CI 0.72–0.84) compared with mildly
active men (RR 0.81; 95 % CI 0.75–0.87). Similarly, for
women, the relative risk was 0.69 (95% CI 0.53–0.90) for
those who were highly active, compared with 0.76 (95 %
CI 0.66–0.89) in the moderately active group. Similar results
were observed when moderately active persons were
compared with mildly active individuals (RR of 0.81 for men
and 0.76 for women).
These results suggest that physical activity should include
occupational and/or leisure time activity and incorporate
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Evidence-based recommendation

Grade

Physical Activity
EBR 7: All adults should be advised to participate in at least 30 minutes of moderate intensity
activity on most days or preferably every day of the week.

accumulated bouts of moderate intensity activities such as
brisk walking, cycling, taking public transport and household
physical activity. Adults who are moderately active and
are able to increase their activity should be encouraged to
do so. This may involve changes to intensity, duration or
frequency of activity. Any increase in activity should be done
gradually irrespective of the level of fitness.

Effects of physical activity on other CVD risk
factors
Several randomised controlled trials142-145 and metaanalyses146-148 provide evidence for a significant effect of
physical activity on CVD risk factors. All forms of exercise
appear to be effective, with a positive influence on CVD
risk factors: lowering LDL-C and triglycerides,146 increasing
HDL-C146 and insulin sensitivity,148 reducing body fat144, 147
and lowering BP.142, 144, 146

2.1.3 Smoking
There is overwhelming evidence that smoking has a
strong, dose-dependent association with cardiovascular
events, including CHD, stroke, peripheral arterial disease
and cardiovascular death.149-157 Men who smoke are three
times more likely to die aged 45–64 years, and twice as
likely to die aged 65–84 years than non-smokers.150 The
Nurse’s Health Study showed that female smokers had
nearly 1.9 times the risk of total mortality from smoking
than non-smokers.154 Passive smoking also increases the
burden of CVD.158 Smoking cessation reduces these risks
substantially, although the decrease is dependent on the
duration of cessation.157, 159 This section summarises the
published evidence for smoking cessation for the primary
prevention of cardiovascular events.
During the period of the literature search, one high-quality
randomised controlled trial of smoking cessation149 and one
secondary analysis of a longitudinal study were located.160
The randomised controlled trial assessed the effects of a
smoking cessation program on long-term mortality among
5,887 middle-aged volunteers with asymptomatic airway

B136-140

obstruction. Intervention included a 10-week smoking
cessation program, strong physician support and 12 group
sessions using behaviour modification and nicotine gum,
plus either ipratropium or a placebo inhaler. At five years,
21.7% of the intervention participants had stopped smoking
compared with 5.4% of usual care participants. After up to
14.5 years of follow-up, all-cause mortality was significantly
lower in the special intervention group than in the usual care
group (8.83 per 1000 person-years vs. 10.38 per 1,000
person-years; p = 0.03). The hazard ratio for mortality in the
usual care group compared with the special intervention
group was 1.18 (95% CI 1.02–1.37).
Longitudinal data also support smoking cessation as an
important primary prevention strategy. In England and Wales
between 1981 and 2000, smoking prevalence in adults
aged 25–84 years decreased from 43% to 28% in men
and from 35% to 24% in women. Using that information
and a validated mortality model to estimate the deaths
prevented or postponed by changes in population smoking
prevalence, the authors estimated that 29,460 deaths
were prevented or postponed by the reduction in smoking
prevalence.160
The number of studies identified during the literature search
was small. However, the recommendations presented
here also take into account the results of literature prior to
2002. Specifically, one randomised controlled trial found
that advice to change diet and smoking habits reduced the
relative risk of CHD mortality after 23 years in men with high
triglyceride concentrations (HR 0.56. 95% CI 0.34–0.93, p
= 0.027).151 Men with normal triglyceride concentrations did
not appear to achieve the same long-term benefit.
Five observational studies of over 293,000 patients support
these results.150, 153-155, 157 In one study, cause-specific
mortality was monitored for 50 years in 34,439 male British
doctors. For those born between 1900 and 1909, the
probabilities of dying in middle age (35–69) were 42% vs
24% (a two-fold death rate ratio) for smokers and nonsmokers, respectively, but were 43% vs 15% (a three-fold
death rate ratio) for those born in the 1920s. Cessation at
age 60, 50, 40 or 30 years provided an approximate 3, 6, 9
or 10 additional years, respectively, of life expectancy.150
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Table 3: Effect of physical activity on CVD outcomes: summary of key evidence

Reference

Study details

Intervention Results

Hamer et al (2008)136

Good quality SR (n=18
Walking
prospective cohort studies).
459,833 participants free
from CVD at baseline.

Lollgen et al (2009)137

Good quality SR (n=38
prospective cohort studies)

For highest vs lowest walking category:
CVD events (HR 0.69, 95% CI 0.61-0.77)
all-cause mortality (HR 0.68, 95% CI
0.59-0.78). Walking pace was a stronger
independent predictor of overall risk compared
with walking volume (48% vs 26% risk
reductions, respectively).

Physical activity

All-cause mortality. Highly vs mildly active: Men
(RR = 0.78, 95% CI 0.72-0.84); Women (RR
0.69, 95% CI 0.53-0.90. There is a doseresponse curve from sedentary subjects to
those with mild and moderate exercise. This
association was similar for sex and age.

Primary prevention. Study
duration > four years.
>271,000 participants.
Nocon et al (2008)138

Fair quality SR (n=33
cohort studies). 883,372
participants. Follow-up
from 4 to >20 years.

Physical activity

CV mortality by 35% and all-cause
mortality by 33% in both men and women.

Orozco et al (2008)147

Good quality SR (n=8
RCTs; 10 interventions)
5,095 participants at risk
of diabetes. Study duration
ranged from one to six
years.

Exercise or
exercise and diet

Exercise and diet interventions had a modest
effect on blood lipids, and improved SBP
and DBP by 4 mmHg, (95% CI -5 to -2) and
2 mmHg, (95% CI -3 to -1), respectively.
Exercise alone or diet alone did not
demonstrate these effects.

Shaw et al (2008)128

Good quality SR (43 RCTs). Exercise + diet
3,476 participants who are vs diet or no
obese or overweight. Trials treatment
at least 3 months length.
Unclear those with existing
CVD.

Exercise + diet resulted in a greater weight
reduction than diet alone (WMD - 1.0 kg;
95% CI -1.3 to -0.7).  exercise intensity
increased the magnitude of weight loss (WMD
-1.5 kg; 95% CI -2.3 to -0.7). Exercise alone
DBP (WMD -2 mmHg; 95% CI -4 to -1),
triglycerides (WMD - 0.2 mmol/L; 95% CI
-0.3 to -0.1) and fasting glucose (WMD - 0.2
mmol/L; 95% CI -0.3 to -0.1).

Shiroma et al (2010)139

Fair quality review based on Physical activity
previous robust SR (n=54
prospective cohort studies).
>957,000 people.

Compared with no activity, physical activity
provides a significant and consistent benefit
in the order of 30-40% risk reduction for CHD
and CVD. Consistent benefit for sex, age and
ethnicity. Higher intensity had greater effects
than moderate intensity.

Thomas et al (2006)148

Good quality SR (n=14
Aerobic, fitness
RCTs) 377 participants with or PRT exercise
type 2 diabetes mellitus.
vs no exercise
Trials ranged from 8 weeks
to 12 months duration.

Exercise significantly improves glycaemic
control and reduces visceral adipose tissue
and plasma triglycerides, but not plasma
cholesterol, in people with type 2 diabetes
even without weight loss.

Light or
Woodcock et al (2010)140 Good quality SR (n=22
prospective cohort studies). moderate
977,925 people (334,738
physical activity
men and 643,187 women).
Included studies with
>10,000 general/healthy
people.

2.5 h/week moderate intensity activity risk
of mortality by19% (95% CI 15-24), while 7 hr/
week of moderate activity mortality risk by
24% (95% CI 19-29). Smaller effects found in
trials of walking alone.

CI: confidence interval, CHD: coronary heart disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure;
PRT: progressive resistive training; RCT: randomised controlled trial; SBP: systolic blood pressure; WMD: weighted mean difference.
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Evidence-based recommendation

Grade

Smoking
EBR 8: All smokers should be advised to stop smoking.

A14, 149

Practice point
Smoking
PP 10: All smokers should be offered advice about methods to aid smoking cessation, including counselling services, and
if assessed as nicotine dependent, nicotine replacement therapy or other appropriate pharmacotherapy should be used.

Another two case controlled studies involving 1,274
subjects and 3,372 controls indicated that smoking is
associated with an increased risk of MI156 and CHD-related
mortality,152 and a dose-response relationship exists
between the total tar consumption per day and risk. The
odds ratio for subjects smoking medium and high-tar-yield
compared with low-tar-yield cigarettes was 1.86 (95% CI
1.21–2.87) and 2.21 (85% CI 1.47–3.34), respectively.156
The INTERHEART study demonstrated the dose-response
relationship between number of cigarettes smoked and MI.13
People who smoked over 40 cigarettes per day were found
to have an almost 10-fold relative risk of MI compared with
non-smokers (OR 9.16, 99%CI 6.18–13.58).
Several Cochrane reviews have been undertaken related
to different therapies for smoking cessation. Nicotine
replacement therapy can increase smoking cessation by
50–70%.161 Some antidepressants, for example bupropion
and nortriptyline, but not selective serotonin reuptake
inhibitors, aid long-term smoking cessation.162 Varenicline,
a nicotine receptor partial agonist, leads to a two-fold
success rate compared with non drug quit attempts and
appears to be more beneficial than bupropion.163 Tailored
behavioural strategies via group or individual approach have
demonstrated modest effects for smoking cessation.164,
165
Strategies and support provided from a range of health
professionals including physicians, community pharmacists
or nurses are effective.166-168 Telephone counselling improved
smoking cessation rates particularly when three or more
call-backs were made.169 Other approaches using the

internet may also be useful where tailored information is
provided.170
Overall, the evidence shows a dose dependent relationship
between smoking and CVD events. A range of behavioural
and support interventions have been shown to improve
smoking cessation. Although there are several high-level
reviews for interventions for smoking cessation, the literature
was not systematically searched and hence the guidance is
included as a practice point.

2.1.4 Alcohol
Alcohol has a complex role in Australian society. Most
Australians drink alcohol, generally for enjoyment, relaxation
and sociability, and do so at levels that cause few adverse
effects. However, a substantial proportion of people drink
at levels that increase their risk of alcohol-related harm.171
As such, alcohol is known to have both beneficial and
harmful effects on the risk of cardiovascular events and the
psychological consequences of the disease.172 The 2007
National Drug Strategy Household Survey indicated that
approximately 10% of Australian adults have never had a
full serve of alcohol and about 17% have not consumed
alcohol in the past year.173 On the other hand, the number of
Australians who drink daily and weekly was approximately
8% and 14%, respectively. This section summarises the
evidence for alcohol consumption from systematic reviews
and individual trials considered for the primary prevention of
cardiovascular events.
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Several systematic reviews of observational studies have
consistently reported lower CVD mortality and CVD events
with light to modest alcohol consumption.174-178 The most
recent meta-analysis involving 84 observational studies
(>2 million participants) found reduced relative risks for
alcohol drinkers relative to non-drinkers for CVD mortality
(21 studies; RR 0.75, 95% CI 0.70–0.80), incident CHD (29
studies; RR 0.71, 95% CI 0.66 to 0.77), CHD mortality (31
studies; RR 0.75, 95% CI 0.68–0.81), incident stroke (17
studies; RR 0.98, 95% CI 0.91–1.06) and stroke mortality
(10 studies; RR 1.06, 95% CI 0.91–1.23).175 Dose-response
analysis revealed that the lowest risk of CHD mortality
occurred with 1–2 drinks a day, but for stroke mortality
it occurred with ≤1 drink per day. Secondary analysis of
all-cause mortality demonstrated lower risk for drinkers
compared with non-drinkers (RR 0.87, 95% CI 0.83–0.92).
Modest alcohol intake was found to lower stroke incidence
and mortality, but, unlike the risk for CHD, the risk of
all stroke subtypes increased significantly with heavier
drinking.175, 179 It is also noted that the association of alcohol
consumption differs by stroke subtype; there is a lower
risk of ischaemic stroke but increased risk of haemorrhagic
stroke.175 This is likely due to the fact that studies analysing
the effect of alcohol on BP reported linear BP elevations at
levels above 20 g/day for women and 30 g/day for men.174
A recent meta-analysis of 44 intervention studies (mix of
random and non random studies) found alcohol significantly
increased levels of HDL-C (pooled mean difference 0.094
mmol/L, 95% CI 0.064–0.123), apolipoprotein A1 (0.101
g/L, 95% CI 0.073–0.129) and adiponectin (0.56 mg/L,
95% CI 0.39–0.72). Alcohol decreased fibrinogen levels
(−0.20 g/L, 95% CI −0.29 to −0.11), but did not affect
triglyceride levels. Different study designs and beverage
types demonstrated consistent findings.175 These biomarker
studies provide indirect pathophysiological support for a
protective effect of moderate alcohol use on CHD.
It is important to note that studies reported here focus on
the link between alcohol intake and CVD only and do not
consider other known detrimental effects of high alcohol
consumption, including the risk of alcohol abuse. The
results of the most recent meta-analysis generally reinforce
the current national alcohol guidelines which recommend
consuming light to moderate amounts of alcohol to prevent
alcohol-related harm.171

People with atrial fibrillation
Among 34,715 healthy middle-aged women (>45 years and
free of AF at baseline) participating in the Women’s Health
Study, consumption of up to two alcoholic beverages per
day was not associated with an increased risk of incident
AF. Heavier consumption of two or more drinks per day,
however, was associated with a small but statistically
significant increased risk of AF (hazard ratio 1.60, 95% CI
1.13–2.25).180

People with raised blood pressure
A cohort of the Physicians’ Health Study assessed total
and CVD mortality among 14,125 men with raised BP who
had reported to be either non-drinkers or rare drinkers,
or light to moderate drinkers.181 During 75,710 personyears of follow-up, there were 1,018 deaths, including 579
from CVD. Compared with individuals who rarely or never
drank alcoholic beverages, those who reported monthly,
weekly and daily alcohol consumption, respectively, had
multivariate adjusted relative risks for CVD mortality of 0.83
(95% CI 0.62–1.13), 0.61 (95% CI 0.49–0.77) and 0.56
(95% CI 0.44–0.71) (p<0.001 for linear trend). In the same
groups, relative risks for total mortality were 0.86 (95% CI
0.67–1.10), 0.72 (95% CI 0.60–0.86) and 0.73 (95% CI
0.61–0.87), respectively (p<0.001 for linear trend). These
results, which require confirmation in other large-scale
studies, suggest that light to moderate alcohol consumption
is associated with a reduction in risk of total and CVDrelated mortality in hypertensive men.

People with diabetes
Two systematic reviews assessing the effect of alcohol use
on the incidence and complications of diabetes mellitus
in adults were identified. In the first, the risks of fatal and
total CHD were significantly lower in all three categories
of alcohol consumers (<6, 6 to <18 and ≥18 g/day) than
in non-consumers; relative risks ranged from 0.34 to
0.75.182 Similar results were reported in the second review:
compared with no alcohol use, moderate consumption (1–3
drinks/day) was associated with a 33–56% lower incidence
of diabetes and a 34–55% lower incidence of diabetesrelated CHD.183 It is clear from these reviews and those
noted above there is no difference in effect between those
with or without diabetes.

Practice point
Alcohol
PP 11: All adults should be advised to follow the current Australian guidelines to reduce health risks from drinking alcohol
(2009).
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2.1.5 Multiple lifestyle interventions
One Cochrane review184 and three trials185-187 using lifestyle
change interventions to improve cardiovascular outcomes
were located. In the Cochrane review, 55 trials using
education or counselling with or without pharmacotherapy
to reduce CVD risk factors were assessed.188 The trials were
all more than six months in duration using counselling or
education to modify more than one CVD risk factor in adults
from general populations, occupational groups or specific
risk factors (i.e. diabetes, hypertension, hyperlipidaemia,
obesity) and all involved people aged 40 years or older with
no evidence of CVD at baseline (trials with more than 25%
participants with prior CVD were excluded). The interventions
had some effect on risk factors, demonstrating reductions in
SBP (53 trials; WMD -2.71 mmHg, 95% CI -3.49 to -1.93),
DPB (53 trials; WMD -2.13 mmHg, 95% CI -2.67 to -1.58 )
and blood cholesterol (50 trials; WMD -0.24 mmol/L, 95% CI
-0.32 to -0.16). In general, lifestyle intervention was ineffective
for improving cardiovascular outcomes, including total
mortality and CHD mortality (OR 1.00, 95% CI 0.96-1.05 and
OR 0.99, 95% CI 0.92-1.07 respectively).

However, the interventions showed benefits in total mortality
and combined fatal and non-fatal cardiovascular events in
people with hypertension (16 trials) and diabetes (5 trials) (OR
0.78, 95% CI 0.68–0.89) and (OR 0.71, 95% CI 0.61–0.83),
respectively.
In several randomised controlled trials, intensive interventions
to address lifestyle factors were used,143, 145, 185, 186, 189-191
while in another, motivational interviewing based on an AR
profile was investigated.187 The group-based interventions
resulted in modest improvements in body weight, waist
circumference and BP, while motivational interviewing, used
in the latter study demonstrated a small difference compared
with controls in terms of 10-year Framingham risk profile.
In that study, the effects on individual risk factors (e.g., BP,
cholesterol and smoking) were generally modest where they
occurred at all.
Collectively, this evidence indicates that for the general
population, lifestyle interventions can modestly reduce the
levels of individual CVD risk factors, but have not been
consistently found to affect CVD outcomes. The reduction
in number of CVD events by multiple lifestyle interventions
appears to be related to the initial level of AR.

Practice point
General Lifestyle
PP 12: Adults at higher absolute risk of CVD should be given more frequent and sustained lifestyle advice, support and
follow-up to achieve behavioural change.

Table 4: General lifestyle advice

Lifestyle factor

Advice

Diet

Consume a varied diet rich in vegetables, fruits, wholegrain cereals, lean meat, poultry, fish,
eggs, nuts and seeds, legumes and beans, and low-fat dairy products

Fats

Limit foods containing saturated and trans fats

Salt

Limit salt to <6g/day (approximately 2300 mg sodium)

Alcohol

Limit alcohol intake to ≤2 standard drinks per day

Physical activity

At least 30 minutes physical activity on most or preferably every day of the week

Weight

Limit energy intake to maintain a healthy weight. Ideal weight should be BMI <25 kg/m2 and
waist circumference <94 cm in men (<90 cm in Asian men) or <80 cm in women (including
Asian women)

Smoking

Stop smoking using counselling, and if required nicotine replacement therapy or other
medication
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2.2 Pharmacotherapy
2.2.1 Blood pressure-lowering therapy
Blood pressure-lowering reduces CVD risk
BP lowering using pharmacotherapy results in reduction in
both total mortality and mortality from CHD and stroke.192,
193
However, questions remain about which drugs to use, at
what dose and whether BP should be reduced to a limited
extent only – a treat to target approach – or reduced as
far as possible. This section summarises the evidence for
lowering BP from systematic reviews and individual trials
considered for the primary prevention of cardiovascular
events.
Two large systematic reviews of BP-lowering drugs versus
placebo in people without a history of CVD demonstrate
that pharmacological lowering of BP reduces the incidence
of CHD events and strokes in the order of 20–25% and 30–
45%, respectively. The first review analysed the results from
147 randomised trials of BP-lowering drugs in preventing
CHD and stroke events.192 The preventive effect of BPlowering therapies in people without a history of CVD, and
those with and without high blood pressure was similar. For
people without a history of CVD, active treatment resulted in
a 10 mmHg reduction in SBP or 5 mmHg reduction in DBP,
and led to a relative risk of CHD events of 0.79 (95% CI
0.72-0.86) and for stroke of 0.54 (95% CI 0.45–0.65).
In the second review, a quantitative assessment of elevated
BP trials was performed to investigate to what extent
lowering of SBP and DBP contributed to prevention of
CVD.193 A total of 12,903 young (30–49 years of age)
people, 14,324 old (60–79 years of age) and 1,209 very
old (≥80 years of age) people were assessed. In the young,
old and very old, the median follow-up period was 5.0, 3.9
and 3.8 years, respectively, and active treatment reduced
SBP and DBP by a similar amount in each cohort. However,
with increasing age, the ratio of DBP to SBP lowering
significantly decreased from 0.55 (95% CI 0.46–0.64) in
the young to 0.39 (95% CI 0.29–0.49) and 0.32 (95% CI
0.01–0.63) in the old and very old, respectively (p=0.004).
Despite this, active treatment reduced all cardiovascular
events and the risk of stroke and CHD events to a similar
extent in all three age strata. In addition, active treatment
reduced total mortality by 17% (95% CI 6–26; p=0.003) and
cardiovascular mortality by 21% (95% CI 7–33; p=0.004) in
old people. This was not the case in the young and very old
groups (p≥0.28), although this result was expected given
the relatively short period of follow-up in young people and
long period in the very elderly.
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The HYVET trial examined the effects of a diuretic on people
aged 80 or over with raised BP. This randomised trial found
that treatment with a diuretic reduced the relative risk of
fatal and non-fatal stroke, but not significantly (hazard
ratio 0.70, 95% CI 0.49–01.01, p=0.06). The same study
demonstrated significant reductions in all cause mortality
(hazard ratio 0.79, 95% CI 0.65–0.95, p=0.02) and CVD
events (hazard ratio 0.79, 95% CI 0.69–0.90, p=0.0004).194
Collectively, these data demonstrate that active treatment
with BP-lowering therapies improves cardiovascular
outcomes.

People with diabetes
In people with type 2 diabetes, BP-lowering therapy
reduces CVD risk to an equal or greater extent than for the
population without diabetes.192, 195

People with CKD
There is a growing body of evidence to suggest that people
with CKD receive the same or similar benefits from BPlowering therapy as those in the general population. Other
evidence shows benefits of BP lowering in this population
for cardiovascular events but not mortality.196 Much less
evidence is available for people on maintenance dialysis;
however, the available evidence suggests that treatment
using agents that lower BP reduces cardiovascular
morbidity and mortality.197 Treatment for BP lowering in
people on dialysis is highly complex and specialist advice
and management is usually required. While more studies
are required, the possible risks and benefits of BP lowering
should be considered for all people receiving dialysis.

Other considerations
The benefits of BP lowering using an AR approach have
not been assessed. Meta-analysis clearly demonstrates
reductions of CVD risk from lowering BP, which is consistent
across all subgroups.
Is it also noted that BP lowering reduces important nonCVD related conditions such as heart failure, glaucoma and
diabetic and non-diabetic nephropathy.47, 192

Table 5: Effect of blood pressure-lowering on CVD outcomes: summary of key evidence

Reference

Study details

Intervention

Results

BP Lowering
Treatment Trialists’
Collaboration;
Turnbull et al
(2008)198

Good quality SR (n=31
RCTs); 190,606 participants.
Compared age groups <65
and above 65. Mixed primary
and secondary prevention.

Comparison of BPlowering regimens
against placebo
or less intensive
control

No difference in reductions in major CV events
between age groups for any comparison.
For each 5mmHg SBP, risk of CVD events
11.9% (5.3-18%) for those aged <65 and
9.1% (3.6-14.3%) for those aged ≥65.

Law et al (2009)192

Good quality SR (n=147
RCTs); 464,000 participants.
26 RCTs specifically with no
history of CVD.

All BP lowering
medications
vs placebo or other
class of drug

For a reduction of 10mmHg SBP or 5mmHg
DBP: CHD events (RR 0.79, 95% CI 0.720.86), stroke (RR 0.54, 95% CI 0.45-0.65).
Preventative effect similar in people with
and without history of CVD. Effect is similar
for all classes of blood pressure-lowering
drugs (although CCBs slightly more effective
for stroke prevention and BBs slightly less
effective). CCBs heart failure by 19%
whereas for other classes 24%. Consistent
RR for CHD (0.84) and stroke (0.70)
irrespective of initial BP.

Wang et al (2005)193 Good quality SR (n=10 RCTs).
12,903 young (30-49 yrs
old) from 3 trials; 14,324 old
(60-79 yrs) and 1209 very old
(≥=80 yrs old) from 8 trials.
Limited to trials with available
individual data. Combined
primary and secondary trials.

All BP lowering
medications vs
placebo or no
treatment

BP in young (8.3/4.6 mmHg), old (10.7/4.2
mmHg) and very old (9.4/3.2 mmHg). 17%
all-cause mortality (p=0.003) and 21% CVD
morality (p=0.004) in those 60-79 but not in
the younger or older groups. No difference in
CVD events for different ages but absolute
benefit with increasing age. Effects related to
SBP rather than DBP.

Wright et al
(2009)199

All BP lowering
medications
vs placebo or other
class of drug

Low-dose thiazides in mortality (RR 0.89,
95% CI 0.83-0.96) and CV events (RR
0.70, 95% CI 0.64-0.76). BBs CV events
(RR 0.89 95% CI 0.8-0.98) but not CHD or
mortality. ACEi mortality (RR 0.83, 95%CI
0.72-0.95) and CV events (RR 0.76, 95% CI
0.67-0.85). CBBs CV events (RR 0.71, 95%
CI 0.57 to 0.87) but not CHD or mortality.
Moderate to high BP in primary prevention
ARR 3.7-5.1 (NNT for 5 years 20-27); Mild BP
in primary prevention ARR 0.75-0.82 (NNT
120); secondary prevention ARR 5.5 (NNT
18).

Good quality SR (n=24 RCTs;
28 arms). 58,040 people,
42,196 (72.7%) were primary
prevention. Included trials
had >70% of people with BP
>140/90 mmHg at baseline
and were for >1year duration.

ACEi: ACE inhibitor; ARR: absolute risk reduction; BB: beta blocker; BP: blood pressure; CCB: calcium channel blocker; CI:
confidence interval; CHD: coronary heart disease; CV: cardiovascular; CVD: cardiovascular disease; DBP: diastolic blood pressure; MI:
myocardial infarction; NNT: number needed to treat; RCTs: randomised controlled trials; RR: relative risk; SBP: systolic blood pressure.
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2.2.2 Lipid-lowering therapy
Lipid-lowering reduces CVD risk
High plasma cholesterol is a well-known, modifiable
risk factor for CVD. A 10% increase in TC is associated
with a 27% increase in the incidence of CHD,200 and the
relationship persists, irrespective of smoking status, the
presence or absence of elevated BP, or a history with or
without vascular disease.19, 201-203 Lipid lowering therefore
plays an important role in the prevention of cardiovascular
events.
Most of the cholesterol in blood plasma is carried by LDL-C
and the strong relationship between TC and CVD suggests
that LDL-C is a powerful risk factor.204 Moreover, the results
of epidemiological studies, as well as trials with clinical
endpoints, confirm that a reduction in LDL-C must be of
primary concern in the prevention of CVD.205 This section
summarises the evidence for lowering blood lipids from
systematic reviews and meta-analyses considered for the
primary prevention of cardiovascular events.
The preponderance of evidence suggests that, compared
with placebo, statins reduce the risk of death or
cardiovascular events in populations without a history of
CVD, irrespective of age and gender and across a wide
range of cholesterol levels (see Table 6).206-212 One metaanalysis of 14 trials found all-cause mortality was reduced
by statins (RR 0.83, 95% CI 0.73–0.95) as were combined
fatal and non-fatal CVD events (RR 0.70, 95% CI 0.61–
0.79). Combined fatal and non-fatal stroke events were
reduced (RR 0.78, 95% CI 0.65–0.94) as were combined
fatal and non-fatal CHD events (RR 0.72, 95% CI 0.65–
0.79). There was no clear evidence of any significant harm
caused by statins or effects on patient quality of life.208
Another meta-analysis of 26 trials (mixed primary and
secondary prevention) focusing on the comparison of
high and low doses of statins, reported a strong benefit
of statin use, with a reduction in major vascular events in
people without previous CVD (RR 0.75, 95% CI 0.69–0.82
per 1 mmol/L reduction in LDL-C) and a 0.4% lower risk
difference per year in those taking statins.209 This result
is similar to the approximately 20% reductions found in
those with existing CVD (across all subgroups). The data
confirmed an approximate linear relationship between
LDL-C reduction and relative risk reduction of CVD events,
independent of presenting levels, and that more intensive
treatment can further lower the risks.
Similar benefits were observed in another meta-analysis of
10 trials, 94% of whom were in people without established
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CVD but with CVD risk factors.206 During a mean follow-up
of 4.1 years, statin therapy significantly reduced the risk
of all-cause mortality (OR 0.88, 95% CI 0.81–0.96), major
coronary events (OR 0.70, 95% CI 0.61 to 0.81) and major
stroke events (OR 0.81, 95% CI 0.71–0.93). There was
no increased risk of cancer and the effects were similar in
various clinical subgroups.
In contrast, two smaller meta-analyses showed trends
towards decreased all-cause mortality that just failed to
reach statistical significance. These include a recent metaanalysis of 11 trials specifically excluding those with preexisting CVD (RR 0.93, 95% CI 0.86–1.00).207 No individual
or composite CVD endpoints were considered as part of
this review although there was a 1 mmol/L mean difference
in LDL-C levels overall between the intervention and control
groups after an average of 3.7 years of statin treatment
(2.4 mmol/L on statin therapy vs. 3.5 mmol/L in control
group; compared with 3.6 mmol/L at baseline). Finally, a
slightly older meta-analysis based on only two trials found
that statins were associated with a statistically significant
reduction in the risk of non-fatal MI (RR 0.60, 95% CI 0.37
to 0.97) and of CHD death plus non-fatal MI (RR 0.66, 95%
CI 0.46–0.96), but not all-cause mortality (RR 0.73, 95% CI
0.53–1.01) or CVD mortality (RR 0.67, 95% 0.40–1.10).211
Three recent stroke specific primary prevention metaanalyses of those at high risk of CVD (all of which involved
trials that included people with other CVD events at
baseline) also confirm the risk reduction offered by statin
therapy is in the order of 20% due primarily to the reduction
in ischaemic stroke and other CVD events without
any significant decrease or increase in haemorrhagic
stroke.213-215
Although similar overall, variations in results from the five
most recent meta-analyses highlight the differences in the
inclusion criteria (particularly the percentage of participants
found to have existing CVD), review dates, outcomes
chosen (individual versus composite endpoints), early
termination of some included trials, and data analysis and
reporting.
Collectively, the evidence confirms that there is a
continuous, graded, strong relationship between serum
cholesterol and risk for major cardiovascular events.208,
209
Statin trials consistently found significant reductions in
TC (net difference -0.89 mmol/L, 95% CI -1.20 to -0.57
mmol/L) and LDL-C (net difference -0.92 mmol/L, 95%
CI -1.10 to -0.74 mmol/L).208 The effect of statin therapy
appears to be related primarily to LDL-C reductions, which
is confirmed in the recent meta-analysis of 26 trials that
found a 25% relative reduction in CVD events for those

without CVD at baseline for each 1.0 mmol/L decrease in
LDL-C.209
The benefit of statin therapy is greatest for individuals at
higher levels of risk.208 Of all the methods to modify lipids,
the weight of evidence suggests that statins are the most
effective agents and should be the first-line agent to reduce
lipids.208, 209, 216-219
Other than statins, lipid-lowering pharmacotherapy includes
fibrates, bile acid binding resins), niacin (nicotinic acid) and
selective cholesterol absorption inhibitors (e.g. ezetimibe).
Fibrates effectively lower triglycerides and increase HDL-C.
However, they lower TC and LDL-C much less than
statins.216, 219 A meta-analysis of 10 long-term, placebo
controlled trials (two trials were exclusively primary
prevention and two further trials were mixed) found on
average fibrates reduced TC by 8% and plasma triglyceride
levels by 30% and increased HDL-C levels by 9%. LDL-C
was also reduced by 7% although most individual trials
reported no statistically significant changes in LDL-C
levels.220 There were no significant differences in the efficacy
of the various fibrates in reducing triglyceride or increasing
HDL-C levels. The use of fibrates significantly reduced the
occurrence of non-fatal MI (OR 0.78, 95% CI 0.71–0.86) but
had no significant effect on CVD or all-cause mortality, fatal
MI or stroke – all of which have been found in other metaanalyses to be significantly reduced by statins.
Another recent meta-analysis of 18 trials (four primary
prevention trials, three mixed primary and secondary trials,
and 11 secondary prevention trials) found overall benefit of
fibrates for the prevention of major CVD events (RR 0.90,
95% CI 0.82–1·00; p=0.048) primarily due to reduction in
coronary disease (RR 0·87, 95% CI 0.81–0.93; p<0·0001)
with no effect on stroke (RR 1.03, 95% CI 0.91–1.16), CVD
mortality (RR 0.97, 95% CI 0.88–1.07) or all-cause mortality
(RR 1.00, 95% CI 0.93–1.08).221 Fibrates significantly
reduced the risk of retinopathy (RR 0·63, 95% CI 0.49–0.81)
and progression of albuminuria (RR 0.86, 95% CI 0.75–
0.98). There was no significant increase in the risk of serious
adverse events (RR 1.21, 95% CI 0.91–1.61; p=0.19). The
only data reported for the four primary prevention trials
found a significant reduction in coronary events (RR 0.75,
95% CI 0.58–0.97). One further meta-analysis specific to
those with diabetes also found a significant reduction in
non-fatal coronary events (RR 0.84, 95% CI 0.74–0.96)
but no effect on stroke or mortality outcomes.222 The
number needed to treat (NNT) to prevent one CHD event
over 10 years was 26 for those without pre-existing CHD.
In general, fibrates are easy to use. However, particular
care should be taken when co-administering statins with
gemfibrozil due to the possible increased risk of myopathy.

One trial of the bile acid resin cholestyramine monotherapy
reported from the mid 1980s found a significant 19%
reduction in risk of CHD death and/or nonfatal myocardial
infarction, but an increase in side effects (mainly
gastrointestinal irritation).223
Ezetimibe is a relatively new agent that inhibits cholesterol
absorption from the small intestine. Two meta-analyses
(both with mixed primary and secondary prevention trials)
were consistent in their findings that a combination of
ezetimibe plus statin significantly reduced LDL-C and
TC compared with statin alone.224 Patients on ezetimibe/
statin relative to those on placebo/statin were more likely to
reach the LDL‑C treatment goal (RR 3.4, 95% CI 2.0–5.6;
p<0.0001).224 Monotherapy with ezetimibe, for patients
where a statin was not considered appropriate, also
significantly reduced LDL-C levels compared with placebo
(p<0.00001) but the reductions were smaller than that
demonstrated for statins.225
During the finalisation of this Guideline, the landmark
SHARP trial reported that in a population of 9,270 with CKD
(15% with history of vascular disease i.e. angina, stroke or
peripheral vascular disease), a combination of ezetimibe
10 mg plus simvastatin 20 mg daily reduced LDL-C by
an average of 0.85 mmol/L (SE 0.02; approximately 66%
compliance, median follow-up of 4.9 years).226 There was
a 17% reduction in major atherosclerotic events (non-fatal
MI or coronary death, non-haemorrhagic stroke or any
arterial revascularisation procedure) with combined therapy
compared with placebo (RR 0.83, 95% CI 0.74–0.94) with
no evidence of adverse effects.
Nicotinic acid, or niacin, has been found to reduce
cholesterol. One meta-analysis of 30 trials (in mixed primary
and secondary populations) found niacin significantly
reduced TC (10%), increased net HDL-C (16%), reduced
LDL-C (12%) and reduced triglycerides (20%).227 Similar
results were found in another meta-analysis which included
seven trials of niacin (all secondary prevention) which found
a 17% reduction in non HDL-C and a 17% reduction in
CHD risk, over 6.2 years although there was significant
heterogeneity among the mostly small trials and most
used combination therapy (mainly with statins).218 Only
one main outcome trial in those with existing MI reported
significant reduction in events by 14% with no change in
mortality although the eight-year follow up of this trial found
significantly reduced mortality with niacin monotherapy.228,
No outcome trials for niacin were found in those without
existing CVD.

229

Omega 3 fatty acid (fish based rather than plant based)
has been found to significantly reduce levels of triglycerides
and increase levels of HDL-C but has not been found
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to reduce TC or LDL-C.230, 231 While observational data
suggest a reduction in CVD events with n-3 fatty acids
(refer to section 2.1.1) only one major outcomes trial has
been published. The JELIS trial involved 18,645 Japanese
people with TC >6.5mmol/L (26% of participants had a prior
history of MI, angina or revascularisation therapy). Fish oil
supplementation (1,800 mg/day) was given in addition to
regular statin therapy. After a mean follow-up of 4.6 years
there was a significant reduction in major coronary events
(OR 0.81, 95% CI 0.69–0.95), but this benefit was not
statistically significant in the primary prevention subgroup
(OR 0.82, 95% CI 0.63–1.06).232
An important result of the studies reported here is that the
benefits of lipid-lowering therapy depend on initial levels of
risk: the absolute reductions in risk were highest in people
at the highest baseline risk irrespective of initial lipid levels.
The decision to treat people at moderate levels of risk with
lipid-lowering pharmacotherapy is more complex and can
be determined by responsiveness to lifestyle interventions,
taking into consideration other risk factors not included in
the FRE.

Other considerations
In clinical practice, it is important to consider and exclude
treatable causes for dyslipidaemia before starting treatment,
since often the treatment of underlying disease improves
dyslipidaemia and no other lipid-lowering therapy is
necessary. Causes of dyslipidaemia may include diet and
alcohol influences, hypothyroidism, diabetes, liver disease,
nephrotic syndrome and steroid treatment.
A family history of premature CVD and/or central adiposity
should also be considered as both these factors increase
overall risk, independently of traditional risk factors.233, 234
A family history of premature CVD refers to an event that
occurs in relatives including parents, grandparents, uncles
and/or aunts before the age of 55 years.

Table 6: Effect of lipid-lowering on CVD outcomes: summary of key evidence
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Reference

Study details

Intervention

Results

Allerman et al
(2006)222

Good quality SR (8 RCTs).
12,249 participants with type
2 diabetes +/- CVD (78%
were primary prevention)

Fibrates vs placebo

CHD events (RR 0.84, 95% CI 0.74–0.96).
No effect on death due to CHD, MI or stroke.
No difference between primary and secondary
prevention trials.

Amarenco et al
(2009)213

Good quality SR (n=26 RCTs). Statins vs placebo
165,792 participants. Mix of
primary and secondary
prevention.

Each 1.0 mmol/L decrease in LDL-C equates
to a reduction in relative risk for stroke of
21.1% (95% CI 6.3–33.5, p=0.009).

Ara et al (2008)225

Good quality SR (n=13 RCTs).
No clinical outcome studies of
>12 weeks found so included
studies using surrogate
outcomes.

Ezetimibe monotherapy significantly  LDL-C
levels compared with placebo (p<0.00001).
Ezetimibe and statin significant LDL-C and
TC compared with statin alone (p<0.00001).

Brugts et al
(2009)206

Good quality SR (n=10 RCTs). Statins vs placebo
70,388 participants. Inclusion control or usual care
of trials if >80% without CVD
or reported primary prevention
data separately. Mean followup at least 1 yr.

all-cause mortality (OR 0.88, 95% CI 0.810.96), major coronary events (OR 0.70, 95%
CI 0.61-0.81), major strokes (OR 0.81, 95%
CI 0.71-0.93).

Cholesterol
Treatment Trialists’
Collaboration;
Baigent et al
(2010)209

Moderate quality SR (n=21
RCTs of statins vs control).
129,526 subjects; 54%
(70,025) without prior CVD.

25% in major vascular events in those
without CVD at baseline per 1.0 mmol/L
reduction in LDL cholesterol (1.4% vs 1.8%
per year; RR 0.75, 95% CI 0.69−0.82).

Ezetimibe alone or
+ statin vs statin
alone, placebo or
other

Statins vs placebo

Reference

Study details

Intervention

Results

Corvol et al
(2003)216

Moderate quality SR (n=38
All lipid-lowering
RCTs). 10 primary, 28
therapies
secondary prevention studies.
83,161 subjects, mean followup of 4.7 years

Lipid-lowering therapies overall stroke by
approx. 17%, with the most convincing effects
from statins (RRR 26%). 22% of MI. NNT
overall stroke =735, MI=93. No difference
between primary and secondary trials.

Delahoy et al
(2009)212

Good quality SR (n=25
Statins vs placebo
RCTs; 8 identified as
primary prevention and 2
mixed primary/secondary
prevention). Total 155,613
subjects. Mean follow-up of at
least 1 year.

Meta regression analysis for every 25 mg/dL
(0.65-mmol/L) reduction in LDL-C: vascular
mortality (RR 0.89, 95% CI 0.87-0.92);
major CV events (RR 0.86, 95% CI 0.840.88); major coronary events (RR 0.84, 95%
CI 0.82-0.86); and stroke (RR 0.90, 95%
CI 0.86-0.94). No difference between primary
and secondary trials reported (no data given)

Henyan et al
(2007)214

Good quality SR (n=37
RCTs). Mixture of primary and
secondary CVD prevention
(focus on prevention of
stroke). 100,560 participants,
mostly white males with a
history of hyperlipidaemia.

Statins vs placebo

CV events (RR 0.83, 95% CI 0.76-0.91),
ischaemic stroke (RR 0.79, 95% CI 0.630.99), no effect on haemorrhagic stroke (RR
1.11, 95% CI 0.77-1.60)

Jun et al (2010)221

Good quality SR (n=18 RCTs)
Primary (n=4), secondary
(n=11) studies and 3 were
mixed. 45,058 participants
mean age 46–68 years, mean
follow-up 2.7–8.8 yrs.

Fibrates vs
placebo

Primary prevention only: coronary events (RR
0.75, 95% CI 0.58–0.97).
Combined data: major CVD events (RR 0.90,
95% CI 0.82–1.00; p=0.048), CHD (RR
0.87, 95% CI 0.81–0.93), stroke (RR 1.03,
95% CI 0.91–1.16), CVD mortality (RR 0.97,
95% CI 0.88–1.07) or all-cause mortality (RR
1.00, 95% CI 0.93–1.08).

Mikhailidis et al
(2007)224

Good quality SR (n=5 RCTs).
5,039 adults with
hypercholesterolaemia who
have failed to reach goals
on statin alone. Minimum
treatment duration of 6
weeks. 3/5 trials included
those with CHD.

Ezetimibe + statin vs Ezetimibe co-administered with ongoing statin
placebo + statin +/- therapy provides significant additional lipida fibrate
lowering in patients not at LDL-C target on
statin therapy alone, allowing more patients to
reach their LDL-C target (RR 3.4, 95% CI 2.05.6; p<0.0001). Consistent results in those
with and without CHD.

Navaneethan et al
(2009)235

Good quality SR (n=26 RCT
Statins
and quasi RCTs). 25,017 CKD vs placebo
patients not requiring dialysis
but +/- CVD.

all-cause mortality (RR 0.81, 95% CI 0.740.89) and CV mortality (RR 0.80, 95% CI
0.70-0.90). Statins decreased 24-hour urinary
protein excretion but didn’t seem to change
renal function (creatinine clearance). No
difference in adverse effects.

O’Regan et al
(2008)215

Good quality SR (n=42 RCTs;
14 RCTs with no prior stroke
or <10% CHD); 24 RCTs
with either all stroke or CHD.
Others mixed populations.
121,000 participants.

Statins vs
placebo or usual
care

all-cause mortality (RR 0.88, 95% CI
0.83–0.93), combined stroke (RR 0.84, 95%
CI 0.79–0.91) –due to in ischaemic stroke
without difference in haemorrhagic stroke or
fatal stroke. CVD mortality (RR 0.81, 95% CI
0.74-0.90)

Ray et al (2010)207

Good quality SR (n=11 RCTs)
65,229 participants without
CVD. Mean follow-up ranged
from 2.2–4.9 years

Statins vs
placebo

Non-significant all-cause mortality (RR 0.91;
95% CI 0.83–1.01).
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Reference

Study details

Intervention

Results

Robinson et al
(2009)218

Moderate quality SR (n=23
RCTs); 132,021 participants.
Mixed primary and secondary
prevention. 14 statin trials, 7
fibrate trials, 6 niacin trials,
and 1 trial each of bile acid
sequestrant, diet, and ileal
bypass surgery.

All lipid-lowering
therapies

The relationship between non–HDL-C
lowering and CHD risk reduction is similar
for statins and fibrates (only one fibrate
trial). Most lipid-modifying drugs used as
monotherapy appear to have an approx. 1:1
relationship between percent non–HDL-C
lowering and CHD reduction.

Saha et al (2007)220

Good quality SR (n=10 RCTs)
36,489 participants. 2
trials completely primary
prevention, and 2 others
partly. Mean duration of
follow-up ≥1 year

Fibrates vs placebo

No significant benefit on mortality, fatal MI, or
stroke. non-fatal MI (OR 0.78, 95% CI 0.71–
0.86) in patients with non-LDL dyslipidaemia
to a comparable extent with that seen with
statins in patients with high LDL-C levels.

Studer et al
(2005)219

Good quality SR (n=97
RCTs) Follow-up of at least
6 months. For primary
prevention only (<10% CHD
at baseline): 9 statin RCTs; 3
fibrate RCTs; 1 resin RCT; no
niacin RCT; 1 small RCT of
n-3 fatty acid; 5 diet RCTs.

All lipid-lowering
therapies

Statins: all cause mortality (RR 0.86, 95% CI
0.76-0.99)
Fibrates: all cause mortality (RR 1.25, 95%
CI 1.05-1.48)
Resins: no difference in all cause mortality
n-3 fatty acids: no difference in all cause
mortality
Diet: no difference in all cause mortality

Taylor et al (2011)208 Good quality SR (n=14 RCTs). Statins vs placebo
34,272 participants. Trials of
minimum duration of one year,
>6 months follow-up, <10%
pre-existing CVD.

all-cause mortality (RR 0.83, 95% CI
0.73–0.95), CVD events (RR 0.70, 95%
CI 0.61–0.79), combined fatal and nonfatal stroke (RR 0.78, 95% CI 0.65–0.94),
combined fatal and non-fatal CHD events
(RR 0.72, 95% CI 0.65–0.79). No difference in
harms.

Thavendiranathan
et al (2006)210

Good quality SR (n=7 RCTs).
42,848 participants; 90% had
no history of CVD (inclusion
of >80% without CVD); Mean
follow-up 4.3 years.

Statins vs placebo,
active control, or
usual care

major coronary (RR 0.71; 95% CI 0.60–
0.83) and cerebrovascular events (RR 0.86;
95% CI 0.75–0.97), but not CHD disease
mortality (RR 0.77; 95% CI 0.56–1.08) or
overall mortality (RR 0.92; 95% CI 0.84–1.01).

Ward et al (2007)211

Good quality SR (n=31 RCTs)
Adults with, or at risk of, CHD
(2 RCTs specifically without
CVD, multiple trials with or
without CVD)

Statins vs placebo

Overall: all-cause mortality (RR 0.84; 95%
CI 0.78-0.90), CHD mortality (RR 0.77; 95%
CI 0.72-0.83) and fatal MI (RR 0.55; 95% CI
0.45-0.67).
Two exclusively primary prevention studies:
non-fatal MI (RR 0.60, 95% CI 0.37- 0.97)
and CHD death plus non-fatal MI (RR
0.66, 95% CI 0.0.46–0.96), but not all-cause
mortality (RR 0.73, 95% CI 0.53–1.01) or CVD
mortality (RR 0.67, 95% 0.40–1.10).

Zhou et al (2006)236

Good quality SR (n=8 RCTs;
4 pravastatin trials (25,572
participants), 2 simvastatin
trials (24,980 participants),
and 2 atorvastatin trials
(13,143 participants). % of
those with existing CVD not
specified. Minimum follow-up
of 1 year.

Statins vs placebo

Pravastatin, simvastatin, and atorvastatin,
when used at their standard dosages, show
no statistically significant difference in their
effect on long-term cardiovascular prevention.

CHD: coronary heart disease; CI: confidence interval; LDL-C: low density lipoprotein cholesterol; MI: myocardial infarction; NA: not
available; OR: odds ratio; RCTs: randomised control trials; RR: relative risk; RRR: relative risk reduction; SR: systematic review; TC: total
cholesterol.
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2.2.3 Antiplatelet therapy
Aspirin is of limited benefit when risks/benefits
are considered
For people with established CVD the benefit to risk profile
of long-term aspirin for reducing the risk of MI, stroke and
vascular death is well established.237-240 However, the role
of aspirin in primary prevention is less clear. This section
summarises the evidence for antiplatelet agents from
systematic reviews and individual trials considered for the
primary prevention of cardiovascular events and does not
consider other reported effects for aspirin such as cancer.241
Evidence from three meta-analyses239, 242, 243 indicates that
aspirin does not affect all-cause or CVD-related mortality,
but does have a small benefit for the reduction of nonfatal vascular events (e.g., MI or stroke) – a benefit driven
largely by a reduction in non-fatal MI among men. In the
most recent meta-analysis by the Antiplatelet Trialists’
Collaboration, based on six primary prevention trials, aspirin
(at doses of 75–100 g/day) reduced the relative risk of
serious vascular events by approximately 12% (ARR 0.51%
aspirin vs. 0.57% control per year, p=0.0001); a result driven
largely by a 23% relative reduction in non-fatal MI (0.18% vs.
0.23% per year, p<0.0001).239 All-cause mortality and stroke
incidence were not shown to be affected, and the reduction
in non-fatal MI was statistically significant in men, but not in
women. Conversely, for ischaemic stroke, the proportional
risk reduction was greater in women than in men, although
that result was not statistically significant. Aspirin increased
the relative risk for gastrointestinal and extracranial bleeds
by 54% (AR 0.10% vs 0.07% per year, p<0·0001).
These results concur with another good-quality metaanalysis where a review of the same six primary prevention
trials involving 51,342 women and 44,114 men, showed
that low-dose aspirin (50–500 mg daily) was associated
with a 12% and 14% reduction in the relative risk of
cardiovascular events (non-fatal MI, non-fatal stroke and
cardiovascular mortality) in men and women, respectively,
but with an approximate 70% increase in the risk of major
bleeding events.242 For women, there was a significant
reduction in the likelihood of stroke (mainly ischaemic stroke)
whereas in men, no significant effect was observed on all
strokes; however, a significant 32% reduction in the relative
risk of MI was observed.
Based on the absolute benefits and risks observed in this
analysis242 (absolute benefit: 0.30% and 0.37%; AR 0.25%
and 0.33%, for women and men, respectively), aspirin
therapy for an average of 6.4 years prevents approximately
three cardiovascular events per 1,000 women and results
in 2.5 major bleeding events. In 1,000 men treated for the

same period, aspirin prevents four cardiovascular events
and results in three major bleeding events.242 There was no
evidence that higher doses of aspirin are more effective in
reducing the risk of cardiovascular events. It is questionable
whether the additional resources required to treat such a
large number of people to prevent a small number of events
is justified. In addition, any effect of aspirin on cardiovascular
events needs to be balanced against the potential for harm.
In one subsequent study, the benefits of once-daily aspirin
(100 mg) or placebo in 3,350 patients without clinical CVD,
identified with a low ankle brachial index (ABI, ≤0.95) were
assessed.244 After a mean follow-up of 8.2 ± 1.6 years, no
statistically significant difference was found between groups
for the primary endpoint of a composite of fatal or non-fatal
coronary events or stroke or revascularisation (13.7 events
per 1,000 person-years in the aspirin group vs 13.3 in the
placebo group; hazard ratio, 1.03; 95% CI 0.84–1.27).
Furthermore, the combined secondary endpoint (composite
of the primary endpoint or angina, intermittent claudication
or TIA) also failed to show statistical significance (22.8
events per 1,000 person-years in the aspirin group vs 22.9
in the placebo group; hazard ratio, 1.00; 95% CI 0.85–1.17).
Major haemorrhage requiring admission to hospital occurred
in 34 participants in the aspirin group and 20 in the placebo
group (hazard ratio, 1.71; 95% CI 0.99–2.97). Although
the study was underpowered to identify a potentially small
beneficial effect of aspirin, given the large NNT to benefit
as identified in the analysis above, questions remain of the
usefulness of routine aspirin for preventing CVD.
Studies modelling the potential benefits and harms of
aspirin on 5- and 10-year risk of CVD are conflicting. In the
Antiplatelet Trialists’ Collaboration review, the proportional
reduction did not differ significantly between individuals
with predicted 5-year risk of CHD less than 2.5%, 2.5–5%,
5–10%, or 10% or more; although statistical analysis in the
highest risk group was limited by small participant numbers.
In that meta-analysis, the majority of people were not taking
statin therapy. When the risk was assumed to be halved
by other drugs first (e.g. statin and BP lowering), then the
further absolute benefit of adding aspirin was found to be
only half as large as was suggested by the trials, but the
main bleeding hazards would remain. In that case, the
benefits and hazards of adding long-term aspirin in people
without pre-existing disease were found to be approximately
equivalent.239
Other modelling based on older meta-analysis data, found
that a risk of CHD of ≥15% over 10 years was the point
where benefit was greater than harm for people without
existing CVD.245 Recently, another study modelling by risk
category and age group found benefits were greater than
harms in those with cardiovascular risk >15% up to the age
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of 80 years; however, for men 70–79 years, consideration of
lipid and blood pressure-lowering therapies was suggested
first before reassessment of whether aspirin added
additional net benefit.246 It is important to consider that
there is significant overlap between the major risk factors
for CVD events which might be prevented with aspirin and
risk factors for bleeding with treatment. Given the various
assumptions in all models and small absolute benefits but
increased risk of harm with aspirin, a conservative approach
to the use of aspirin is suggested for prevention of CVD.

Table 7: Effect of aspirin on CVD outcomes: summary of key evidence

Reference

Study details

Intervention

Results

Antithrombotic
Trialists’ (ATT)
Collaboration;
Baigent et al
(2009)239

Good quality SR (n=22
RCTs). Included six
primary prevention trials,
95,456 participants.

Aspirin vs placebo

12% CV events (0.51% aspirin vs. 0.57% control per
year, p=0.0001), non-fatal MI (0.18% vs. 0.23% per
year, p<0.0001), no effect on vascular mortality (0.19%
vs 0.19% per year, p=0.7). Risk of CV events in those
with diabetes (RR 0.88, 95% CI 0.67–1.15). major
GI and extracranial bleeds (0.10% vs. 0.07% per year,
p<0.0001). No difference in those at low, moderate and
high risk.

Berger et al
(2006)242

Good quality SR (n=6
RCTs –same as above).
51,342 women and
44,114 men.

Aspirin vs placebo

CV events (OR 0.88, 95% CI, 0.79 to 0.99). No effect
on MI or CV mortality. In men, 32% MI (OR 0.68, 95%
CI 0.54–0.86). In women, 24% ischaemic stroke (OR
0.76,; 95% CI 0.63–0.93). Aspirin risk of bleeding in
both men and women.

Calvin et al
(2009)243

Good quality SR
(n=8 RCTs). 89,392
participants without
CVD; 11,634 with
diabetes.

Aspirin vs placebo

Overall mortality (OR 0.93, 95% CI 0.85–1.03), MI (OR
0.79, 95% CI 0.66–0.95), and ischaemic stroke (OR 0.73,
95% CI 0.43–1.22). For those with diabetes: MI (RR 0.86,
95% CI 0.67–1.11), ischaemic stroke (RR 0.62, 95% CI
0.31–1.24).

De Berardis et
al (2009)247

Good quality SR (n=6
RCTs). 10,117 diabetic
participants without
CVD.

Aspirin vs placebo

Major CV events (RR 0.90, 95% CI 0.81-1.00), CV
mortality (RR 0.94, 95% CI 0.72-1.23), all-cause mortality
(RR 0.93, 95% CI 0.82-1.05), MI (RR 0.86, 95% CI
0.61–1.21), stroke (RR 0.83, 95% CI 0.60–1.14). risk
of MI in men (RR 0.57, 95% CI 0.34- 0.94). No effect for
stroke for men or women.

Pignone et al
(2010)249

Moderate quality SR
(n=9 RCTs). 11,787
diabetic participants
without CVD.

Aspirin vs placebo

CHD events (RR 0.91, 95% CI 0.79 –1.05), Strokes (RR
0.85, 95% CI 0.66 –1.11).

Zhang et al
(2010)248

Moderate quality SR
(n=7 RCTs). 11,618
diabetic participants
without CVD.

Aspirin vs placebo

Major CV events (RR 0.92, 95% CI 0.83–1.02), all-cause
mortality (RR 0.95, 95% CI 0.85–1.06), CV mortality
(RR 0.95, 95% CI 0.71–1.27), stroke (RR 0.83, 95% CI
0.63–1.10), MI (RR 0.85, 95% CI 0.65–1.11). Trend to
major bleeding risk (RR 2.46, 95% CI 0.70–8.61).

CI: confidence interval; CV: cardiovascular; CVD: cardiovascular disease; GI: gastrointestinal; MI: myocardial infarction; OR: odds ratio;
RCTs: randomised controlled trials; RR: relative risk; SR: systematic review.
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People with diabetes
Four systematic reviews239, 243, 247, 248 and one clinical
guideline249 were identified with data on aspirin for
primary prevention of CVD among diabetic individuals.
These reviews consistently report that aspirin therapy
is associated with a statistically non-significant 8–12%
reduction in risk of major cardiovascular events in people
with diabetes. When individual endpoints are considered
in people with diabetes, sex-specific trends have also
been reported: that is, reduced risk of MI in men and
reduced risk of stroke in women.247, 248 As the effects in
people with diabetes are smaller than those for the general
population, a conservative approach to use of aspirin
therapy is suggested for prevention of CVD.

People with atrial fibrillation
The increased risk of stroke in people with non-valvular AF
is well recognised and scoring systems (e.g. CHADS2*)
are recommended to determine risk levels and need for
pharmacotherapy. Three robust systematic reviews250-252
and three notable randomised controlled trials253-255 have
investigated the benefits of antiplatelet or anticoagulant
therapy in primary prevention populations. Two separate
reviews report consistent reductions in the combination of
stroke, MI or vascular death (OR 0.71, 95% CI 0.51–0.97)
with aspirin (75–125 mg daily or 125 mg every second
day),250 and clear benefits of warfarin for preventing stroke
(OR 0.39, 95% CI 0.26–0.59), all cause mortality (OR
0.69, 95% CI 0.50–0.94) and the combined endpoint of
all stroke, MI or vascular death (OR 0.56, 95% CI 0.42–
0.76).251 A third systematic review assessed the relative
effect of long-term oral anticoagulant treatment compared
with antiplatelet therapy on major vascular events in eight
trials involving 9,598 individuals.252 Overall, warfarin and
related oral anticoagulants reduced stroke, disabling stroke
and other major vascular events by about one-third and are
clearly recommended compared with antiplatelet therapy.
However, anticoagulation therapy may be unsuitable for
a small percentage of individuals with AF. In a trial, 7,554
patients with AF in whom warfarin therapy was unsuitable
were assigned clopidogrel (75 mg/day) plus aspirin
(75–100 mg/day) or aspirin alone.254 The primary outcome
was the composite of stroke, MI, non-central nervous

*CHADS2 score is a clinical prediction rule for estimating the risk of stroke
in patients with non-rheumatic AF. The score is calculated by the presence
of Congestive heart failure (1 point); Hypertension: BP consistently above
140/90 mmHg (or treated hypertension on medication) (1 point); Age ≥75
years (1 point); Diabetes mellitus (1 point); or Prior Stroke or TIA (2 points).

system systemic embolism or death from vascular causes.
At a median of 3.6 years of follow-up, the incidence of major
vascular events was 6.8% and 7.6% per year for clopidogrel
plus aspirin and aspirin alone, respectively (RR 0.89, 95%
CI 0.81 - 0.98; p=0.01). The difference was primarily due to
a reduction in the rate of stroke with clopidogrel. However,
the benefits were offset by an increased incidence of major
bleeding (2.0% per year for people receiving dual antiplatelet
therapy and 1.3% per year for individuals receiving aspirin
alone, RR 1.57, 95% CI 1.29–1.92; p<0.001). It is unclear
from this study what percentage were individuals without
established CVD. Another recent trial randomised 5,599
patients with AF, in whom warfarin therapy was deemed
unsuitable, to receive apixaban, a novel factor Xa inhibitor (at
a dose of 5 mg twice daily) or aspirin (81–324 mg/day). The
trial was terminated early for safety concerns with apixaban
found to significantly reduce the risk of stroke or systemic
embolism (HR 0.45, 95% CI 0.32–0.62; P<0.001) and
non-significantly reduce mortality per year (HR 0.79, 95% CI
0.62–1.02; P=0.07).256 No difference in adverse events was
found.
Readers are referred to an Australian evidence summary25
and international guidelines for a discussion of the general
evidence related to AF management.26-29

Dual antiplatelet therapy is not appropriate for
primary prevention
Only one high-quality randomised controlled trial has
examined the efficacy and safety of dual antiplatelet
therapy with clopidogrel and aspirin vs aspirin alone in
a primary prevention population. In the Clopidogrel for
High Atherothrombotic Risk and Ischaemic Stabilization,
Management, and Avoidance (CHARISMA) trial,
approximately 2,289 of the 15,603 participants were free
of existing CVD at baseline.254 Individuals were randomly
assigned to receive clopidogrel (75 mg/day) plus low-dose
aspirin (75–162 mg/day) or placebo plus low-dose aspirin
and followed for a median of 28 months. The primary
efficacy endpoint was a composite of MI, stroke or death
from cardiovascular causes. In the primary prevention
cohort, the rate of cardiovascular death for single vs dualantiplatelet therapy was 1.8% and 3.0%, respectively
(p=0.07).254 Furthermore, multivariate analysis of the
primary prevention group showed a trend towards excess
cardiovascular death (HR 1.72, 95% CI 0.99–2.97; p=0.054)
with dual-antiplatelet therapy. Results from the CHARISMA
trial suggest that a dual antiplatelet strategy with clopidogrel
and aspirin should not be used for primary prevention.
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Evidence-based recommendation

Grade

Pharmacotherapy
EBR 9: Aspirin or other antiplatelet therapy is not routinely recommended for primary prevention of
CVD.

B234, 237, 238, 242, 243

For adults at high risk of CVD
EBR 10: Adults at high absolute risk of CVD should be simultaneously treated with lipid and blood
pressure-lowering pharmacotherapy in addition to lifestyle advice unless contraindicated or clinically
inappropriate.

B192, 195, 204, 206, 207

Consensus-based recommendations
For adults at moderate risk of CVD
CBR 3: Adults at moderate absolute risk of CVD should have their risk factors initially managed by lifestyle interventions.
Pharmacotherapy for blood pressure and/or lipid lowering is not routinely recommended but may be considered if 3–6
months of lifestyle intervention does not reduce the individual’s risk factors.
CBR 4: Adults at moderate absolute risk of CVD may be treated with pharmacotherapy for blood pressure and/or lipid
lowering in addition to lifestyle intervention if one or more of the following applies:
•
•
•
•

Persistent blood pressure ≥160/100 mmHg
Family history of premature CVD
Aboriginal and Torres Strait Islander peoples
Other populations where FRE is known to underestimate risk (South Asians, Maori and Pacific Islanders, people
from the Middle East).

For adults at low risk of CVD
CBR 5: Pharmacotherapy for blood pressure and lipid lowering is not routinely recommended for adults at low absolute
risk of CVD.
CBR 6: Adults at low absolute risk of CVD who have persistent blood pressure ≥160/100 mmHg may be treated with
blood pressure-lowering pharmacotherapy in addition to lifestyle intervention.

2.2.4 Pharmacological approaches to
simultaneously lower blood pressure and
lipids
There is robust evidence to support the efficacy of
using medication to reduce both BP and cholesterol to
reduce CVD risk. Several studies have evaluated the coadministration of amlodipine and atorvastatin, and found
the same or improved effectiveness from simultaneously
administering both drugs, compared with a single drug
regimen.257-259 In the AVALON trial,257 co-administration
of amlodipine and atorvastatin was compared with single
drug therapy, and placebo in 847 patients. At week
8, 45% of the people receiving amlodipine 5 mg once
50

daily and atorvastatin 10 mg once daily reached both
their BP and LDL-C targets, compared with 8.3% with
amlodipine (p<0.001), 28.6% with atorvastatin (p<0.001)
and 3.5% with placebo. At 28 weeks, 67.1% of people
co-administered amlodipine and atorvastatin (mean doses,
7.6 mg and 28.4 mg, respectively) achieved both targets.
Furthermore, the Framingham study estimated 10-year risk
of CHD in that group declined from baseline levels of 15.1%
to 6.9% at week 28.
Similar results were observed in the ASCOT-LLA259
and the RESPOND study.258 In the ASCOTT-LLA study,
people with baseline hypertension and TC ≥6.5 mmol/L,
received atorvastatin (10 mg once daily) in addition to their

antihypertensive routine for a mean duration of 3.3 years.
This combined treatment led to a 36% reduction in the
relative risk of non-fatal MI and fatal CHD, compared with
the group receiving placebo plus antihypertensive therapy. In
the RESPOND study, the use of amlodipine and atorvastatin
together did not differ from the efficacy achieved with
each medication alone. However, the estimated 10-year
Framingham risk with combination therapy declined from
baseline values of 15.8–18.0% to 7.3–10.7%.
Comparative and non-comparative studies investigating the
efficacy of single pill combination therapy with amlodipine
and atorvastatin in people with elevated BP and lipids at
baseline have, in general, demonstrated similar results.
The proportion of people achieving both improved BP and
LDL-C levels in those trials ranged from 48.3% to 57.7%260and 10-year Framingham risk scores were reduced by up
to 52%.263

263

2.3 Initiation and maintenance of
pharmacotherapy
2.3.1 Blood pressure-lowering therapy
Blood pressure-lowering therapy should be
determined by individual needs and aimed
towards optimal blood pressure levels
The relationship between BP and CVD risk is continuous,
and guidelines have recommended reduced BP targets
over recent years as evidence of benefit and safety have
accumulated.14, 47, 264-268 While there has been general
consensus that the most important clinical implication is
to achieve the correct total dosage to achieve appropriate
BP control,192, 269 new data from several systematic reviews
has reopened the issue as to whether lowering BP as far as
possible – a ‘lower the pressure the better’ approach – is
of any greater value than lowering it to below standard BP
targets (i.e. 140/90 mmHg).269-271

different SBP targets were found; however, seven trials
comparing different DBPs were identified involving 22,089
adults. Despite a -4/-3 mmHg greater achieved reduction in
SBP/DBP (p<0.001), attempting to achieve ‘lower targets’
instead of ‘standard targets’ had no significant effect on
total mortality (RR 0.92, 95% CI 0.86–1.15), MI (RR 0.90,
95% CI 0.74–1.09), stroke (RR 0.99, 95% CI 0.79–1.25),
congestive heart failure (RR 0.88, 95% CI 0.59-1.32), major
cardiovascular events (RR 0.94, 95% CI 0.83–1.07) or endstage renal disease (RR 1.01, 95% CI 0.81–1.27).
These results coincide with other systematic reviews that
have confirmed a proportional relationship between BP
levels and cardiovascular events.269, 271 A meta-analysis
of 30 trials and more than 149,000 people demonstrated
that the relationship between the odds ratio for fatal and
non-fatal cardiovascular outcomes and the corresponding
within-trial differences in SBP is curvilinear,269 and when
these outcomes were combined, there was no further
benefit if the within-trial differences in SBP exceeded
~15 mmHg. In another systematic review, the incidence
of major cardiovascular events in BP-lowering trials was
calculated after classifying each trial into four categories
according to people’s baseline cardiovascular risk: low
risk, elderly, diabetic and high risk. Of note, low rates of
major cardiovascular events (3–6% in five years) were only
achieved in trials enrolling low risk people.271 In contrast, the
incidence of major cardiovascular events in trials enrolling
elderly hypertensive people, hypertensive people with
diabetes or people with previous CVD or events was rarely
reduced to below 12–14% in five years. People enrolled
in these trials remained at high risk despite aggressive BP
reduction and extensive use of concomitant medications,
suggesting that pre-existing high risk sets a ceiling effect to
the benefits of treatment.
Current evidence indicates that more intensive BP lowering
produces greater reductions in cardiovascular events and
all-cause mortality. Although treatment targets are generally
recognised and can be used to monitor treatment effects,
the extra effort required to achieve lower levels of BP should
be assessed against the benefits and risks to the individual
patient.

The Blood Pressure-lowering Treatment Trialists’
Collaboration found that BP lowering reduced major
cardiovascular events.272 The magnitude of this effect could
be attributed to the degree of BP lowering. More recently, a
Cochrane review was conducted to determine if lower BP
targets (≤135/85 mmHg) are associated with a reduction
in mortality and morbidity as compared with standard BP
targets (≤140–160/90–100 mmHg).270 No trials comparing
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People with diabetes
BP lowering reduces cardiovascular events and all-cause
mortality in people with type 2 diabetes to a similar or even
greater extent than for the general population.195 However,
the target levels for BP therapy have been based on little
direct evidence.
Two major recent randomised controlled trials are of
particular interest in informing target BP levels for those
with diabetes. The ADVANCE trial randomised 11,140
participants with type 2 diabetes to either perindoprilindapamide versus placebo (double-blind comparison)
and intensive glucose control with a gliclazide MR-based
regimen (target A1C ≤6.5%) versus standard glucose
control (open comparison).273 During an average follow-up
period of 4.3 years, the risks of major macrovascular and
microvascular events were considered jointly and separately,
in addition to renal events and death. Those treated to lower
SBP (achieved mean updated SBP during the study 134.7
mmHg) were found to have reduced all-cause and CVD
mortality (OR 0.86, 95% CI 0.75–0.98; and OR 0.81, 95%
CI 0.68–0.98, respectively) but surprisingly had no effect
on stroke (OR 0.99, 95% CI 0.81–1.19). Compared with
neither intervention, combination treatment with BP lowering
and intensive glucose control reduced the risk of all-cause
mortality by 18% (95% CI 1–32%, p=0.04), reduced new
or worsening nephropathy by 33% (95% CI 12–50%,
p=0.005), reduced new onset of macroalbuminuria by 54%
(95% CI 35–68%, p<0.0001) and reduced new onset of
microalbuminuria by 26% (95% CI 17–34%).
The ACCORD investigators tested the effect of a target
SBP <120 mmHg on a composite outcome of non-fatal
MI, non-fatal stroke or death from cardiovascular causes.274
In that trial, 4,733 participants were randomly assigned to
lower their BP by receiving either intensive therapy (SBP
target <120 mmHg) or standard therapy (SBP target <140
mmHg). The mean follow-up period was 4.7 years and 34%
of participants had existing CVD. After one year, the mean
SBP was 119.3 mmHg and 133.5 mmHg in the intensive
therapy and standard therapy groups, respectively and
this difference was maintained throughout the study. The
annual rate of the primary outcome was similar between
groups: 1.87% in the intensive-therapy group and 2.09% in
the standard-therapy group (HR 0.88, 95% CI 0.73–1.06;
p=0.20). However, the incidence of serious adverse events,
including deterioration in renal function, was significantly
higher in participants randomised to the intensive-therapy
group (3.3% vs 1.3%, p<0.001). Of interest, however, was
the annual incidence of stroke, a pre-specified secondary
outcome: 0.32% and 0.53% in the intensive therapy and
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standard therapy groups, respectively (HR 0.59, 95% CI
0.39–0.89; p=0.01).
During finalisation of these guidelines, two meta-analyses
were published that updated previous meta-analyses
with important trials such as those discussed above.275,
276
One meta-analysis included 13 trials (mixed primary
and secondary prevention) and found that intensive BP
control (achieving SBP ≤135 mmHg) was associated
with a reduction in all-cause mortality (OR 0.90, 95% CI
0.83–0.98 and a reduction in stroke (OR 0.83, 95% CI
0.83–0.98), but with an increase in serious adverse effects
(OR 1.2, 95% CI 1.08–1.32). There were similar outcomes
for other macrovascular and microvascular (cardiac, renal
and retinal) events compared with standard BP control
(SBP ≤140 mmHg).275 More intensive BP control (SBP ≤130
mmHg) was associated with further reduction in stroke only
and there was a 40% increase in serious adverse events
compared to standard BP control (95% CI 1.19–1.64;
P=0.01), but significant heterogeneity was noted.
The other meta-analysis included 31 trials (mixed primary
and secondary prevention) and reported intensive therapy
(mean SBP 129 mmHg vs SBP 139 mmHg) significantly
reduced the risk of stroke (RR 0.61, 95% CI 0.48–0.79;
based on five trials) but not MI (OR 0.87, 95% CI 0.74–1.02;
based on six trials).276 The effects were found to occur with
reductions in SBP or DBP with meta-regression analysis
noting the risk of stroke decreased by 13% (95% CI 5–20%)
for each 5 mmHg reduction in SBP and by 11.5% (95% CI
5–17%) for each 2 mmHg reduction in DBP.
In general, people with diabetes appear to benefit from
modestly more aggressive thresholds for treatment than the
general population with targets towards SBP 130 mmHg
and DBP 80 mmHg. However, based on the ACCORD and
ADVANCE study results and the newer meta-analyses,
this target is currently being reconsidered by a number of
organisations world-wide and the SBP may be adjusted
upwards. Until such deliberations are complete, the general
international BP target for people with diabetes remains
≤130/80 mmHg.

People with CKD
Recent evidence considered during the finalisation of
these guidelines suggests that treating people with CKD
to lower BP targets than the general population does not
improve clinical outcomes.277 New targets are currently
being considered internationally and may be adjusted
upwards. The EWG, after detailed consultation locally and
internationally, has adjusted the recommended targets
for Australia based on the recent evidence. Target BP for

people with CKD is now ≤140/90 mmHg and for people
with micro or macroalbuminuria (UACR >2.5 mg/mmol
in men and >3.5 mg/mmol in women) the target is now
130/80 mmHg. Available evidence suggests that treatment
using agents that lower BP reduces CVD morbidity and
mortality for people on maintenance dialysis;197 however,
specialist advice and management of BP is usually required
for people on dialysis.

Initiation of blood pressure-lowering treatment
There is now a large body of evidence on BP-lowering
therapies, both those comparing active treatment versus
placebo and those comparing different treatment regimens.
Results from nine systematic reviews of BP-lowering drugs
in the prevention of cardiovascular events192, 198, 199, 269, 272,
278-281
confirm that:
a) The main benefits of BP-lowering therapies are due
to the reduction of BP and are largely independent of
the drugs employed;
b) Thiazide diuretics, calcium channel blockers (CCB),
angiotensin-converting enzyme (ACE) inhibitors, and
angiotensin receptor blockers (ARBs) have similar
BP-lowering outcomes and significantly reduce
cardiovascular morbidity and mortality;
c) There is no interaction between age and effect
of treatment on cardiovascular events for any BPlowering treatment compared with control.194, 198
Apart from beta-blockers, in primary prevention, no one
class of agent appears to offer a major advantage over
another. However, there are exceptions in certain situations.
In terms of medication adherence and/or persistence, two
systematic reviews assessed the results of trials involving
ARBs, ACE inhibitors, CCBs, beta-blockers and diuretics.278,
282
In one meta-analysis of eight trials, ARBs provided a
non-significant BP reduction compared with ACE inhibitors
(net difference 1.8/1.0 mmHg).278 However, compliance at
12 months with ARBs was consistently higher (42–64%)
than that observed for other therapeutic classes. This is
similar to the other systematic review of 17 trials, which
found adherence lowest for diuretics and beta-blockers, and
highest in ARBs and then ACE inhibitors.282
With regard to individual endpoints (e.g. stroke, MI, heart
failure) the literature does suggest differences between
various BP-lowering therapies. Beta-blockers have been
found to be less effective in reducing the risk of stroke,192,

heart failure.283, 284 In one large meta-analysis, therapies
other than CCBs (with the exception of non-cardioselective
beta-blockers) reduced the incidence of heart failure by 24%
(19–28%). CCBs reduced the incidence of heart failure by
19% (6–31%).192
The first class of drugs to use for management of elevated
BP has always been a matter of debate. Low-dose thiazide
diuretics have been recommended based on results
obtained in a systematic review of 24 trials and more
than 58,000 participants.199 In that review, the reduction
in morbidity and mortality was similar between low-dose
thiazides, ACE inhibitors and CCBs; however, the authors
note that the data for thiazide diuretics is more robust than
that available for the latter therapeutic classes. In contrast,
first-line therapy with high-dose thiazide diuretics or betablockers is inferior to first-line therapy with low-dose
thiazides199 and, in some reports, the use of high-dose (four
times standard) thiazides has increased the risk of sudden
cardiac death.192
The extent of BP reductions is similar at standard doses for
the five therapeutic categories of blood pressure-lowering
agents: average reduction was 9.1 mmHg systolic and 5
mmHg diastolic.192, 195 However, in practice, more than one
drug is often required to lower BP to optimal levels and, in
these situations, the effect of combinations of two or more
drugs on BP is additive. Furthermore, the adverse effect
profiles of drugs can be minimised by using half-standard
or standard doses, rather than titrating any given drug to
higher doses. The exceptions are ACE inhibitors and ARBs,
where the adverse effects are either present or absent.14 In
a large meta-analysis, one drug at standard dose reduced
the incidence of CHD by about 24% and stroke by 35% in
60–69 year olds with a DBP of 90 mmHg.192 Three drugs
at half standard doses approximately doubled this effect,
reducing CHD by 45% and stroke by 60%. At higher BPs
(e.g. 180/105 mmHg) and lower BPs (e.g. 120/75 mmHg),
the effect of one drug at standard dose is about 7% and
9% greater and smaller, respectively. Three drugs at half
standard dose is about 12% and 14% greater and smaller.
In summary, thiazide diuretics, CCBs, ACE inhibitors and
ARBs are all suitable for initiation of BP-lowering therapy.
In addition, they can all be used for maintenance of BPlowering therapy, either as monotherapy or in combination.
Beta-blockers appear to offer less clinical efficacy in terms
of CVD prevention.

while CCBs may have a slightly superior effect on stroke
prevention.192, 269, 272, 283 In contrast, the benefit of CCBs
does not appear to extend equally to the prevention of
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Table 8: Blood pressure-lowering targets: summary of key evidence

Reference

Study details

Intervention

Results

Arguedas et al
(2009)270

Good quality SR (n=7
RCTs). 22,089 subjects
comparing different DBP
targets.

All BP-lowering
medications
with lower or
vs standard BP
targets.

No difference between standard targets (≤140/90) and
lower targets (≤135/85). Mortality (RR 0.92, 95% CI
0.86-1.15), MI (RR 0.90, 95% CI 0.74-1.09), stroke (RR
0.99, 95% CI 0.79-1.25), CHF (RR 0.88, 95% CI 0.591.32), major CV events (RR 0.94, 95% CI 0.83-1.07), or
end-stage renal disease (RR 1.01, 95% CI 0.81-1.27). No
difference for diabetes and CKD.

Bangalore et al
(2011)275

Good quality SR (n=
13 RCTs) 37,736
participants with type 2
diabetes or pre diabetes.

All BP-lowering
medications vs
placebo or less
intensive control.

Intensive BP control had 10% all-cause mortality,
17% stroke, and a 20% in serious adverse effects
with similar outcomes for other macrovascular and
microvascular events. For targets <130 mm Hg SBP,
40% in serious adverse events (heterogeneity noted)
without other benefits. Meta–regression analysis found
only stroke with BP.

BP Lowering
Treatment
Trialists’
Collaboration;
Turnbull et al
(2003)272

Good quality SR
(n=29 RCTs). 162,341
participants. Most trials
selected people on basis
of existing CVD or risk
factors.

All BP-lowering
medications vs
placebo or less
intensive control.

Regimens targeting lower BP goals stroke and CV
events without any convincing evidence of j-curve
relationship.

Law et al
(2009)192

Good quality SR
(n=147 RCTs; 464,000
participants). 26 RCTs
specifically with no
history of CVD.

All BP lowering
medications
vs placebo or
other class of
drug.

For a reduction of 10mmHg SBP or 5mmHg DBP:
CHD events (RR 0.79, 95% CI 0.72-0.86), stroke
(RR 0.54, 95% CI 0.45-0.65). No significant trend in
proportional disease reduction with lower pre-treatment
blood pressure, indicating a constant proportional effect
(although too few data <110/70 mmHg).

Reboldi et al
(2011)276

Good quality SR
(n=31 RCTs). 73,913
participants with
diabetes.

All BP-lowering
medications
with lower or
vs standard BP
targets.

Overall, treatment stroke by 9% (P=0.0059), and MI
by 11% (P=0.0015). Allocation to more-tight, compared
with less tight, BP control stroke by 31% (RR 0.61,
95% CI 0.48–0.79) but not risk of MI (OR 0.87, 95% CI
0.74–1.02). Meta-regression found clear link between
BP and stroke but not MI.

Upadhyay et al
(2011)277

Good quality SR (n=3
RCTs). 2,272 adults with
non–dialysis-dependent
CKD but excluded type
1 diabetes and had few
with type 2 diabetes.

All BP-lowering
medications
with lower or
vs standard BP
targets.

Included trials failed to demonstrate improved outcomes
for lower BP targets. Lower-quality evidence suggests
that a low target may be beneficial in subgroups with
proteinuria greater than 300 to 1000 mg/d. Participants
with lower targets required more BP medications and had
a slightly higher rate of adverse events.

BP: blood pressure; CI: confidence interval; CHF: chronic heart failure; CKDL: chronic kidney disease; CV: cardiovascular; CVD:
cardiovascular disease; DBP: diastolic blood pressure; MI: myocardial infarction; RCTs: randomised controlled trials; RR: relative risk; SBP:
systolic blood pressure; SR: systematic review.
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Table 9: Blood pressure-lowering therapy: summary of key evidence

Reference

Study details

Intervention

Results

BP Lowering
Treatment
Trialists’
Collaboration;
Turnbull et al
(2008)198

Good quality SR
(n=31 RCTs); 190,606
participants. Compared
age groups <65 and
above 65. Mixed
primary and secondary
prevention.

All BP-lowering
medications vs
placebo or less
intensive control.

No difference in reductions in major CV events between
age groups for any comparison. No difference between
the effects of any class of drug on risk of CV events.

Bramlage et al
(2009) 278

Fair quality SR (n=8
cohort studies) Mixed
primary and secondary
prevention

All BP lowering
medications.

Persistence was higher with ARBs than any other
therapeutic class.

Kronish et al
(2011)282

Good quality SR (n=17
cohort studies). Mixed
primary and secondary
prevention.

All BP lowering
medications.

ARBs had the highest adherence followed by ACEi,
CCBs, diuretics and BBs. After consideration of
publication bias there was no difference between ARBs
and ACEi (HR 1.10, 95% CI 0.94-1.30) or diuretics and
BBs (HR 1.13, 95% CI 0.89-1.44). The pooled mean
adherence ranged from 28% for BBs to 65% for ARBs.

Law et al
(2009)192

Good quality SR
(n=147 RCTs; 464,000
participants). 26 RCTs
specifically with no
history of CVD.

All BP lowering
medications vs
placebo or no
treatment.

Effect is similar for all classes of blood pressure-lowering
drugs for CHD although CCBs were slightly more effective
for stroke prevention and BBs slightly less effective.
CCBs HF by 19% whereas for other classes 24%.
One drug at standard dose reduces CHD and stroke by
approximately 24% and 35%, respectively in 60–69 year
olds with SBP of 90 mmHg. Three drugs modelled at half
standard doses approximately double this effect.

Musini et al
(2009)280

Good quality SR (n=9
RCTs).
460 patients with
primary hypertension
defined as BP >140/90
mmHg at baseline.

Loop diuretics vs
placebo.

The BP-lowering effects of loop diuretics is modest
(approx. 8/4 mmHg) and whether the effects are greater
or lower than other classes of BP-lowering agents is
difficult to say.

Webb et al
(2010)281

Good quality SR
(n=389 RCTs). Mixed
primary and secondary
prevention.

All BP lowering
medications vs
placebo or no
treatment.

Compared with other drug classes, CCBs and non-loop
diuretic drugs reduced interindividual variation in SBP
whereas ACEi, ARBs, and BBs increased it. CCB was
most effective vs placebo. Interindividual variation in SBP
accounted for the effects on risk of stroke independently
of differences in mean SBP.

Wright et al
(2009)199

Good quality SR (n=24
RCTs; 28 arms). 58,040
people, 42,196 (72.7%)
were primary prevention.
Included trials had
>70% of people with
BP >140/90 mmHg at
baseline and were for
>1 year duration.

All BP lowering
medications
vs placebo or
other class of
drug.

Low-dose thiazides mortality (RR 0.89, 95% CI 0.830.96) and CV events (RR 0.70, 95% CI 0.64-0.76). BBs
CV events (RR 0.89, 95% CI 0.8-0.98) but not CHD or
mortality. ACEi mortality (RR 0.83, 95% CI 0.72-0.95)
and CV events (RR 0.76, 95% CI 0.67-0.85). CCBs CV
events (RR 0.71, 95% CI 0.57 to 0.87) but not CHD
or mortality. Overall there are more trials of low-dose
thiazides but CCBs and ACEi have similar effect and BBs
are less effective.

ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; BB: beta blocker; BP: blood pressure; CCB: calcium
channel blocker; CHD: coronary heart disease; CV: cardiovascular; HF: heart failure; RCTs: randomised controlled trials; RR: relative risk;
SBP: systolic blood pressure; SR: systematic review.

55

Evidence-based recommendations

Grade

Blood pressure-lowering therapy
EBR 11: Treatment should begin with any one of the following agents:
•
•
•
•

ACE inhibitor
Angiotensin receptor blocker
Calcium channel blocker
Low-dose thiazide or thiazide-like diuretic

EBR 12: If monotherapy does not sufficiently reduce blood pressure add a second agent from a
different pharmacological class.

A192, 199

A192

Practice points
Blood pressure-lowering therapy
PP 13: If blood pressure is not responding to pharmacotherapy, reassess for:
•
•
•
•
•
•
•
•
•

non-adherence
undiagnosed secondary causes of raised blood pressure
hypertensive effects of other drugs
treatment resistance due to sleep apnoea
undisclosed use of alcohol or recreational drugs
unrecognised high salt intake (particularly in patients taking ACE inhibitors or angiotensin receptor blockers)
‘white coat’ raised blood pressure
technical factors affecting measurement
volume overload, especially with CKD

PP 14: If dual therapy at higher doses does not sufficiently reduce blood pressure, add an additional agent.
PP 15: If combination therapy does not sufficiently reduce blood pressure, consider specialist advice.
PP 16: Treatable secondary causes for raised blood pressure should be considered before commencing blood pressure
drug therapy.
PP 17: The following combinations should generally be avoided:
• potassium-sparing diuretic plus either ACE inhibitor or angiotensin receptor blocker
• beta-blocker plus verapamil
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2.3.2 Lipid-lowering therapy
Lipid-lowering therapy should be determined
by individual needs and should aim towards
optimal lipid levels
Evidence from several systematic reviews and metaanalyses suggests that more intensive lipid modification
produces greater reductions in cardiovascular events.209,
213, 216
In a meta-analysis of 26 randomised trials (mixed
populations) of statins, each 1.0 mmol/L decrease in LDL-C
equated to a 25% reduction in major vascular events in
people without previous CVD (RR 0.75, 95% CI 0.69–0.82)
and a 0.4% lower risk difference per year.209 However, there
are no clinical trials that have evaluated the relative and
absolute benefits of cholesterol lowering to different TC and
LDL-C targets in relation to clinical events. Establishing a
cholesterol target for therapy is therefore an extrapolation
from the apparent benefits indicated by major trials of lipid
lowering, while maintaining appropriate margins for safety,
given that there are still no long-term follow up studies of
statin therapy.
The recommendations in these guidelines also refer to levels
of non-HDL-C and triglycerides. Non-HDL-C refers to the
cholesterol in LDL, intermediate density lipoprotein and very
low-density lipoproteins and is calculated by subtracting
HDL-C from TC. Unlike LDL-C, the calculation of nonHDL-C does not require triglycerides to be less than 4.5
mmol/L. This makes it particularly useful for people with
high triglycerides. Triglyceride levels are also important.
Hypertriglyceridaemia is associated with the development of
early onset CVD and significantly increases the risk of acute
pancreatitis.285
The evidence for fixed-dose or individual titration of statin
therapy is limited. One large meta-analysis performed a
pre-determined assessment on the effects of statin dose
on outcomes based on secondary prevention studies.286
Intuitively, one would expect that as the dose of a drug is
increased, a greater amount of benefit is attained. However,
with statin therapy, this was not the case above a certain
dose. Over the range of doses reported, all statins, with
the exception of pravastatin, showed some evidence of a
dose response for reduction in TC and/or LDL-C with fixed
dosing, but not with dose titration. Overall, there appeared
to be no major difference between dose titration regimens or
use of a fixed dose in studies of longer duration.
In summary, lipid lowering reduces cardiovascular events
irrespective of initial lipid levels. Targets for lipid-lowering
therapy have been developed by extrapolation from the
apparent benefits indicated by major trials of lipid lowering,

therefore treatment for lipid lowering should aim towards
these targets rather than consider them definitive.

Order of lipid-lowering treatment
Lipid-lowering pharmacotherapy includes statins, fibrates,
bile acid binding resins, niacin (nicotinic acid) and selective
cholesterol absorption inhibitors (e.g. ezetimibe). The
effectiveness of each of these agents is covered in section
2.2.2 Lipid-lowering therapy. Of all the methods to modify
lipids, the weight of evidence suggests that statins are the
most effective and should be the first-line agent.216-219
The lipid-lowering efficacy provided by the different statins
appears to be fairly similar.211, 217, 236 For the reduction of
cardiovascular events, meta-analyses suggest that although
the point estimates of their effect sizes vary, the confidence
intervals overlap in each case except for non-fatal MI where
simvastatin can just be differentiated from pravastatin (RR
0.62, 95% CI 0.56–0.69 and 0.78, 95% CI 0.70–0.87,
respectively).211 Another meta-analysis of 164 short-term
primary and secondary trials found rosuvastatin 5 mg/day,
atorvastatin 10 mg/day and lovastatin or simvastatin 40
mg/day reduced LDL-C by about 35%, but fluvastatin and
pravastatin produced smaller reductions.217 Rosuvastatin
10 mg/day, atorvastatin 20 mg/day and lovastatin or
simvastatin 80 mg/day reduced LDL-C by about 45% and
rosuvastatin 80 mg/day by about 60%. In clinical practice,
the choice of statin is more likely to be related to the dosage
required for lowering TC and LDL-C. Combination therapies
(e.g., statins and ezetimibe) may also be considered when
target LDL-C levels are not achievable with statins alone.
Systematic reviews have confirmed that statins, as first-line
therapy, are safe and easy to use.208, 287, 288 Liver dysfunction
is occasional and reversible. Rhabdomyolysis is very rare
and severe muscle pain may require immediate cessation
of therapy. Because statins are prescribed on a long-term
basis, possible interactions with drugs that are metabolised
by the cytochrome P450 pathway (e.g. cyclosporin,
macrolides, azole antifungals, calcium antagonists, protease
inhibitors, sildenafil, warfarin, digoxin, nicotinic acid, fibrates,
etc.) also deserves particular attention. In cases where there
is potential for interaction via this pathway, pravastatin is
an acceptable alternative to atorvastatin or simvastatin.
All patients started on a statin should be advised to report
unexplained muscle pains or other adverse effects promptly,
especially if associated with fever or malaise. If such effects
are mild, a different statin may be tried and/or the statin
dose reduced after discussing the risks involved with the
patient. If severe side effects are experienced, statin therapy
should be discontinued.
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Due to the weight of evidence in favour of statins, fibrate
monotherapy cannot be recommended as first-line
treatment for raised lipid levels, but may be considered in
those whose triglyceride levels remain elevated despite
treatment with the maximally tolerated dose of statins and
who have persistently low HDL-C levels. Triglyceride levels
greater than 10mmol/L pose a risk of pancreatitis and
should be treated with fenofibrate, nicotinic acid or fish oil as
first-line therapy.

CVD events, non-fatal MI or non-fatal stroke, compared
with simvastatin alone.292 Of interest, however, was a

Nicotinic acids and ezetimibe may be considered in addition
to statin therapy where insufficient lipid control has been
achieved. Bile acid sequestrants using cholestyramine
may be considered as monotherapy where statins are
not tolerated or are contraindicated. They may also be
considered in addition to statin therapy. Overall, there is
limited evidence for various lipid lowering agents either in
combination with statins or alone.

Collectively, these findings do not support the routine use of
combination therapy with fenofibrate and statins to reduce
CVD risk in people with type 2 diabetes, except in those
with dyslipidaemia. Clinicians should note that in primary
prevention, the treatment threshold is determined by the
level of AR while the treatment target for triglycerides is
<2.0mmol/L. In contrast, in secondary prevention of CVD
for people with type 2 diabetes, the treatment threshold is
a triglyceride level above 2.3 mmol/L in combination with
HDL levels below 1.0 mmol/L (refer to the National Evidencebased Guideline on Secondary Prevention of Vascular
Disease in type 2 diabetes currently being drafted).

People with diabetes
Several systematic reviews have looked exclusively at
responses to lipid modification of people with type 2
diabetes. The results from these reviews are consistent and
suggest that people with diabetes gain similar benefits from
statin therapy as people without.206, 208, 209, 211, 289 Perhaps
the best evidence for people with diabetes comes from the
Collaborative Atorvastatin Diabetes Study (CARDS), a large
study conducted entirely in people with diabetes who did
not have either raised cholesterol levels or a clinical history of
CVD, even though many were hypertensive.290 In that study,
the AR reduction attributable to statin therapy was 1.70%
(95% CI, 0.11–3.29) for all-cause mortality and 1.35% (95%
CI 0.30–2.40) for total stroke. The NNT for four years to
prevent one death was 59 (95% CI 30.4–88.5).
The evidence for fibrates in people with type 2 diabetes
is less clear. One systematic review of 11 trials (78% of
population were deemed primary prevention) reported a
significant reduction in non-fatal coronary events (RR 0.84,
95% CI 0.74–0.96) but no effect on stroke or mortality
outcomes.222 In the largest study included in the review, the
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study, fenofibrate therapy did not significantly reduce
the risk of coronary events.291 However, it did reduce total
cardiovascular events, mainly due to fewer non-fatal MIs and
revascularisations. Furthermore, in people with dyslipidaemia
(defined as low HDL-C with high triglycerides), the benefit of
fenofibrate appeared to be more pronounced. In that group,
CVD events occurred in 16.3% of people randomised to
placebo and 14.0% in people receiving fenofibrate (p=0.06).
A more recent trial (ACCORD) found that the combination of
fenofibrate and simvastatin did not reduce the rate of fatal
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possible benefit according to lipid subgroups. People with
dyslipidaemia displayed a more pronounced benefit (p=0.057
for interaction), similar to the result reported in the FIELD
study.291 However, in contrast to the FIELD study, a gender
difference was observed, with the primary outcome rate
increasing by 38% for women and decreasing by 18% for
men.292

People with CKD
The benefits provided by statin therapy for people with CKD
are similar to those observed in the general population. Statin
therapy decreased all-cause mortality (RR 0.81, 95% CI
0.74–0.89) and cardiovascular mortality (RR 0.80, 95% CI
0.70–0.90) among people with non-dialysis dependent CKD
to an extent similar to that found in the general population.235,
293
The same authors reported that statins reduced fatal
cardiovascular events (RR 0.81, 95% CI 0.73–0.90) and nonfatal cardiovascular events (RR 0.78, 95% CI 0.73–0.84), for
all stages of CKD but had no significant effect on all-cause
mortality (RR 0.92, 95% CI 0.82–1.03).293 Importantly there
were no significant differences in adverse events reported
(including rhabdomyolysis and elevated liver enzymes).
However, trials usually included people with pre-existing CVD.
Meta-regression analysis found that treatment effects did not
vary significantly with stage of CKD. This is consistent with a
subgroup analysis in another meta-analysis, which found no
difference in the effect of statins with varying levels of GFR.209
The Study of Heart and Renal Protection (SHARP) represents
the largest trial of lipid modification in people with CKD
performed to date.294 In that study, 9,438 participants
with advanced CKD and no known history of CHD were
randomised to one of three treatment arms: ezetimibe
10 mg plus simvastatin 20 mg daily, matching placebo
or simvastatin 20 mg daily. In the latter arm, participants
were re-randomised at one year to either ezetimibe 10 mg
plus simvastatin 20 mg daily, or to placebo. The primary

endpoint was a composite of MI, coronary death, ischaemic
stroke or any revascularisation procedure. Compared
with placebo, randomisation to ezetimibe 10 mg plus
simvastatin 20 mg daily yielded average LDL-C differences
of 1.10 mmol/L at one year and 0.85 mmol/L at 2.5 years.
Recent evidence from the SHARP trial, published during the
finalisation of these guidelines, showed similar reductions
in LDL-C (0.85 mmol/L) at a median follow up of 4.9 years.
This data reported a 17% proportional reduction in major
atherosclerotic events compared with placebo (RR 0.83, 95%
CI 0.74-0.94) with no evidence of adverse effects.226 While
this evidence did not result in a regrading of recommendation
EBR14, the outcome data further support the use of
ezetimibe in combination with a statin if LDL-C levels are not
sufficiently reduced on a statin alone.
A secondary analysis from the Justification for the Use
of Statins in Prevention – an Intervention Trial Evaluating

Rosuvastatin (JUPITER) trial reported positive effects from
statin therapy on cardiovascular and mortality outcomes
among people with moderate CKD (eGFR <60 ml/min/1.73
m2) at study entry (n=3,267), compared with those with
baseline eGFR ≥60 ml/min/1.73 m2 (n=14,528).295 Over
a median follow-up period of 1.9 years, a higher rate of
vascular events was observed in the group with moderate
CKD (HR 1.54, 95% CI 1.23–1.92, p=0.0002). In the same
group, rosuvastatin was associated with a 45% reduction
in risk of the combined primary endpoint – MI, stroke,
hospital stay for unstable angina, arterial revascularisation or
confirmed cardiovascular death (HR 0.55, 95% CI 0.38–0.82,
p=0.002) and a 44% reduction in all-cause mortality (HR
0.56, 95% CI 0.37–0.85, p=0.005). An almost identical effect
of rosuvastatin on the primary endpoint was observed among
those with more preserved renal function (HR 0.57, 95% CI
0.45–0.72, p<0.001).

Evidence-based recommendations

Grade

Lipid-lowering therapy
EBR 13: Statins should be used as first-line therapy

A206, 208, 209

EBR 14: If LDL-C levels are not sufficiently reduced on maximally tolerated doses of statin, one
or more of the following may be added:
• ezetimibe
• bile acid binding resin
• nicotinic acid.

C224-226
D219,223
D218,227

EBR 15: Where statins cannot be tolerated at all, one or more of the following can be used:
• ezetimibe
• bile acid binding resin
• nicotinic acid.

D225
D223
D227-229

EBR 16: If triglyceride levels remain elevated, treatment with one of the following may be
considered:
• fenofibrate (especially if HDL is below target)
• nicotinic acid
• fish oil.

C220-222
C218, 227
C230-232

Practice point
PP 18: Treatable secondary causes of dyslipidaemia should be considered before commencing lipid lowering
pharmacotherapy
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2.3.3 Principles of pharmacological
therapy
A number of issues should be considered when making
treatment decisions for the management of CVD risk.

Balancing the benefits and risks of treatment
For all individuals, a clinical judgment should be made
to assess the balance between the benefits and risks of
pharmacological treatment. Clear benefits in preventing
cardiovascular events and reducing premature mortality
have been demonstrated for BP and lipid-lowering therapy
in many clinical trials. However not all clinical situations in
which their use may be considered have been covered by
clinical trials, e.g. in the elderly.
Use of these therapies are associated with risks and other
negative effects which should be taken into consideration
when deciding the appropriateness of implementing the
treatment recommendations contained in these guidelines.
These therapies may be contraindicated in some situations
and their use may result in troublesome side effects. In
addition, polypharmacy may be unaffordable to some, may
increase the risk of side effects and may impact on quality
of life.
The appropriateness of general treatment targets to the
individual should also be considered. CVD risk associated
with lipid and BP levels is continuous and specific targets
are somewhat arbitrary and should be used as a guide to
treatment and not as a requirement, especially if they cannot
be easily achieved without causing unwanted effects. The
risks associated with the effort required to reach a particular
target as opposed to achieving a near-target value may
outweigh any small absolute benefit. Any reduction in a risk
factor will be associated with some benefit.

Prescribing pharmacological treatment
Benefits and risk should be carefully considered before
initiating or changing pharmacological treatment.
The primary consideration is clinical need and clinical
appropriateness of a particular therapy. The choice of
agent should be guided by clinical effectiveness but once
the decision on the class of drug has been made, further
consideration should be given to the cost to both the
individual and government. The use of cheaper alternatives
such as generic medications instead of more expensive
options achieves similar health gains while increasing
consumer and societal affordability.
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2.4 Populations requiring special
consideration
2.4.1 People with diabetes
CVD is the major cause of death in people with diabetes
with nearly 11,900 Australian deaths in 2005 of which CVD
was involved in more than 50%: CHD (48%), stroke (16%)
and PVD in 6%.30 Diabetes approximately doubles the risk
for a range of cardiovascular diseases independently of
traditional risk factors.296 While diabetes is a clear risk factor
for CVD the role of improved control of blood glucose for
preventing CVD morbidity and mortality in people with type
2 diabetes is unclear although it has been found to prevent
or reduce microvascular complications (retinopathy, renal
disease and neuropathy).30

Lifestyle
Lifestyle modification and support (particularly diet, weight
control and physical activity) is critically important in diabetes
care.30 The lifestyle recommendations in these guidelines
for CVD prevention in the general population apply equally
for people with diabetes.

Pharmacotherapy
BP lowering reduces cardiovascular events and all-cause
mortality in people with type 2 diabetes in the same manner
as for the general population.192, 195 While no difference is
noted between different classes of BP-lowering therapy for
CVD outcomes,195 there is clear evidence that in people
with type 2 diabetes, antihypertensive therapy with an
ARB or ACE inhibitor decreases the rate of progression
of albuminuria, promotes regression to normoalbuminuria
and may reduce the risk of decline in renal function.31, 297, 298
The benefit in terms of renal protection was also found in
the recent ROADMAP study which included 4,447 people
with type 2 diabetes and normoalbuminuria but additional
risk factors (33.4% had pre-existing CVD).297 While overall
baseline BP was already low (mean 136/81 mm Hg)
treatment to low BP targets (<130/80 mmHg) was achieved
by more people in the intervention arm using an ARB vs
other agents (80% vs 71%). Treatment with ARB prevented
(8.2% vs 9.8%) and delayed the onset of microalbuminuria
(23% delay to onset; p=0.01). An increase in CVD mortality
was noted although numbers are low (15 v 3) and the
difference greater in those with CHD (2.0% mortality
with ARB v 0.2% mortality with other agents, p=0.02). A
post hoc analysis found a reduction in combined cardiac
morbidity (acute coronary syndrome, silent MI, coronary

revascularization and hospitalization because of congestive
heart failure) (1.1% v 2.3%; p<0.01).
Given the importance of preventing and managing renal
complications in people with diabetes, these classes of
drugs (ACE inhibitor or ARB) should be preferred as first-line
therapy. However, more than one agent is often needed to
reduce BP. In a pre-specified subgroup analysis from the
ACCOMPLISH trial, those with diabetes (n=6,946; 15%
had previous MI and 8% had previous stroke) significantly
reduced the risk of CVD events with a combination of a
CCB plus an ACE inhibitor compared with those treated
with a combination of a thiazide diuretic plus an ACE
inhibitor (HR 0.79, 95% CI 0.68–0.92, p=0.003) even
though mean blood pressure was similar in both groups
(~132/73 mmHg).299 In the pre-specified subgroup analysis
of the ASCOT trial for those with diabetes (n=5,137, at least
38% had pre-existing CVD), the CCB based combination
(mostly with an ACE inhibitor) compared to the Beta Blocker
combination (mostly with a thiazide diuretic) reduced
the risk of combined CVD events and procedures (HR
0.86, 95% CI 0.76–0.98, p=0.026). There was a greater
reduction of in-trial BP with the CCB based combinations
compared to those using Beta Blocker based combinations
(mean difference on CCB combination was 3.0 mmHg
SBP and 1.9 mmHg DBP lower), however, there was no
difference by the end of the study (~135/75 mmHg in each
group).300 In the ADVANCE trial (n=11,140, 32% had major
macrovascular disease) treatment with a fixed dose ACE
inhibitor plus a diuretic reduced the risk of combined macro
and micro disease (HR 0·91, 95% CI 0·83–1·00, p=0·04)
compared to placebo.273 Evidence for BP targets for those
with diabetes has also been recently updated (refer to
section 2.3.1 Blood pressure-lowering therapy).
Several systematic reviews have looked exclusively at
responses to lipid modification of people with type 2
diabetes. The results from these reviews are consistent and
suggest that people with diabetes gain similar benefits from
statin therapy as people without.206, 209, 211

In the CARDS study, the AR reduction attributable to
statin therapy was 1.70% (95% CI 0.11–3.29) for all-cause
mortality and 1.35% (95% CI 0.30–2.40) for total stroke. The
NNT for four years to prevent one death was 59 (95% CI
30.4–88.5).211, 301
Evidence for the benefit of lipid lowering with fibrates
in people with type 2 diabetes is less clear. In the trials
performed to date, fenofibrate therapy alone did not
significantly reduce the risk of coronary events or stroke in
people with type 2 diabetes,222, 291 nor did the combination
of fenofibrate and simvastatin.292 However, two of those
trials (ACCORD and FIELD studies), demonstrated beneficial
effects with fenofibrate therapy on lowering microvascular
complications.291, 292
The role of aspirin for the primary prevention of
cardiovascular events in people with type 2 diabetes has
been assessed in four systematic reviews.239, 243, 247, 248 These
reviews consistently report that aspirin therapy is associated
with a modest non-significant reduction in risk of major
cardiovascular events in people with diabetes. Given that
these effects are less than those for the general population
the recommendations to not routinely treat with aspirin
are consistent for people with or without diabetes (refer to
section 2.2.3 Antiplatelet therapy).
Readers are referred to other guidelines for information on
pharmacotherapy specific to diabetes care (blood glucose
management).30 Recommendations for the secondary
prevention of CVD in those with diabetes is covered in
the National Evidence-Based Guideline on Secondary
Prevention of Vascular Disease in type 2 diabetes (currently
being drafted). While recommendations are consistent in
primary and secondary populations some of the grading
of individual recommendations differs slightly, due to the
underlying evidence for the different populations.

Evidence-based recommendations

Grade

Populations requiring special consideration: people with diabetes
EBR 17: Blood pressure-lowering therapy in people with diabetes should preferentially include
an ACE inhibitor or angiotensin receptor blocker.

A297, 298, 302, 303

EBR 18: If monotherapy does not sufficiently reduce blood pressure add one of the following:
• Calcium channel blocker
• Low dose thiazide or thiazide-like diuretic.

B299, 300
C273, 299
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2.4.2 People with CKD
People with CKD are at significantly increased risk of
cardiovascular events. In a pooled analysis of four large
community-based, longitudinal studies, CKD (eGFR 15–60
ml/min/1.73 m2) was associated with a 20% increased risk
of cardiovascular events and death.304 This is consistent with
a recent meta-analysis, which found CKD and albuminuria
are independent predictors of all-cause mortality and
cardiovascular mortality in the general population.305 For
this reason, individuals with CKD should be identified early
so that appropriate preventative measures can be taken.
This section provides a summary of the evidence for CKD,
as it pertains to absolute CVD risk reduction. The reader is
directed to the main text for more detailed information.

Lifestyle
Limited evidence exists on the effects of lifestyle
modification (i.e. smoking, physical activity and alcohol)
on CVD outcomes in patients with CKD. Dietary
recommendations outlined for the prevention of CVD apply
equally to those with CKD. Furthermore, all adults should
be encouraged to participate in at least 30 minutes of
moderate intensity activity on most or preferably every day
of the week and all smokers should be advised to stop.

Pharmacotherapy
High BP is common in CKD and represents a major
target for intervention to prevent disease progression. In
general, the clinical evidence suggests that people with
CKD receive the same or similar benefits from BP-lowering
therapy as the general population, irrespective of the level
of kidney function. A recent systematic review considered
during finalisation of these guidelines, included three trials
which compared different BP targets in adults with CKD
and showed no difference in outcomes for people treated
to lower BP targets (<125/75 to 130/80 mmHg) versus
higher targets (<140/90 mmHg).277 More BP-lowering
pharmacotherapy was needed to achieve the lower BP
targets, and this group had a slightly higher rate of adverse
events. Much less evidence is available for people on
maintenance dialysis. However, the available evidence
suggests that treatment using agents that lower BP reduces
cardiovascular morbidity and mortality for this group.197
While more studies are required, the possible risks and
benefits of BP lowering should be considered for all people
receiving dialysis.
Two meta-analyses provide evidence that ACE inhibitors
and ARBs are the preferred agents for BP lowering in
people with CKD because of their renoprotective effects
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more than their impact on mortality outcomes. In the first
meta-analysis,302 ACE inhibitors compared with placebo
significantly reduced the risk of developing microalbuminuria
in normoalbuminuric people with diabetes (RR 0.60, 95%
CI 0.43–0.84). No subgroup analysis was conducted for
those with and without existing CVD. No effect was seen
for doubling of creatinine (RR 0.81, 95% CI 0.24–2.71) or
all-cause mortality (RR 0.81, 95% CI 0.64–1.03). When
compared with CCBs, ACE inhibitors significantly reduced
progression to microalbuminuria (RR 0.58, 95% CI 0.40–
0.84). The effect of ACE inhibitors was independent of
baseline BP, renal function and type of diabetes; however,
there was insufficient data to be certain that these factors
are not important effect modifiers.
The second meta-analysis303 compared the survival
effects of ACE inhibitors and ARBs in 49 trials with mixed
populations of primary and secondary CVD. No significant
difference was found in the risk of all-cause mortality for
ACE inhibitors compared with placebo (RR 0.91, 95% CI
0.71–1.17) and ARBs compared with placebo (RR 0.99,
95% CI 0.85–1.17). However, ACE inhibitors showed a
significant reduction in the risk of all-cause mortality when
given at maximally tolerated dose compared with half or less
than half the maximally tolerated dose (RR 0.78, 95% CI
0.61–0.98). ACE inhibitors and ARBs had similar beneficial
effects on renal outcomes.
The benefits provided by statin therapy are similar in people
with CKD to those observed in the general population.
In a Cochrane review, statin therapy decreased all-cause
mortality and cardiovascular mortality among people
with non-dialysis dependent CKD to an extent similar
to that found in the general population.235 The same
authors reported in an expanded meta-analysis that
statins significantly reduced lipid levels in those with CKD,
irrespective of stage of disease, but showed no benefit
on all-cause mortality.293 A secondary analysis from the
JUPITER trial in people with moderate CKD (eGFR <60 ml/
min/1.73 m2) at study entry (n=3,267), compared with those
with baseline eGFR ≥60 ml/min/1.73 m2 (n=14,528) and
found rosuvastatin was associated with a 45% reduction
in risk of the combined primary endpoint – MI, stroke,
hospital stay for unstable angina, arterial revascularisation or
confirmed cardiovascular death (HR 0.55, 95% CI 0.38–
0.82; p=0.002) and a 44% reduction in all-cause mortality
(HR 0.56, 95% CI 0.37–0.85, p=0.005).295 Recently, the
landmark SHARP trial reported a combination of ezetimibe
10 mg plus simvastatin 20 mg daily reduced LDL-C by an
average of 0.85 mmol/L and reduced major CVD events
by 17% (RR 0.83, 95% CI 0.74–0.94) compared to statin
therapy alone, without evidence of adverse events.226

In summary, the evidence suggests that, apart from choice
of agent for initiation of BP-lowering treatment, people with
CKD should be managed for CVD risk in the same way as
the general population.

Evidence-based recommendation

Grade

Populations requiring special consideration: people with CKD
EBR 19: Blood pressure-lowering therapy in people with CKD should begin with an ACE inhibitor
or angiotensin receptor blocker.

A302, 303
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Chapter 3:

Monitoring of Pharmacotherapy
The goal for management of absolute CVD risk is to reduce the person’s
level of AR. This is achieved by treatment of multiple individual risk factors
such as blood pressure and lipid levels which have been shown to have a
continuous association with the risk of CVD events.

Moderate reductions in several risk factors is considered
more effective in reducing overall CVD risk than a major
reduction in one factor.5 Decisions regarding management of
risk are therefore made according to the person’s AR level,
while response to treatment is monitored by measurement
of individual risk factors.
In people with moderate to high CVD risk, having an
effective strategy for monitoring treatment response is
essential for achieving long-term CVD prevention. There is
some evidence to support the use of monitoring, particularly
to measure response to treatment of individual risk factors
and for adherence. In general, the literature to support
medication monitoring and/or adherence is consistent and
reports either improvement in individual risk factors or, in
some instances, a reduction in overall CVD risk.

3.1 Maximising the benefits of
pharmacotherapy
The literature reports several methods for monitoring
adherence to pharmacological interventions in terms of
effect (e.g. BP or lipid levels). These methods include selfmonitoring,306 tele-monitoring,306 case management307 and
individualised provision of information.308, 309 These studies
consistently report that regular monitoring of individual risk
factors is associated with improvement in CVD risk factor
outcomes. Furthermore, several studies310-312 report that
lack of monitoring contributes to poor adherence to statin
therapy and therefore worse outcomes.
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Although targets for BP and lipid levels have been generally
agreed, based on extrapolations of what has been achieved
in clinical trials, the relationship between BP levels, lipid
levels and CVD risk is known to be continuous. Therefore,
targets should be considered indicative and should be
used for monitoring treatment effects and adherence to
medication while considering the individual person’s risk/
benefit profile. After commencement of BP lowering therapy
and until treatment is stable or targets achieved, BP levels
should be reviewed at intervals of six weeks unless there
are concerns or indications for more frequent monitoring.
Similarly, after commencement of lipid therapy, lipid levels
should be reviewed at 12 weekly intervals.
Monitoring of patient response to treatment may lead to
reconsideration of appropriate management. In some
patients who make significant and sustained lifestyle
changes such as smoking cessation or loss of 10–20%
of body weight, there will be a consequent significant
reduction of individual risk factors. Reduction or withdrawal
of pharmacotherapy may be considered in these cases;
however, monitoring should continue for at least 12 months
to ensure a sustainable impact on the risk factors.

Consensus-based recommendations
Maximising the benefits of pharmacotherapy
CBR 7: Pharmacotherapy for blood pressure-lowering should aim towards the following targets while balancing the
risks/benefits:
• ≤140/90 mmHg for adults without CVD (including those with CKD)
• ≤130/80 mmHg for adults with micro or macro albuminuria (UACR >2.5 mg/mmol in males and >3.5 mg/mmol in
females)
• ≤130/80 mmHg for all adults with diabetes
CBR 8: Pharmacotherapy for lipid lowering should aim towards the following targets while balancing the risks/benefits:
• TC <4.0 mmol/L
• HDL-C ≥1.0 mmol/L
• LDL-C <2.0 mmol/L
• Non HDL-C <2.5 mmol/L
• TG <2.0 mmol/L

Practice point
Maximising the benefits of pharmacotherapy
PP 19: Adults who commence pharmacotherapy should have their medication adjusted as required and response
assessed regularly (approximately 6-12 weekly) until sufficient improvement has been achieved or maximum tolerated
dose has been reached.
PP 20: Reduction or withdrawal of pharmacotherapy may be considered in adults who make sustained lifestyle
changes which significantly reduce their risk. (e.g. smoking cessation, significant weight loss).

3.2 Patient adherence
Failure to take prescribed medication is a major barrier
to optimal prevention of CVD, however the literature
concerning interventions to improve adherence to
medications remains surprisingly weak. One Cochrane
review involving 78 trials found only modest effects for
interventions to improve adherence to medications across
a range of populations and settings. Conflicting evidence
for short-term interventions on compliance was found and
very few studies reported changes in patient outcomes.313
Almost all of the interventions that were effective for longterm compliance were complex, including combinations
of more convenient care, information, reminders, selfmonitoring, reinforcement, counselling, family therapy,
psychological therapy, crisis intervention, telephone followup and supportive care.

most effective, but this finding was dominated by findings
from a single large trial – the Hypertension Detection and
Follow-Up study. Self-monitoring (18 trials) was associated
with a reduction in SBP (2.5 mmHg) and DBP (1.8 mmHg)
and may be a useful adjunct strategy. Other interventions
assessed in this systematic review did not produce clear
results. Educational interventions directed at physicians (10
trials) did not change BP control, but education for patients
(20 trials) may have a modest effect although heterogeneity
was noted. Use of health care professionals such as
nurses and pharmacists (12 trials) demonstrated generally
favourable but heterogeneous results. Lastly, reminders
(postal, computer or telephone) improved follow-up and
control of patients, but produced heterogeneous results in
terms of BP reduction.

One recent Cochrane review (72 trials) assessed different
interventions to improve BP control in hypertensive adults
in a primary care, outpatient or community setting.314
Organisational interventions (nine trials) to enable regular
review in tandem with a rigorous stepped-care approach
to antihypertensive drug treatment were found to be the

Another Cochrane review (38 trials) specific to BPlowering therapy in an ambulatory setting suggested that
simplifying dosing regimens was the most consistently
effective intervention (seven out of nine studies).
Motivational strategies (e.g. financial incentives or reminder
packages/aids) and complex interventions involving

65

more than one technique were less consistent. Effects
were generally modest and patient education alone was
largely ineffective.315 Further, in a systematic review of
11 trials investigating the effects of home BP monitoring
on medication adherence, six of the 11 trials reported
a statistically significant improvement in medication
adherence; 84% of these were complex interventions using
home BP monitoring in combination with other adherenceenhancing strategies such as patient counselling by nurses,
pharmacists or telephone-linked systems, patient education
and the use of timed medication reminders.316 Two
moderate quality reviews of simplifying doses by using fixeddose combinations to improve adherence for raised BP
reported improved compliance with combination treatment
(24% decrease risk of non-compliance in one review).317, 318
Another systematic review (11 trials) found strategies for
patient re-enforcement and reminding (e.g. telephone
reminders or pharmacist review) to have the most consistent
benefits in improving adherence for lipid-lowering therapy
(four of six trials were positive with absolute improvement in
adherence of 6–24%).319 Other strategies found to increase
adherence, included simplification of the drug regimen
(11% improvement) and patient information and education
(13% improvement), although results were inconsistent
and the quality of some studies was low. One high-quality
systematic review (21 trials) in people with type 2 diabetes
failed to find clear benefits for various strategies including
nurse-led interventions, home aids, diabetes education,
pharmacy led interventions, adaptation of dosing and
frequency of medication taking.320 The evidence is difficult to
interpret due to heterogeneity; however overall there seems
to be a modest improvement in adherence from the more
complex interventions.
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Guidelines development groups and terms of reference
The guidelines development process was coordinated by
the National Stroke Foundation on behalf of the National
Vascular Disease Prevention Alliance (NVDPA) with partner
agencies represented on the advisory and/or expert
working group committees as appropriate. The guidelines
have been developed according to the processes outlined
in the document NHMRC Standards and Procedures for
Externally Developed Guidelines (2007).

Project Committees
Three groups were established in the development of the
guidelines.

Advisory Committee
The Advisory Committee had 17 representatives from
a wide range of backgrounds including diabetes,
nephrology, stroke, cardiology, Indigenous health, general
practice, economics, a consumer and the Pharmaceutical
Benefits Advisory Committee (PBAC). The Committee was
responsible for:
• overseeing operational aspects of the guidelines
development
• determining the topics and questions to be addressed
in the guidelines
• advising on a plan for communication, dissemination
and implementation
• assisting the EWG as needed (particularly in regard to
responding to consultation where significant difference
in opinion exists)
• developing recommendations for periodically updating
the guidelines
• regular reporting to the full committee of the NVDPA.
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identified research
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• assisting with the drafting of the guidelines document
• linking with members of the corresponding group where
relevant
• assisting with the consultation process
• assisting with the response to feedback gained during the
consultation process.
The NVDPA is grateful to the members of the EWG
who provided their time and expertise to develop these
guidelines.
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Appendix 2:

Guidelines development process report

1. Methodology
These guidelines were developed according the standards
outlined in the NHMRC Standards and Procedures for
Externally Developed Guidelines (2007).

2. Clinical questions
The clinical questions were initially framed by building on
the work undertaken in the development of the Guidelines
for the Assessment of Absolute Cardiovascular Disease
Risk. Further refinement was undertaken after consultation
with international guidelines groups in Scotland and New
Zealand. Questions were then grouped under topics and
circulated to experts for comment. Some experts were
consulted individually for further detailed comments. In
response to the comments from experts, the questions
were modified for further discussion and final approval at a
face-to-face meeting of the Advisory Committee held on 26
November 2009.
The clinical questions are outlined below:

Absolute risk assessment
1.

Which AR assessment method is most predictive
of future CVD events in a mixed adult (aged >18)
population not known to have CVD or diabetes?

2. Which AR assessment method is most predictive
of future CVD events in a mixed adult (aged >18)
population not known to have CVD and who have
diabetes?
3. Which AR assessment method is most predictive
of future CVD events in a mixed adult (aged >18)
population not known to have CVD and who are

72

overweight (defined as BMI within the range 25.0–
29.9 kg/m2) or obese (BMI ≥30kg/m2)?
4. Which AR assessment method is most predictive
of future CVD events in adult (aged >18) Aboriginal
and Torres Strait Islander peoples not known to have
CVD?
5. Which AR assessment method is most predictive of
future CVD events in adult (aged >18) people with
chronic kidney disease (eGFR <45ml/min1.73 m2) not
known to have CVD?

Aims of treatment, monitoring and follow-up
6. Is there evidence that multiple risk intervention is
more effective in reducing CVD events and all cause
mortality than intervention on single risk factors?
NOTE: evidence was systematically identified but
used in narrative review (rather than comprehensive
critical appraisal and summary process) to form
important part of main body of guidelines.
7. What evidence exists to support the benefit of
monitoring treatment effects? Report evidence for
secondary outcomes defined as AR levels; individual
risk factor levels; side effects; compliance with
treatment.
8. Do strategies to promote concordance with
medication reduce the risk of CVD? NOTE: as for
Q6 evidence was systematically identified but used in
narrative review to form important part of main body
of guidelines.

Blood pressure
9. Does pharmacological blood pressure-lowering
reduce CVD events and all cause mortality compared
to ‘control’?

10. What is the evidence for one blood pressure-lowering
drug class or any combination of drug classes being
more effective than any other blood pressure-lowering
drug class or combination for reducing CVD events
and all cause mortality? Report evidence for secondary
outcome defined as: Reduction of BP.
11. Should blood pressure therapy be initiated with a single
drug or with a combination?
12. Should antihypertensive therapy employ drugs at fixed
doses or should individuals always be titrated to target
blood pressure levels?

Diet and nutrition
21. Is there evidence that following dietary advice reduces
CVD events and all cause mortality? Report evidence
for outcomes: BP; Lipid parameters; Diabetes.

Physical activity
22. Is there evidence that physical activity reduces CVD
events and all cause mortality?

13. Does more intensive blood pressure-lowering produce
greater reductions in CVD events and all cause
mortality?

23. What is the evidence for physical activity type and
dose or any combination of type/doses being more
effective than any other physical activity type and dose
or combination for the reduction of CVD events and
all cause mortality? Report evidence for secondary
outcomes: BP; Lipid parameters.

Lipids

Alcohol

14. Does pharmacological lipid modification compared to
control reduce CVD events and all cause mortality?

24. What is the evidence that the patterns and levels of
alcohol consumption alter CVD events and all cause
mortality? Report evidence for secondary outcomes:
BP; Lipid parameters.

15. What is the evidence for one lipid modifying drug class
or any combination of drug classes being more effective
than any other lipid-modifying drug class or combination
for the reduction of CVD events and all cause mortality?
Report evidence for secondary outcome defined as:
Reduction of blood lipids.
16. Should lipid lowering therapy employ drugs at fixed
doses or should individuals always be titrated to target
lipid levels?
17. Does more intensive lipid modification treatment
produce greater reductions in CVD events and all cause
mortality?

Antiplatelets
18. Does antiplatelet therapy compared to control reduce
CVD events and all cause mortality? Report evidence
for secondary outcome: Bleeding complications.
19. What is the evidence for one antiplatelet therapy or
dose or any combination of therapy/doses being more
effective than any other antiplatelet therapy/dose or
combination for the reduction of CVD events and
all cause mortality? Report evidence for secondary
outcome: Bleeding complications.

Obesity

Smoking
25. Does smoking cessation reduce CVD events and all
cause mortality?

Depression
26. Does treatment (pharmacological and non
pharmacological) of depression reduce CVD events and
all cause mortality?

3. Literature review
The systematic literature review was undertaken according
to the process outlined in the NHMRC Standards and
Procedures for Externally Developed Guidelines (2007) by
an external group from the Centre for Allied Health Evidence
(iCAHE), University of South Australia, led by Dr Susan Hillier
and Professor Karen Grimmer-Somers.
Searches were conducted in relevant databases using
an agreed search protocol which lists details of search
terms, inclusion/exclusion criteria, and data extraction and
appraisal methodology. Additional hand searching was
conducted by the NSF project team in several key journals
to identify any major trials or meta-analyses published after
the systematic literature review.

20. Does reducing weight reduce CVD events and all cause
mortality? Report evidence for secondary outcomes:
BP; Lipid parameters.
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3.1 Criteria for considering studies for the
review

3.2 Search strategy for identification of
studies

Search dates

A broad search strategy using the following databases and
sources was used to identify potential studies:

The search dates were 2006 to June 2010 for the first five
questions relating to assessment of CVD risk which updated
the search conducted for the Clinical Guidelines for the
Assessment of Absolute Cardiovascular Disease Risk (which
used no limits on the date of publication). The search dates
were 2002 to June 2010 for the remaining questions relating
to management of absolute CVD risk. Hand searching was
conducted between June 2010 and May 2011.

Types of studies
Existing guidelines, systematic reviews (Level 1 evidence,
based on the NHMRC Levels of Evidence and Grades
for Recommendations for Developers of Guidelines
(2009), randomised controlled trials (Level II evidence)
were considered for inclusion, crossing intervention and
diagnostic domains. Where there was a scarcity of Level I
or Level II evidence, it was planned to expand the review to
consider lower levels of evidence. Studies were limited to
English language only.

Types of participants
The review included research conducted in adults without
pre-existing CVD or in those with and without CVD but
where those without CVD were reported separately.

Types of outcomes
In principle, the primary outcome for each question
was cardiovascular events (definition for CVD as for the
Guidelines for the Assessment of Absolute Cardiovascular
Disease Risk).
The secondary outcome of interest was AR reduction,
followed by surrogate outcomes such as individual risk
factor reduction as specified in the questions (e.g. BP
control).
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• Medline
• Embase
• Cinahl
• PsychINFO
• Cochrane Library, including CENTRAL Cochrane
Controlled Trial Register (CCTR) and DARE for some
topics.
In addition, the following websites were searched including
Australian Centre for Clinical Effectiveness, National Institute
for Health and Clinical Excellence, National Library for
Health, Swedish Council on Technology Assessment in
Healthcare, US Agency for Healthcare Research and Quality,
and the US National Guidelines Clearing House. The EWG
were sent interim search reports and asked to identify any
additional studies.
Hand searching undertaken after the online database
searching included the following journals: British Medical
Journal, New England Journal of Medicine, LANCET,
Circulation, Journal of the American Medical Association,
Archives of Internal Medicine, Medical Journal of Australia
and Diabetes Care.
The Cochrane library was also reviewed to incorporate new
or updated reviews. Hand searching was undertaken to
identify major meta-analyses or landmark trials to maximise
the currency of the text. In one situation, literature identified
after the comprehensive literature review period was
deemed by the EWG to be sufficiently important to result
in a change to the recommendations (i.e. BP targets for
those with CKD). This decision took into consideration the
quality of evidence (all high-quality meta-analyses), the need
to provide clinicians with the most useful recommendation,
alignment to draft international CKD guidelines, and the
likely scenario that the current guidelines could be out of
date before they were published.

In addition to the initial searches, economic literature was
searched via EBSCOhost database (Econlit & CINAHL),
Ovid database (EMBASE, Medline), BioMed central and
Cochrane library database (Health Technology Assessment,
NHS Economic Evaluation). A broad search strategy of
Australian and international literature (developed countries
including European, North American and Canadian) for the
years 2002–2010 was used. The cut-off dates build on the
SIGN guidelines used during the systematic review phase.

Search terms
Search terms were used for each group of clinical
questions/topics. Search terms were based on those
reported in the Supplementary Guidelines Material (SIGN)
where the first series of strings are disease/population
identifiers and the additional strings relate to the specific
question, i.e. intervention (e.g. alcohol and euphemisms).
Search strategies used in other databases were adjusted
for different databases, but were substantially the same.
Searches were combined with guidelines, systematic review,
and trial filters as appropriate.

3.3 Study selection
One reviewer assessed the titles and available abstracts
of all studies identified by the initial broad searches (based
on population and intervention) and excluded any clearly
irrelevant studies. Two reviewers then independently
assessed papers identified as potentially eligible studies
using the inclusion criteria and resolved disagreements on
inclusion by consensus, with reference to a third reviewer
if necessary. This second phase thus focused on selection
of studies based on the outcomes, treatment comparisons
and any population subgroups (e.g. diabetes, CKD) which
may have different effects of an intervention.

Search terms used in the economic literature review were
essentially the same for each database. A broad population
identifier (CVD or cardiovascular disease OR coronary
disease OR heart attack OR stroke) was used followed by
the following terms: Exp “cost and cost analysis”; Costs.
ti/ab; Cost effective$.ti/ab; Cost benefit analys$.ti/ab; Exp
health care costs/; (economic adj2 evaluat$).ti/ab; and
finally primary prevention. Additional snowballing searches
were undertaken. The total number of hits was 204 of
which 28 were considered in more detail by one member
of the project team. Reviewing staff at Deakin University
scrutinised the 16 abstracts for omissions and 9 additional
appropriate papers were retrieved and reviewed.
The following criteria were used to select economic studies:
• overseas evidence in developed countries of Europe, UK,
North America, Canada
• AR of cardiovascular disease criteria
• primary prevention population included has no previous
history of CVD
• BP-lowering diuretics, beta blockers, CCBs, ACE
inhibitors
• cholesterol-lowering medications statins
• antiplatelets (aspirin)
• adults 35–84
• health outcome measured in Disability Adjusted Life Years
(DALYs) or QALYs.

Hand searching identified 44 potential new trials or metaanalyses of which 9 were included in the final guidelines.
During finalising of the guidelines two further meta-analyses
on BP treatment in those with diabetes were identified and
included.
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3.4 Search results

Questions 1-5: Absolute risk assessment
Sources:
Databases:
Medline; Embase; Cinahl; PsychINFO;
Cochrane Library, including CENTRAL
Cochrane Controlled Trial Register
(CCTR)
Other sources: See protocol for
details of guidelines and internet sites;
pearling; EWG.

Dates

Total hits

Retrieval list

Included

2006-2010

287

31+3+5

15

Search terms: as per Assessment
guidelines then adapted

CVD or cardiovascular disease OR coronary disease OR heart attack OR stroke;
AR assessment OR Global risk assessment OR Multivariate risk assessment OR
Framingham OR PROCAM

Outcomes:

Measures of predictive accuracy; odds ratios, relative risk and risk of observed
CVD events (including CVD mortality, MI, CHD, stroke, and peripheral vascular
disease).

Questions 6–8: Aims of treatment, monitoring and follow-up
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

138

31

(Q6) 18
(Q7) and 8) 13

Search Terms:

Multiple intervention, single intervention/treatment, monitor, cardiovascular, primary
prevention, risk factors, compliance, adherence, AR, side effects.

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary (Q7 only): AR levels, Individual risk factor levels, Side effects,
Compliance with treatment.

Questions 9-13:Blood pressure
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

3090

42+4

21

Search Terms:

Blood Pressure; Antihypertensive Agents; Adrenergic beta-antagonists;
DIURETICS; Angiotensin-Converting Enzyme Inhibitors Receptors, Angiotensin;
Angiotensin II Type 1 Receptor Blockers, Calcium Channel Blockers; lower$ adj2
blood pressure$; centrally acting agents; alpha blockers.

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary (Q10 only): BP changes, microvascular complications (particularly for
those with diabetes and/or CKD)

Questions 14-17:Lipids
Sources a/a

76

Dates

Total hits

Retrieval list

Included

2002-2010

413 + 64

49

26

Search Terms:

antilipemic agent; hypocholesterolemic agent$. lipid$ adj2 (low$ or depress$)
lipid modifying drugs; Dislipidaemia; Statins; HMGCoA inhibitors; familial
hypercholesterolemia
Added: HMGCoA Reductase; Inhibitors, Simvastatin, Clofibrate, Procetafen,
Bezafibrate, Niacin, Azetidienes, Colesevelam, Fibrate, Fenofibrate, Nicotinic Acid,
Ezetimibe, Anticholesterolemic agent, Omega-3 fatty acids, Bioacids

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary (Q15 only): lipid changes

Q18-19: Antiplatelets
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

1761

85

16

Search Terms:

Aspirin; Platelet Aggregation Inhibitors; Clopidogrel; dipyridamole; acetylsalicylic
acid; antiplatelet; Warfarin; Antithrombotic agents; Thrombin inhibitors; Thrombin
receptor antagonists; Heparinoids

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary: Bleeding complications

Q20: Obesity
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

321

61

4

Search Terms:

Weight loss; weight reduction; reducing weight; Bariatric surgery; antiobesity
medications; behavioural therapy

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary: Bleeding complications

Q21: Diet and Nutrition
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

1626

32+16

18

Search Terms:

Diet;Intervention; Advice; Lifestyle; Sodium chloride/salt; Saturated fats;
Antioxidants; Omega-3 fatty acids; Soy protein; Glycaemic index or load;
Vegetables; Phytosterols, sterols, stanols; Nuts; Low carbohydrate; Low fat; High
protein; Weight loss/ energy restriction; Fibre pectin; soluble fibre; Trans fats

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary: Blood pressure, Lipid parameters, Diabetes

Q22-23: Physical Activity
Sources a/a
Search Terms:

Dates

Total hits

Retrieval list

Included

2002-2010

1211

103+2

17

Exercise; sports; physical education and training; exertion; physical$ adj2 Fit;
physical$ adj2 fitness; physical adj2 train$; physical adj2 activit$; train$ adj2
strength$; train$ adj2 aerobic$; aerobic$ adj2 exercise$; exercise$ adj2 train$;
Added FITNESS adj (Train$ or program$); Resistance training.
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Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary (Q23): Blood pressure, Lipid parameters

Q24: Alcohol
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

139

76

13

Search Terms:

Alcohol Drinking; Alcohol drinking quantity; Alcohol drinking pattern; ALCOHOLIC
BEVERAGES; BEER; WINE; alcohol; spirits

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality
Secondary: Blood pressure, Lipid parameters

Q25: Smoking
Sources a/a

Dates

Total hits

Retrieval list

Included

2002-2010

417

79

1

Search Terms:

Smoking Cessation; “TOBACCO USE DISORDER” ; TOBACCO;
NICOTINE;Tobacco, Smokeless; SMOKING; (quit$ or stop$ or ceas$ or giv$)
adj2 smoking;TOBACCO; SMOKE POLLUTION; Second hand smoking; Passive
smoking

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality

Q26 – Depression
Sources a/a

78

Dates

Total hits

Retrieval list

Included

2002-2010

1178

22

0

Search Terms:

Depressive disorder; Dysthymic disorder; depression/ depression, involutional/
depression, postpartum/; Seasonal affective disorder; Major depressive disorder;
Treatment pharmacological or other; Screening for depression

Outcomes:

Primary: CVD events (including CVD mortality, MI, CHD, stroke, and peripheral
vascular disease), all case mortality

4. Evidence tables

Methodological quality assessment

Data from included studies was abstracted along with
a methodological appraisal (see below). This included
information including citation, study type, evidence level
(as per NHMRC Levels of Evidence and Grades for
Recommendations for Developers of Guidelines (2009)
patient number and characteristics, intervention/s,
comparison, length of follow-up, outcome measure, effect
size and funding source (as appropriate).

Two reviewers independently assessed the methodological
quality of each included trial and resolved disagreements by
consensus, with reference to a third reviewer if necessary.
Methodological quality of existing guidelines was assessed
using the Appraisal of Guidelines Research and Evaluation
Collaboration (AGREE) Agree instrument. Methodological
quality of included systematic reviews and controlled
trials was assessed using a modified checklist based on
the Scottish Intercollegiate Guidelines Network (SIGN)
Methodology checklist for systematic reviews and metaanalyses and the Guidelines International Network draft

evidence tables. These checklists were developed and used
previously by the NSF. Methodological quality of included
cohort studies was assessed using the SIGN Methodology
checklist for cohort studies. For diagnostic studies identified,
the SIGN Methodological checklist for diagnostic studies
was used.

5. Formulation of recommendations
To assist in the formulation of recommendations, where
a body of evidence exists for each question, the NHMRC
Grades process has been applied. This has resulted in
an Evidence Statement for each question. The project
team including the chair of the EWG, along with input of
individual members of the EWG or corresponding group,
used these statements and the underlying evidence to
draft recommendations. The draft recommendations along
with the summary matrices were initially discussed by the
EWG at a face-to-face meeting of the working group on
7 September 2010. In addition to the summary matrices,
economic modelling on the cost benefit of various drug
therapies was commissioned and used to inform the
development of the recommendations. Subsequent
meetings via teleconferences were undertaken followed
by a modified Delphi process (over two rounds) to achieve
consensus (defined as >75% of responses from EWG) of the
final wording of the recommendations. The recommended
grading matrix was used to guide the strength of the
recommendation.

5.1 Link between research and
recommendations following an absolute
risk approach
These guidelines take an AR approach to the management
of CVD risk which has posed some challenges in formulation
of the recommendations. This is because although there is
robust and compelling evidence in the published literature
which clearly shows that pharmacotherapy reduces the
levels of individual risk factors (blood pressure and lipids)
with consequent reduction in CVD mortality or CVD
events, this evidence is based on a single risk factor/
relative risk approach. Therefore the expert panel carefully
considered the literature before making and grading the
recommendations in an AR paradigm. When examining the
evidence, consideration was given to any heterogeneity
found between subgroups and the generalisability of the
findings. The final grading of these recommendations was
downgraded to account for the uncertainty of applying
evidence from a relative risk approach to an AR paradigm.

Reporting of study results
Study results have been reported in the text of these
guidelines in the same form as reported in the research i.e.
where relative risk reduction has been the measure used in
the study, the results are reported using this term and have
not been converted to AR reduction.

5.2 NHMRC grade of recommendation matrix: evidence-based recommendations
Grade of
recommendation

Description

A

Body of evidence can be trusted to guide practice

B

Body of evidence can be trusted to guide practice in most situations

C

Body of evidence provides some support for recommendation but care should be taken in its
application

D

Body of evidence is weak and recommendation must be applied with caution

Matrix reproduced from NHMRC Levels of Evidence and Grades for Recommendations for Developers of Guidelines (2009)
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Additional guidance

5.3 Guidelines text

Where no robust evidence was found for the search
questions, the EWG followed the consensus process to
develop consensus-based recommendations. Practice
points were provided to give practical guidance to facilitate
the implementation of the guidelines.

The body of the text was drafted by a consultant medical
writer (medScript) based on an agreed framework. Early
drafts were circulated for input from the EWG and finalised
by the project team for public consultation.

CBR

Consensus-based recommendations: developed by the guidelines expert working group
when a systematic review of the evidence found either an absence of direct evidence which
answered the clinical question or poor quality evidence, which was deemed not to be strong
enough to formulate an evidence-based recommendation.

PP

Practice points: developed by the guidelines expert working group where a systematic review
had not been conducted but there was a need to provide practical guidance to support the
implementation of the evidence-based and/or consensus-based recommendations.

6. Consultation
6.1 Correlation with the draft National
Evidence-Based Guideline on Secondary
Prevention of Vascular Disease in type 2
diabetes
These guidelines were developed at the same time as
the National Evidence-Based Guideline on Secondary
Prevention of Vascular Disease in type 2 diabetes
(currently being drafted). The two groups consulted
extensively to ensure that the two guidelines provided a
consistent continuum of care for patients (including cross
representation on each advisory committee). As far as
possible, given the evidence available for the different
populations, the guidelines are consistent. Where there are
differences in the grading of recommendations, this is due to
the difference in evidence for the two populations.

6.2 Public Consultation
In line with the requirement under Section 14A of the
National Health and Medical Research Council Act
1992, the public consultation process invited feedback
during a month-long period in April 2011 and included
an advertisement in the press inviting public comment.
In addition, a notice of the opportunity for comment was
posted on the websites of NVDPA member organisations
and copies of the guidelines were distributed to a broad
group of identified stakeholders and networks. Consumer
organisations were also contacted for comment. Finally,
the draft document was circulated via the networks of
the various experts supporting the project. Five prompted
questions, modified from key questions included in the
Guidelines Implementability Tool, were also included in the
consultation feedback form to provide general feedback.
Overall there were 388 individual comments received
from 24 individuals and 19 organisations (including key
organisations such as the Royal Australian College of
General Practitioners, Stroke Society of Australasia, state
health departments, Australian General Practice Network
and the Cardiac Society of Australia and New Zealand).
Public consultation resulted in many detailed responses,
including many positive comments.
The major contentious issues and changes made in
response to the public consultation are outlined below:
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6.3 Contentious issues and responses
Issue

Response

BP treatment thresholds
Concerns were raised by a number of
individuals and organisations regarding
the lack of a BP treatment for the low AR
group. Suggestions were made to use
the 160/100 mmHg threshold as had
been recommended for the moderaterisk group.

The EWG agreed that pharmacotherapy for low risk adults is generally
not appropriate taking an AR approach. However, it was agreed that a BP
≥160/100 mmHg should be treated with pharmacotherapy, both for the
CVD risk and to prevent non-CVD complications such as heart failure and
renal failure, therefore, a recommendation has been included to treat adults
at low CVD risk who have persistent BP ≥160/100 mmHg with BP-lowering
pharmacotherapy in addition to lifestyle intervention.

Assessment for under
45s and over 75s
Concerns were raised about imputing
age 30 and using FRE as this will
overestimate risk. Similarly concern that
imputing 74 will underestimate risk in the
over 74 age group.

The EWG balanced the lack of strong evidence supporting CVD risk
assessment for people aged under 45 with the need to provide some guidance
for General Practitioners. The EWG therefore agreed that recommendations
would not be made for CVD risk assessment of the under 45 year old age
group (35 for A&TSI peoples). The text has been modified to remove the
recommendations for risk assessment of younger people and to include some
broad guidance on ensuring that people in this age group who have a strong
family history of CVD or single, isolated, elevated risk factors are appropriately
managed. The text was modified for the older age group to clarify that FRE is
used to ensure that age is not the only consideration when assessing risk in
this age group.

Moderate risk treatment
Lack of clarity about this
recommendation.

Recommendation has been divided into two recommendations to clarify the
meaning.

Lipids
Queries arose regarding interpretation
of the evidence especially for low-risk
populations.

References have been reviewed and text modified to ensure that primary and
secondary prevention evidence is appropriately identified. Evidence was also
updated with recent meta-analyses.

Monitoring
Lack of clarity about whether AR is
used to monitor progress of treatment
or whether treatment is monitored by
individual risk factors.

Text inserted to explain that AR is the entry point for treatment and treatment
decisions are made on the basis of risk level, but treatment response is
monitored by measurement of multiple individual risk factors.

7. Strategy for updating the
guidelines
The guidelines will need to be updated no later than five
years after being published (i.e. by 2016/7). However,
given the current national reform activity around guidelines
and standards no decision has been made regarding the
strategy to review the currency of the guidelines and any
method of updating the guidelines. These decisions will be
made by the NVDPA in consultation with the NHMRC and
other bodies (e.g. The Australian Commission on Safety and
Quality in Health Care).
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8. Implementation considerations
8.1 Background
The NVDPA’s new Guidelines for the Management of
Absolute Cardiovascular Disease Risk is an important step
along the path to improved prevention of CVD in Australia.
Of greater importance is the dissemination and application
in practice. Like the guidelines themselves, implementation
strategies should use an evidence-based approach based
on an underlying framework for CVD prevention. In addition
to the various NVDPA guideline development groups,
establishment of this plan was enhanced by obtaining
structured feedback at a meeting of key stakeholders (46
government, non-government, consumer and professional
organisation representatives) on 3 March 2011. This
meeting was called to specifically address implementation
considerations from a broad range of perspectives.

and population level to raise awareness of CVD risk, assess
risk and manage risk to prevent CVD as outlined in diagram
8.2. These guidelines focus only on comprehensive risk
assessment and management aimed at primary prevention
of CVD. Therefore, the guidelines and implementation
strategies should not be considered as a standalone
process but need to be linked to other important strategies
both at an individual and population level to maximise their
impact.

8.3 Levels to consider when implementing
guidelines

8.2 Strategic framework

Local factors operate over several different levels; all need
to be considered to maximise the effect of guidelines. These
levels are broadly described into four main categories:
professional, organisational, consumers and regulatory/
financial. Strategies to address barriers identified at each of
these levels need to be developed. Strategies that enhance
enabling factors should also be created. These are briefly
described below:

These guidelines are one important part of a coordinated
strategic framework for improving CVD prevention in
Australia. This framework includes activities at an individual

1. Professional level: strategies supporting health
professionals to adopt recommendations in the
guidelines. Strategies include:

Diagram 8.2 Strategic framework of CVD prevention
Risk awareness raising

help individuals identify that they may be at risk
General Practice:
Proactive and opportunistic

Community settings and workplaces:
Proactive

Comprehensive risk assessment in primary care
degree of risk determined for CVD, diabetes, CKD

Questions (eg. Family history)

Measurements (eg. Blood pressure)

Blood tests (eg. Cholesterol check)

Management and follow up in primary care
risk factors modified through lifestyle changes and/or medication

Low Risk

Moderate Risk

High Risk

Adapted from “Putting prevention first,” Department of Health (England) 2008
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Established Disease

a. dissemination/distribution of the guidelines
b. education and training
c. audit and feedback, reminders or decision support
tools
d. use of local consensus processes.
2. Organisational level: strategies supporting organisational
change to facilitate adoption of the guidelines. Such
strategies may include quality improvement systems,
accreditation processes, adoption of policies and
protocols.
3. Consumer level: strategies supporting behaviour change
among consumers in relation to the guidelines.
4. Regulatory or financial level: strategies targeting
regulatory systems to support change at all levels. This
may include change in reimbursement items for GPs,
incentives, approval and cost of medicines.

8.4 Evidence-based implementation of
clinical guidelines
Several systematic reviews of evidence for guidelines
implementation have been undertaken.321-329 While
most strategies have been found to lead to small to
moderate improvement (e.g. 5–10%) there is no simple
or single strategy that will apply in all settings.326 However
methodological weaknesses and poor reporting of the study
setting and uncertainty about the generalisability of the
results limit the strength of the conclusions.326
It is suggested that strategies to implement the guidelines
will be most effective where a concrete plan is developed
that tailors specific strategies based on an analysis of
local factors necessary for clinical behaviour change.321
Such factors include assessment of both the barriers and
enablers to achieving the recommendations in the clinical
guidelines.321 More than one approach is often needed
to overcome barriers because these occur at different
operational levels within the health system. These levels are
discussed above.

• educational meetings alone are not likely to be effective
for changing complex behaviours but can be effective if
used with other interventions324
• inter-professional collaboration (collaboration between
professionals within and across locations) may have a
positive effect in patient outcomes329
• interventions tailored to identified barriers (for example,
through interactive group work) are more likely to improve
professional practice than no intervention or dissemination of guidelines alone321
• printed education materials may have some benefits
compared with no material but the effect is unclear compared with other interventions323
• local opinion leaders can successfully reduce non-compliance with evidence-based practice322
• quality improvement collaboratives may have some
benefit, but the evidence for this, although positive, was
limited.328 However, this approach has been successfully utilised by the Australian Primary Care Collaboratives
(APCC) to improve best-practice care for diabetes and
chronic heart disease in general practice.330

8.5 Recommended implementation
activities
Considering the evidence for guideline implementation,
strategies to implement the Guidelines for the Management
of Absolute Cardiovascular Disease Risk will need to be
chosen based on the target audience and level of focus
(e.g. professional, organisational, consumer or regulatory/
financial level). Each strategy will need to consider potential
barriers (or enablers) and be tailored to address identified
factors. Some initial examples are provided below.
Consultation with stakeholders and a review of the evidence
has led to potential examples of barriers, enablers and
possible solutions for each level to be considered when
implementing the guidelines.

Evidence (generally focused on changes at the professional
level) from recent systematic reviews indicates:
• audit and feedback produce small to modest improvements in adherence to evidence-based care from a large
number of wide ranging studies.327 However, qualityimprovement activities often use a multifaceted strategy
such as educational meetings, reminders, printed material
or opinion leaders with or without audit and feedback 326,
327
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Professional level
Potential barriers
• Recommendations between different guidelines may be inconsistent, as well as guidelines presented as discrete
publications
• G
 uidelines need to be adopted by multiple stakeholders, all of whom may have different roles to play in their
implementation
• Change in clinical practice requires adopting new principles and beliefs about risk assessment and management (e.g.not
treating individuals at low AR, moving away from treatment based on single risk factor targets, use of the Framingham
Risk Equation, etc.)
• Education on a relative risk approach may continue for some time through other agencies
• Different descriptions/definitions of risk
• Evidence base for interventions taking an AR approach
• Health professionals (particularly GPs) have little time and heavy workloads
• Workforce shortage of allied health professionals may create issues for appropriate referral
• Training (at post graduate and undergraduate level): different curricula for different health professionals, messages from
curriculum and supervisors may be inconsistent
• Relevant CVD risk data not currently integrated into medical software used in primary care
• Concept of lifestyle prescription still vague amongst health professionals and consumers
• Limited evaluation of ‘Lifescripts’ program

Potential enablers
• APCC network and systems
• IT platforms used in most primary care settings
• Health reform including Medicare Locals, performance reporting and role of the Australian Commission on Safety and
Quality in Health Care in implementation of guidelines and setting national clinical standards
• Pressure of colleagues and system
• Local champions, e.g. proposed lead clinicians groups
• Clinical and professional association networks
• Proposed expansion of practice nurse/allied health professionals roles in management of patients
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Potential activities at professional level
Dissemination: Ensure broad access to information regarding new guidelines
Target audience
GPs
Practice nurses
Health care professionals
Medical specialists
Clinical networks Primary health care organisations (PHCOs)
Medicare Locals
Aboriginal Health Workers and similar Health Professional Associations
Emergency departments (especially rural)
• Publication in a variety of sources/formats:
o summaries in medical journals
o summaries drawing various, related guidelines together
o use websites and NHMRC Clinical Practice Guidelines Portal
o develop and distribute concise and/or integrated summaries
o distribute via endorsing organisations, clinical networks and other existing networks
o promote heavily on launch via media and PR
o electronic dissemination and inclusion in medical software (see below)
• Presentations and educational activities (see below)
• Ensure alignment and inclusion in other guidelines, e.g. Red Book, CARPA Manual
• Use of existing industry representatives where appropriate

Education: individuals, groups: Move practice from relative risk to AR approach
Target audience
GPs
Practice Nurses
Health care professionals
Specialists
Emergency departments
Undergraduate and post graduate course coordinators for all health professionals
• Education resources developed and promoted e.g. algorithms (important to develop separate resources and
education for indigenous population)

• Professional development. Use of key opinion leaders in educational activities:
o workshops (face to face)
o online educational activities
o conference presentations
o education outreach to individual practices
• Use existing programs, e.g. National Prescribing Service (NPS) education program, RACGP
• Link to CPD points for all relevant activities and disciplines
• Pathways (e.g. Practice protocols for GP clinics/Indigenous heath providers/emergency departments to develop
roles for each health professional, i.e. practice nurses, allied health in addition to GP)
• Up-skill other people, e.g. practice nurses
• Regular reminders about available programs to referring practitioners for management
• Work with undergraduate and post-graduate education providers (all relevant disciplines) to include in curriculum
and communicate out to supervisors
• Use of existing industry representatives where appropriate
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Reminders or clinical decision support tools (CDST): Support practice of AR
Target audience
Primary

Medical software industry (e.g. PEN), RACGP
Secondary

GPs, Practice nurses, specialists
• Integrate recommendations into current systems (including automatic calculation of risk)
• Integrate guidelines with other guidelines in CDST and with clinical history
• Link with audit and feedback tools
• Ensure inclusion of mechanisms to prompt management action and recall so practice IT systems can be used to
send reminder letters to patients for assessment
• Resources developed and promoted, e.g. algorithms
• Consolidation of referral databases to lifestyle management programmes

Audit and feedback: Highlight current practice and actions for improvement
Target audience
GPs
Practice Nurses
Practice Managers
Health care professionals
Specialists
• Build on current work to establish systems to audit clinical data to determine adherence to recommendations
(including benchmarking)
• Build capacity for easily developed reports on performance at practice and individual level.
• Involvement in primary care collaborative and QI activities
• Link feedback with other strategies for education such as key opinion leaders
• Publications, conference presentations.

Local consensus processes: Inclusion of participating providers in discussion to ensure that they
agree that the chosen clinical problem is important and the approach to managing the problem is
appropriate
Target audience
GPs
Practice nurses
Specialists
Primary health care organisations (PHCOs)
Health care professionals
• Involvement in primary care collaborative and QI activities
• Supported discussions at local level to develop consensus
• Solutions to improve systems for QI (see organisational level solutions)
• Use existing programs and clinical and association networks.
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Consumer level
Potential barriers
• Concept of risk (particularly AR) is complex and difficult to explain
• Behaviour change recommended in guidelines often difficult to maintain (particularly lifestyle and maintaining
medications over time)
• Consumers often at GP for reasons other than a risk assessment
• Consumers may receive too much information and material that is too complex
• Concept of lifestyle prescription still vague amongst health professionals and consumers
• Social, geographical and cultural barriers to access to services (particularly A&TSI communities and those in
remote settings)

Potential enablers
• Health reform establishing new agencies that may support implementation (e.g. National Prevention Agency and
its social marketing activities)
• Other agencies developing information for consumers that may send common messages (e.g. RACGP Red Book,
CARPA Manual, NPS fact sheets)
• Community networks e.g. NACCHO and its state organisations

Potential activities at consumer level
Education or systems to involve consumers: Improves awareness, engagement and adherence to
management
Target audience
General population >45 years old (> 35 years if A&TSI population)
Consumer Health Forum, relevant peak and professional bodies who are involved in producing information for consumers
• Develop online and printed educational materials for consumers including simple explanations of risk
• Support inclusion of common consumer messages in communication channels of other agencies and websites
(e.g. Consumers Health Forum, NACCHO, Better Health channel, RACGP Red Book, NPS, etc.)
• Campaigns educating people of CVD risk, and need for risk assessments
• Include consumers in development of material and develop in line with standard health literacy levels and also
consider Indigenous and Culturally and Linguistically Diverse (CALD) backgrounds
• Develop online consumer tools aimed at prompting discussion with GP
• Develop evidence-based tools health professionals can use to demonstrate risk and how it will change over time
and through modification of risk factors.
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Organisational level
Potential barriers
• Data for quality improvement, and to support decision making is not integrated into clinical software
• Uncertainty around data integrity and validity
• Time required to record and analyse data and plan quality improvement activities
• Geographical barriers in rural and remote services (limited access to adequate staffing and equipment)
• Other agencies may promote data based on relative risk approach

Potential enablers

• Practices already undertaking QI activities
• RACGP developing primary care audit activities
• Health reform including Medicare Locals, performance reporting and role of the Australian Commission on Safety
and Quality in Health Care in implementation of guidelines and setting national clinical standards
• Existing ‘Lifescripts’ program and diabetes lifestyle programs
• Electronic health records activity

Potential activities at organisational level
Systems to focus on quality improvement: Improves access to quality improvement systems
Partners
RACGP
Australian College of Rural and Remote Medicine (ACRRM)
APCC
• Develop nationally agreed performance indicators related to CVD risk reduction
• Improve data collection systems and develop mechanisms to interrogate data and feedback areas for
improvement to practices (and other areas such as CVD and related disease admissions)
• Integrate tools and data into medical software
• Continue to promote practice support programs focusing on IT and data collection
• Consider more intense QI programs which offer practice visits to analyse data broadly, provide feedback and
identify gaps that can drive quality improvement
• Information targeted especially to users: GP vs. practice nurse vs. Aboriginal health workers
• Link other strategies at professional level (e.g. feedback and education)
• Advertise/encourage practices to become involved in APCC around CVD prevention
• Reallocate roles or add workforce to focus on implementing guidelines
•	Introduction of technology, e.g. electronic transmission of ECG and echocardiography from regional to
metropolitan centres
• Change organisational structure and processes designed to improve implementation (e.g. new GP super clinic, or
Medicare Locals)
• Make sure strong input from key opinion leaders (including proposed Lead Clinicians Groups and other existing
clinical governance bodies)
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Regulatory/ financial level
Potential barriers
• Concerns about the potential costs of guideline recommendations
• Potential disconnect between current reimbursement for PBS items and new recommendations
• Current Medicare Benefits Schedule (MBS) policy does not support practice recommended in guidelines
• Limitations of other government policies e.g. Enhanced Primary Care limit of five annual visits prevents people
from receiving a range of specialist care

Potential enablers
• Home medicines review program
• New preventative health agenda
• Current additional supports in MBS and Pharmaceutical Benefits Scheme (PBS) for Indigenous and Torres Strait
Islander peoples
• Current MBS review
• Electronic health records activity
• Development of Medicare Locals
• Accreditation activities

Potential activities at regulatory/financial level
Policy change: System change to support practice of AR
Partners
Australian Government Department of Health and Ageing (MBS, PBS, Preventive Health Agency)
APCC
NHMRC, Commission on Safety and Quality
NPS
• Undertake economic modelling around guideline implementation to provide evidence for policy decision making
• Explore the Practice Incentives Program to identify opportunities to support system and practice change
• Review of PBS criteria for medications recommended in the guidelines to ensure consistency
• Policy change to support programs identifying people in the community who may require risk assessment and
management
• Review Enhanced Primary Care program to broaden scope and provide incentives for private allied health
practices
• Link and integrate policy and programs for related diseases (e.g. vascular, diabetes and kidney)
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Appendix 3:

Economic Considerations
This report was prepared by: Anne Magnus, Deakin Health Economics, Strategic Research Centre- Population Health.

Economic evaluation of NVDPA Guidelines for the
Management of Absolute Cardiovascular Disease
Risk10

1.0 Introduction
Cardiovascular disease is the most expensive disease group
in Australia in terms of annual direct health care costs which
have been recently estimated to be more than $5.2 billion in
2004–05.8 Therefore, providing cost-effective cardiovascular
disease prevention, management and treatment is important
to avoid unnecessary costs to society. This report presents
a review of the cost-effectiveness literature on evidencebased CVD prevention with pharmacotherapy. A systematic
review was conducted as part of the guidelines process
(see Appendix 2, Guidelines development process report for
search strategy). As the breadth of pharmaceuticals under
study was wide (incorporating BP-lowering, cholesterollowering agents, aspirin and combinations of the same) and
the methods used quite disparate, a narrative review was
deemed the most appropriate way to summarise the costeffectiveness evidence. The literature was firstly assessed
for internal validity of each paper and secondly assessed for
its generalisability to the Australian context.
The need to review the cost-effectiveness literature occurs
because, although a newly proposed strategy may be more
clinically effective than the comparator, it may also cost
more to achieve additional health benefits. Or the reverse
situation can occur, where the proposed strategy is less
clinically effective but costs less to achieve its benefits. In
an ideal setting, the proposed strategy would yield both
more benefits and cost less than the current strategy, i.e. it
would dominate current practice by saving more health and
saving dollars. The most efficient strategy is the one with
the lowest incremental cost-effectiveness ratio (ICER). The
strategy with the lowest ICER is not necessarily the one with
the most total health benefits or the one with the least total
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expenditure. What constitutes a cost-effective intervention is
a value judgment and is not the only policy objective used in
the evaluation of proposed changes in the health sector, as
more expensive treatments may be considered necessary
on the basis of value judgements. In previous Australian
policy decisions, $30,000–50,000 per QALY saved has
been considered to represent value-for-money from the
perspective of the health sector.331

2.0 Aim of the guidelines
The aim of the Guidelines for Management of Absolute CVD
Risk project is to develop high-quality clinical guidelines and
resources for management of CVD risk using an absolute
risk approach in adults aged over 45 years (35 for Aboriginal
and Torres Strait Islander peoples) with no previous history
of CVD.
The Guidelines for Management of Absolute CVD Risk make
recommendations that relate to the use of medications
listed on the PBS. The development process has included
an economic assessment of the cost-effectiveness of
initiation and on-going use of CVD preventive drug therapy
(including BP-lowering medications, cholesterol-lowering
medications and potentially antiplatelets) by AR criteria and
a comparison of this approach with the impact and costs
currently incurred by the health system around the use
of these medications. Current practice in Australia is not
easy to describe in detail, but is informed by the previously
existing individual risk factor management guidelines, such
as those for management of hypertension and lipid levels.
Limited survey data of current prescribing patterns in
Australia reflect departures from the perfect adoption of the
existing individual risk factor management guidelines.

2.1 Economic question within the
proposed guidelines

• Was a sensitivity analysis performed?

Is the AR approach to prevention of CVD in adults aged
over 45 years (35 for Aboriginal and Torres Strait Islander
peoples) with no history of CVD, more cost-effective
than current practice from a health sector perspective,
considering lifetime costs and benefits of pharmacotherapy
which includes BP-lowering medications, cholesterol
lowering statins and antiplatelets?

3.2 Evaluation of external validity and
generalisability to the Australian situation

2.2 The economic framework of the
literature review
The objective of this review was to answer the economic
research question by reference to the available literature.
This required estimating the additional direct health sector
cost per additional unit of effect gained, measured in life
years adjusted for quality, using a robust, consistent and
standard method.

3.0 Steps in the economic evaluation
The internal validity of the studies for each class of drug was
undertaken for each drug separately and in combinations,
since this more closely approximated the recommendations
of the guidelines. Studies which examined the drugs in
comparison to placebo were excluded as the objective
was not to assess the cost-effectiveness of these drugs
compared to doing nothing, but rather to compare to
current practice or some other consideration of patient risk
profile.

3.1 Evaluation of internal validity
Using a well-respected strategy proposed by Drummond,332
the following items were used to critically appraise the
economic literature for internal validity:
• Was the study question well defined?
• Were appropriate health care options chosen and clearly
described?
• Was the effectiveness of the health care options
established?
• Were all the relevant costs and consequences identified
for each health care option?
• Were costs and consequences measured accurately?
• Were costs and consequences valued credibly?
• Was differential timing considered?
• Was incremental analysis performed?

• Were all issues of concern presented with results?

Once the evidence from the literature was gathered, each
of the major components of an economic evaluation (i.e.
clinical, economic, epidemiological, health care patterns,
treatment comparators) was verified versus Australian
conditions before a study’s results were deemed potentially
transferable. To this end the patient group, the health
system, the prevention strategy options, the incremental
costs and benefits, and other factors relating to these
particular guidelines were considered.

4 Internal Validity
4.1 Single use of drugs
a) Aspirin
Selection of studies
Five studies examined the cost-effectiveness of aspirin
for single use in the prevention of CVD.333-337 Since it is an
inexpensive drug, even the small health benefits reported
in various meta-analyses noted within these guidelines
would yield a favourable cost-effectiveness ratio. However,
the absolute benefit of aspirin in addition to other effective
pharmacotherapy (to lower BP or lipids) is unclear, while
underpowered recent evidence338 raises questions of the
health benefits at the risk of important side effects, therefore
its use for primary prevention has not been recommended in
these guidelines. For this reason no further evaluation of the
cost effectiveness of aspirin has been included.

b) Lipid-lowering pharmacotherapy
Selection of studies
Five studies examined the cost-effectiveness of statins for
single use in the prevention of CVD.211, 225, 339-341 Gumbs et
al 342 was a systematic review of older cost-effectiveness
literature and Pilote et al339 a cost outcome study with sub
group analysis, so was of limited relevance to this review.
The remaining four studies were all evaluations using Markov
models (two set in the US and two in the UK), comparing
single use of a statin with either current practice or no statin
use (an ambiguous comparator situation that may include
the use of other drugs). The scHARR models211, 225 relating
to the UK health system were the best examples of model
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design and economic evaluation, giving consideration to all
important elements of model design, validation and costeffectiveness assessment that others have excluded, e.g.
much sensitivity analysis and consideration of comparators,
discount rates and compliance issues therefore were
included in the analysis.

When comparing ezetimibe monotherapy with no treatment
in individuals with baseline LDL-C values of 3.0–4.0 mmol/L,
the results ranged from £21,000 to £50,000 per QALY (i.e.
some treatments were cost effective). Results for individuals
with baseline LDL-C values over 5.0 mmol/L were below
£30,000 per QALY (i.e. all treatments were cost effective).

Statins

c) Blood pressure-lowering pharmacotherapy

Ward et al211 estimated the discounted cost per QALY
estimates for primary prevention using statins (as a drug
class) at the age of 45 ranged between £9,500 and £30,500
for men and women as annual CHD risk levels ranged from
3% to 0.5%. By the age of 85 years the corresponding
values were £36,800 and £110,600. In the UK setting
the value for money threshold is usually considered to be
between £20,000 to £30,000 per QALY, making these
drugs cost effective for the younger age groups. Ward et
al211 particularly highlight greater uncertainty in the results
for young persons, which arose in the modelling due to
the requirement to extrapolate benefits well beyond the
timeframes of the trials, and particularly so in the case of
young people.

Selection of studies

The US studies extrapolated trial based efficacy data over
a timeframe of 5 –25 years rather than lifetime. Ramsay et
al341 reported a drug company-funded study and concluded
that when prescribing atorvastatin compared to no statins,
there was a need to give the expensive drug for a long time
before it became cost effective. At five years the ICER for
atorvastatin was US$137,000/QALY (i.e. not cost effective)
whereas after 25 years the intervention was dominant (i.e.
both cost and health saving). While Ramsey et al was one
of the more relevant studies it used a shorter timeframe
for analysis and was silent concerning the impact of
compliance with therapy. Pletcher et al340 assessed the
cost-utility of ATPIII guidelines compared to current practice
and concluded that the guidelines would be cost-effective
when statin prices were moderate. However Pletcher et
al included the costs of unrelated future health care events
within their analysis, excluded consideration of strokes, and
used a shorter time horizon for evaluation of benefits and
costs.

Ezetimibe
The other scHARR model developed by Ara et al225
evaluated the use of ezetimibe as monotherapy and
concluded there was enormous uncertainty around its costeffectiveness credentials due to the short-term trial periods
for establishment of efficacy. There was a wide range of
results depending on the treatment strategies compared.
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Four studies343-346 were found and examined. Lundkvist
et al343 was eliminated because it evaluated placebo as
the comparator to BP-lowering treatment. One study
related to the US, one to the UK and the remaining study
presented ICERs for four European countries. A number of
weaknesses appeared in the European study comparison346
including reliance on efficacy results from a small trial
(n=59), adoption of the Framingham risk prediction
equations developed in the US without calibration to local
population events, adoption of the same utility weights for
vastly different clinical conditions (MI and angina: stroke
and TIA), and non translation of local country costs to a
comparable unit. The results of this study, while relevant,
were considered of limited use here.

ACE Inhibitors
The US study345 examined the cost effectiveness of ACE
inhibitor therapy as first-line BP-lowering therapy compared
to conventional BP-lowering therapy with beta blockers
or diuretics and presented the ICERs over a lifetime in
40-year-old males only, concluding that the ICERs were
unattractively high.

d) Combination pharmacotherapy
Selection of studies
Eleven studies were identified that evaluated various
combinations of the drugs of interest to this review.
Studies were selected that included aspirin as an element
of the intervention or comparator even though it was not
evaluated as monotherapy. These combination therapy
evaluations were expected to provide more insight into the
potential cost-effectiveness of the proposed guidelines,
however, issues of internal validity were found, that limited
their usefulness. Two were eliminated as they pertained to
developing countries347 and Argentina,348 and were outside
the scope of this evaluation. Three were eliminated as they
were cost-effectiveness studies which measured cost per
reduction in BP349 or cardiac event prevented350 or coronary
event free life years.351 It was necessary to have a common

unit of benefit measurement, which made these studies
of limited value without translation into QALYs. No cost
offsets were incorporated for cardiac events prevented by
the intervention in two studies.350, 352 This meant that the
costs of all the relevant alternatives had not been included
in the analysis. The comparator was either not clearly stated
or referred to as ‘no intervention’ in four studies.350-354 As
no drug regime was stipulated clearly as comparator, the
cost-effectiveness ratios presented in these studies was of
limited value. The remaining two studies (Newman et al and
Ara et al) were stronger economic evaluations having none
of these aforementioned limitations but they were somewhat
limited in scope to either males only355 or the drug
ezetimibe,225 prescribed in addition to statins in patients not
achieving adequate lipid control on statins. Newman et al
did not clearly state the perspective of the analysis, or the
timeframe for measurement of costs and benefits which
limited interpretation of the results. Ara et al considered all
the relevant issues for a sound cost-effectiveness study
but were limited in their modelling by the paucity of clinical
information. Ara et al concluded that comparing the costs
and benefits of adding ezetimibe to ongoing statin treatment
with maintaining statin treatment at the current dose, the
lifetime ICERs range from £25,000 to £66,000 per QALY for
the primary cohorts.
Another issue of concern was the use of US-based
Framingham risk equations to predict CVD events in UK
or Europe without calibration to relevant country CVD risk
profiles and events. It was also uncommon to find Markov
models that have been validated against other source
data. There was little discussion of adherence/compliance
assumptions stated in the modelling when this can have an
impact on both costs and consequences.356 Negative side
effects of therapy were not always included in analyses and
therefore the impact of these remains unclear.

5.0 External validity
5.1 Patient group
Cardiovascular risk factor profile
In assessing the role of any strategy for primary CVD
prevention in Australia it is important to know the number of
CVD events that would be prevented in actual practice as
that is the number that generates the economic impact. The
baseline population risk of an event is determined by the
presence of CVD risk factors which include age, elevated
BP, cholesterol, BMI, smoking, family history of CHD and
diabetes. It is this baseline risk that will be reduced by the
relative risk reduction reported in trials conducted either
in Australia or elsewhere. In order to produce meaningful
comparisons, the Australian population CVD risk factor
profile should be the same as the population profile in costeffectiveness studies and modelling conducted in other
countries. This analysis examined age, BP, cholesterol and
BMI as CVD risk factors to assess the usefulness of the
international cost-effectiveness findings.
Increasing age is a CVD risk factor. There is a higher
proportion in the over 65 years category (16.6% and
18.3%) in both the European and UK 2010 populations
respectively, than in Australia and the US (13.6% and 14.0%
respectively). On this CVD risk factor Australia has a similar
risk profile to the US, without giving consideration to gender
distribution.
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Population age structure, International comparison(a) – at 30 June
2010

2015(b)

2010-2015

Aged
0–14
years

Aged
15–64
years

Aged 65
years
and over

Median
Age

Aged
0–14
years

Aged
15–64
years

Aged 65
years
and over

Median
Age

Total
fertility
rate(c)

Life
expectancy(d)

%

%

%

Years

%

%

%

years

rate

years

Australia

18.9

67.5

13.6

36.9

17.6

66.0

16.4

39.9

1.9

82.0

Canada

16.3

69.6

14.1

39.9

15.8

68.2

16.0

40.9

1.6

81.4

19.9

71.9

8.2

34.2

19.0

71.5

9.4

35.6

1.8

74.0

11.5

75.6

12.9

41.9

10.6

74.4

14.9

43.8

1.0

82.8

France

18.4

64.6

17.0

40.1

18.1

62.8

19.1

41.3

1.9

81.9

Greece

14.2

67.5

18.3

41.6

14.1

66.4

19.5

43.3

1.4

80.1

India

30.8

64.3

4.9

25.0

28.7

65.9

5.4

26.5

2.5

65.2

Indonesia

26.7

67.2

6.1

28.2

24.9

68.5

6.6

30.1

2.0

72.2

Italy

14.2

65.4

20.4

43.3

14.0

64.1

21.9

45.1

1.4

81.6

Japan

13.2

64.2

22.6

44.7

12.4

61.3

26.3

46.6

1.3

83.7

Republic
of Korea

16.2

72.8

11.0

37.9

14.1

73.0

13.0

40.7

1.3

80.0

Malaysia

29.1

66.1

4.8

26.3

27.2

67.0

5.8

28.0

2.4

75.2

New Zealand

20.2

66.8

13.0

36.6

19.6

65.9

14.5

37.4

2.0

81.0

Papua New
Guinea

39.5

58.1

2.5

20.0

37.4

59.8

2.8

20.9

3.8

62.3

Philippines

33.5

62.2

4.3

23.2

31.6

63.6

4.8

24.5

2.9

72.9

Singapore

15.6

74.2

10.2

40.6

12.9

73.6

13.6

43.4

1.3

81.0

South Africa

30.3

65.1

4.6

24.9

29.6

65.1

5.3

25.7

2.4

52.9

Sweden

16.5

65.2

18.3

40.9

17.0

63.0

20.1

41.6

1.9

81.6

United
Kingdom

17.4

66.0

16.6

39.9

17.2

64.9

17.9

40.3

1.9

80.1

United States
of America

20.2

66.8

13.0

36.6

19.8

65.9

14.3

37.2

2.0

79.9

Vietnam

25.1

68.6

6.3

28.5

23.1

70.3

6.6

30.2

2.0

75.4

World

26.9

65.5

7.6

29.1

26.0

65.8

8.2

30.2

2.5

68.9

Selected
countries

China (excl.
SARs and
Taiwan)
Hong Kong

(SARs of China)

(a) Selected countries included major OECD countries, the world’s most populous countries, Australia’s closest neighbours
and trading partners.
(b) International data are United Nations medium variant projections. Australian data are ABS medium series (Series B)
projections.
(c) Births per woman. United Nations are medium variant projections for the period 2010–2015.
(d) Life expectancy at birth. United nations are medium variant projections for the period 2010–2015, for males and females
combined.
Source: All international data and Australian total fertility rate and life expectancy figures have been sourced from
World Population Prospects, 2008 Revision. Australian 2010 estimates from this publication are from ABS, Australian
Demographic Statistics (cat. no. 3101.0) and Australian 2015 population projections are from ABS, Population
Projections, Australia 2006 to 2101 (cat. no. 3222.0).
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Risk factors of BMI, BP and cholesterol between 1980
and 2008 have been the topic of study in recent Lancet
publications.357-359 While there are issues concerning
availability of nationally representative, measured data, the
consistent techniques adopted in these papers were robust
and they demonstrated clearly the degree of uncertainty
surrounding their estimates.
Differences in BMI are linked to gender, dietary composition,
caloric intake, physical activity levels and socioeconomic
status. Australia and US359 have higher BMI profiles than
parts of Europe so the CVD risk factor profile of Americans
is closer to Australians than Europeans, making US
evidence more readily generalisable to the Australian
population than evidence from the UK or Europe.
Differences in BP across populations are linked to
dietary salt, fruit and vegetable intake, lifestyle and use
of medications for BP lowering. BP differences within
populations are also linked to age and gender. Australasia
and the US had the lowest BP in women and BP was lower
than European males in 2008. Falling BP trends have been
estimated for most regions of the world with the highest
falls occurring in Australia and North America357. This would
again suggest greater generalisability of US evidence to the
Australian population as the CVD risk profile is similar on this
risk factor.
Differences in cholesterol across populations are linked to
variations in diet, especially consumption of animal-based
fat compared to plant-based fats, adiposity and use of
cholesterol-lowering medications. No differences between
the countries were reported making up the high- income
region of North America, Australasia and Western Europe,358
so no conclusion can be drawn concerning the relative
generalisability of population CVD risk profiles in international
studies to the Australian population. Rather it would appear
that cholesterol levels in Australian, US, UK and Europe
are sufficiently similar to not be a problem when attempting
to generalise conclusions of cost-effectiveness studies
conducted in these countries.
Thus the populations of the US and Australia have greater
similarity in these major components of CVD risk factor
profiles than Europe and UK. Comparisons of clinical impact
in cost-effectiveness studies can then be more readily
generalised from US studies to Australia.

5.2 Framingham prediction equations
Any application of Framingham CVD prediction equations
(developed in the US population), in international studies
should be first validated or recalibrated to local population
data. This is rarely done and makes the health benefits
reported in UK and European studies subject to bias
(overestimation or underestimation depending on the risk
factor prevalence). When Framingham based predictions
are applied in models to US data, the length of time elapsed
since the estimation of the equations is also important to
consider, since CVD rates have fallen in the US beyond what
could be attributed to shifts in risk factors alone.

5.3 Gender-based data
There is limited data from clinical studies in women
so greater uncertainty surrounds estimates of costeffectiveness of any drug therapy in this group.

5.4 Health system setting
Exactly what constitutes service delivery in UK, US Europe
and Australia requires consideration of access to services
and service offerings. There will be variability in the rates of
conducting procedures, the types of staff working/treating
in and out of hospital settings. What is considered a health
sector cost or health funder cost within these different
country settings differs due to system funding structures
(i.e. the relative mix of public/private/out of pocket costs).
What constitutes ‘usual care’ or current conventional care
will differ between countries and has not necessarily been
enumerated in the studies covered in this review. Results
taken from any other country require consideration of all
these factors before further consideration of translation
of local currency into a common currency and year for
comparison purposes.

5.5 Health care option
For effective comparison, the comparators should be
relevant to the policy question within the proposed
guidelines. Thus this review has not considered placebo as
a valid comparator, but rather current practice since the aim
was to evaluate alternative mixes of existing drugs rather
than the addition of a new adjunctive therapy. In considering
the proposed health care options, caution was taken since
the reviewed modelling over the lifetime of the population far
exceeded the timeframe of trials that contributed benefits of
drug therapy. Trial-based assessments of costs can be quite
different from routine practice in that additional monitoring
may have been required, thus the trial based costings were
not readily generalisable without adjustment to a routine
setting.
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5.6 Resource costs

6.0 Conclusion

Prices of drugs vary over time as patents expire and
prescribing patterns may or may not shift to more generic
drugs. This can contribute to different results in crosscountry comparisons and drug price has often been
identified in sensitivity analysis as the most important factor
influencing the cost-effectiveness outcomes. This was
particularly relevant to the evaluation of expensive statin
therapy and should be factored in to any future modelling
in the Australian setting. US costs are higher than other
countries and have been quite often valued on the basis of
cost-to-charge ratios since data was more readily available
on charges in administrative databases. This made the
resulting estimates further questionable in comparison with
Australia.

It is difficult to extrapolate cost-effectiveness results
from international studies to the Australian context given
differences in health services provision and funding,
pharmaceutical pricing policies and practices, and the
potential variations in CVD risk in target populations. Overall
the evidence from overseas studies was particularly limited,
not only by the number of suitable studies found which
were relevant to the issues addressed in the Guidelines
for Management of Absolute CVD Risk, but also by
several questions relating to internal validity and by some
considerable issues with external validity which prevented
the direct application of overseas cost-effectiveness
conclusions to the Australian situation. However, despite
the limitations, one consistent conclusion recurring in most
analyses wherever conducted was the sensitivity of costeffectiveness results to statin prices.

Compliance with therapy has been previously highlighted
as an issue that has an effect on the generalisability of a
cost-effectiveness study.356 Compliance affects costs in an
unknown direction since scripts can be filled but not taken
(keeping costs high but without benefit) or scripts may not
be filled (reducing overall costs and benefits). Irregular drug
use, affecting costs and unknown impact on benefits has
not been accounted for in any of the models considered
here. Compliance can be measured in trials in several ways,
but it is not well studied in the long term past 3–5 years.
The real impact of compliance is unknown and assumptions
need to be made in each study and the impact on the
results compared in sensitivity analysis.

5.7 Marginal versus average cost
Studies that presented average costs of preventive therapy
were not considered. Studies estimating the incremental
cost effectiveness of therapy were included, since this
evidence informs the research question.

5.8 Other specific issues relating to the
guidelines
For resource allocation policy impact, consideration of final
health outcomes such as mortality and morbidity should be
made in preference to intermediate health outcomes such
as reduction in cholesterol or BP. To this end all studies not
presenting results in the desired format have been excluded.
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7.0 Further work
As the review of international cost-effectiveness literature
did not yield useful evidence with which to compare the new
guidelines, specific cost modelling of the recommendations
using Australian data has also been undertaken by external
consultants as part of the guidelines development process.
This process included cost effectiveness modelling for
various drugs, which was used to inform the development
of the recommendations. Further modelling was done
after completion of the recommendations, to determine
the total costs and the cost effectiveness of the finalised
recommendations.

Table 1. Analysis of studies

Target Population
Author
Annemans

Publication
year

Intervention

Comparator

Study

setting

Type of

evaluation

Analytic

Compliance

50, 55, Patient groups
10 yrs
60
at 2%, 3%, 4%,
5% risk of a fatal
coronary heart
disease event in 10
years using SCORE
algorithm

CountryHealth care
specific rates payer
for both costs
and benefits
applied. The
rates vary
from 3% to
5%

No statement

Age

Both

co-morbidity

horizon

2006

Low-dose aspirin Placebo

Ara et al

2008

Ezetimibe in
Statin
UK
combination with monotherapy
statins

Cost utility

Both

40

Individuals who
have not achieved
cholesterol control
with statins

Lifetime

3.5%

National
Discussed
Health Service

Earnshaw
et al

2011

Low dose aspirin Low dose
US
with omeprazole aspirin alone.
20 mg/d

Cost utility

Men

45,
55,
65

A range of
underlying 10 year
CHD risk (2.5%,
5%, 7.5%, 10%,
15%, 25%)

Lifetime

3%

Third-party
payer

100%
assumed

et al

UK Germany Cost utility
Spain
and Italy

Risk factor/

Discounting Perspective

Gender

Franco et al 2007

Smoking
No
cessation to
intervention
smokers, aspirin
given to all, BPlowering drugs
given to people
with SBP>140
mmHg and
statins given to all

Netherlands Cost
Men
effectiveness

45-55 & Framingham
10 years 4%
55-65 study participants
meeting age and
risk thresholds (low
moderate and high)

Third-party
payer

No statement

Gaziano
et al

Aspirin, CCB,
No treatment
ace inhibitor and
statins for primary
prevention

Developing
country
regions
(WHO)

Cost utility

Both

35-74

Societal

Sensitivity
analysis

Greving et al 2008

Low-dose aspirin No aspirin
no quantity listed

Netherlands Cost utility

Both

Grover et al 2008

Lipid treatment
or hypertension
management

Canada

Jonsson
et al

2006

Multiple levels of
10-year risk for
CHD

Lifetime

3%

45, 55, At various levels
65, 75 of 10 year
cardiovascular
disease risk based
on number of risk
factors

10 yrs

4% for costs Health care
& 1.5% for
payer
benefits

No statement

Cost
Both
effectiveness
(averages)

40–74

2,121 participants
surveyed from the
Canadian heart
health survey
without CVD
who qualify for
lipid treatment
or hypertension
management

Not
stated

3%

Health care
system

No statement

2003

Anti hypertensive The lowest
26 countries Cost
Both
treatment with
change in BP
effectiveness
felodipine

50–80

18,790 trial
patients with
hypertension

Trial
None
length of
3.8 yrs

Societal

No statement

Lamotte
et al

2006

Low-dose aspirin No aspirin

Europe, 4
countries

Cost utility

Both

Not spe 1.5% 10-year risk 10 yrs
of a coronary heart
cified
disease event

Country
specific

Public
healthcare
payer

No statement

Lungkvist
et al

2005

Candesartan
Placebo
anti hypertensive
treatment

Europe

Cost utility

Both

70–89

3%

Societal

No statement

Marshall

2006

Treatment with
Do nothing
aspirin or up to
4 BP-lowering
drugs and statins

UK

Cost
Both
effectiveness

Not spe Taken from the
Health Survey for
cified
England of 1998
using eligibility
criteria for
treatments with
joint British
recommendations

3%

Health
services

100%
assumed

Cost utility

30-70

Montgomery 2003
et al

Hypertensive
medication not
specified clearly

Not stated

No treatment UK
not further
specified

Both

Elderly patients with Lifetime
mild to moderate
hypertension
10 yrs

Low- and high-risk Lifetime
groups defined
with smoking, BP,
diabetes, etc

6% for costs Health
and 1.5% for services
benefits

Discussed
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Target Population
Author
Murray et al

Publication
year

2003

Intervention

Comparator

Statin, diuretic,
BP-lowering drug
and aspirin

No
intervention

Risk factor/

Analytic

Study

Type of

3 World
regions

Cost utility

Both

30100

People with
100 yrs
an estimated
combined risk
of cardiac event
over the next
decade above a
given threshold.
Thresholds
reported as 35%,
25%, 15%, 5%

3%

Decision
makers
not further
specified

Discussed

US

Cost utility

Men

>55
yrs

Regardless of
baseline risk
factors

Not
stated

3%

Not stated

100%

10 yrs

3% for costs Belgian
& 1.5% for
decision
benefits
makers

Discussed

5%

Third-party
payer

Sensitivity
analysis

setting

evaluation

Gender Age

co-morbidity

horizon

Discounting Perspective Compliance

Newman et al 2008

Polypill
Current
combination
standard
therapy of
care
simvastatin,
captopril,
hydrochlorthiazide
and atenolol

Neyt et al

Low dose
pravastatin

Smoking
Belgium
cessation,
or aspirin
interventions

Cost
Men
effectiveness

50 &
60yrs

Moderate and
high risk of
coronary heart
disease

Nordman et al 2003

ACE inhibitors
to all

Conventional US
therapy

Cost utility

Men

40yrs

Requiring
Lifetime
antihypertensives
but no other
comorbidity

Pignone et al

2006

Low-dose
aspirin, a statin,
both drugs as a
combination

No therapy

US

Cost utility

Men

45 yrs Various levels of
old
10-year risk for
CHD

Lifetime

3%

Third-party
payer

100%
assumed

Pignone et al

2007

Aspirin

No therapy

US

Cost utility

Women 65 yrs 7.5% 10-year
Lifetime
risk of a coronary
heart disease
event

3%

Third-party
payer

100%
assumed

Pilote et al

2005

Lipids to people
w/o CVD

Lipids to
people with
CVD

Canada

Cost
outcome
with sub
group
analysis

Both

30-74 Population
surveyed with
Canadian Heart
Health Survey

5%

Societal

No
statement

Pletcher et al

2009

ATP III guidelines
and a number
of risk based
and age-based
strategies

Current
practice

US

Cost utility

Both

35-85 10-year CHD risk 30 years
varying from > 0
to >15%

3%

Healthcare
system

100%
assumed

Ramsay et al

2008

10mg/day
atorvastatin

No HMGCoA
reductase
inhibitor
(statin)
therapy

US

Cost utility

Both

>20yrs People with type 5,10,25
2 diabetes, and years
one additional
risk factor
(retinopathy,
albuminuria,
current smoking
or hypertension),
but no CVD
history

3%

US payer

No
statement

Schwander
et al

2009

eprosartan

enalapril

6 countries Cost utility
within
Europe

Both

Adult

Lifetime

Countryspecific
rates for
both costs
and benefits
applied. The
rates vary
from 3% to
5%

European
health
care-payer
perspective

Compliance
is entered to
the model

Ward et al

2007

Statins for primary Non use of
and secondary
statins
prevention of CHD
or CVD

UK

Both

45-85 Multiple levels of
risk for CHD in
next 10 years

Lifetime

6% for costs National
and 1.5% for Health
benefits
Service
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2009

Cost utility

Populations
of 6 European
countries

Lifetime

Accounts for
increasing
noncompliance
for 5 years
and holds
constant
from then on

Table 2. An overview of economic evaluation study results

Study

Base year/
currency

Cost-effectiveness results

Relevance/quality/
comments

Annemans et al 2006

2003
Euros

Low-dose aspirin is dominant in all countries at all
levels of risk except for Italy due to the higher cost
of a gastrointestinal bleed there.

Not relevant
Aspirin not relevant to the
guidelines
Compared to placebo
Sponsorship from Bayer

Ara et al 2008

2006 British
pounds

The lifetime results for treatment Scenario 1
(ezetimibe 10 mg plus current weighted statin
versus current weighted statin titrated by
one dose) range from £24,000 per QALY for
males aged 45 years with a baseline LDL-C of
3.5mmol/L and no history of CVD to £62,000 per
QALY for females aged 75 years with a baseline
LDL-C of 2.5 mmol/L and no history of CVD.

Relevant study
Well-designed cost-utility study that
acknowledges limitations in the
source data
National Institute for Health
Research HTA Programme
sponsored

Earnshaw et al 2011

2009
US$

Treatment with aspirin for CHD prevention is less
Not relevant
costly and more effective than no treatment in men Aspirin not relevant to the
> 45 years with > 10-year, 10% CHD risks.
guidelines
Sponsorship from Bayer

Franco et al 2007

2003
Euros

The most cost-effective treatment is smoking
cessation therapy, representing savings in all
situations. Statin therapy is the least cost-effective
treatment (ranging from €73,971 to €19,027 per
YLS). Aspirin was the second most cost-effective
intervention (ranging from €2,263 to €16,949
per YLS) followed by antihypertensive treatment
(ranging from Euros 28,187 to Euros 79,843 per
YLS). These rankings were maintained for all age
group/risk group categories analysed.
A cut-off value for the ICER of Euros 20,000 per
YLS was chosen

Limited relevance
Some quality considerations
including: Not a cost-utility study,
limited to males, initial comparator
is no intervention, 10-year time
horizon, adverse events not
included
Sponsorship from the Netherlands
Heart Foundation

Gaziano et al 2006

2001
US$

Across six developing World Bank regions, primary
prevention yielded ICERs of US$746–890/QALY
gained for patients with a 10-year AR of CVD
greater than 25%, and US$1039–1221/QALY
gained for those with an AR greater than 5%.

Not relevant
Conducted for developing
countries
Sponsorship from Fogarty
International Centre, National
Institutes of Health

Greving et al 2008

2005
Euros

Aspirin treatment for primary prevention is costeffective for men with a 10-year CVD risk of >10%
and for women with a risk of >15%. This occurs
much later in life for women than men.

Not relevant
Aspirin not relevant to the
guidelines
Sponsorship from Netherlands
Organization for Health Research
and Development

Grover et al 2008

2002
Canadian $

The average cost-effectiveness of lipid therapy
would be approximately CA$16,700 per
YOLS while hypertension therapy would be
approximately CA$37,100 per YOLS

Limited relevance
Not a cost-utility study
Incremental results not presented
Sponsorship from Astra Zeneca
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Study

Base
year/
Cost-effectiveness results
currency

Relevance/quality/comments

Gumbs et al 2007

Review

Policymakers who want to use economic
evaluations should use those that employed
appropriate methodology and produced valid
results. In that regard it seems that policymakers
are better informed using recent publications,
as the quality of considered studies appears to
have increased over time. However policymakers
should remain critical regarding the methodology
employed as the overall quality of the policy
context economic evaluations is disappointing.
This review focused on the methodology
employed by the studies but policymakers should
also consider whether the results are applicable
to their own setting.

Focussed on quality of the economic
evaluations
Not included in Table 1
Sponsorship not stated

Jonsson et al 2003

1995
Swedish
Krona

The CV-related health care cost per patient
during 3.8 years of follow-up was SEK32, 000
and SEK35,000 for the target groups 90 and 80
DBP, respectively.

Not relevant.
Cost-effectiveness study of cost per
reductions in BP
Some quality considerations including:- no
discussion of compliance issues
Sponsorship from Astra Zeneca

Lamotte et al 2006

2003
Euros

In patients at low risk of CHD and low risk of
gastrointestinal bleed, low-dose aspirin is costeffective.
For patients with an annual risk of CHD of 1.5%,
the model resulted in 10-year savings with lowdose aspirin of on average €201, 281, 797, and
427 per patient in UK, Germany, Spain and Italy
respectively.

Not relevant
Aspirin not relevant to the guidelines
Compared to placebo
Sponsorship from Bayer

Lundkuist et al 2005

2001 Euros

Candesavtan-based antihypertensive treatment
was associated with 0.0289 additional QALY per
patient and an incremental cost per QALY gained
of approximately €13,000.

Not relevant
Compared to placebo
Sponsorship not stated

Marshall 2006

1996
British
Pounds

Cost per cardiovascular event prevented is
strongly determined by cardiovascular risk. For
any treatment it is over £45 000 in an individual at
<10%, 10-year CVD risk and under £30 000 for
any treatment in a patient at over 45%, 10-year
CVD risk.

Not relevant
Cost-effectiveness evaluation per change in
risk category.
Some quality considerations including:-the
costs of coronary events is not included
in the comparisons of health states, age
not specified, short 10-year time horizon,
comparator is do nothing.
Sponsorship not stated

Montgomery et al
2003

2002
British
Pounds

In terms of cost-effectiveness, treatment was
more effective, but also cost more than nontreatment for all age, sex, and risk strata except
the oldest high-risk men and women. Incremental
cost per QALY among low-risk groups ranged
from £1030 to £3304. Cost-effectiveness results
for low-risk individuals were sensitive to the utility
of receiving antihypertensive treatment. Treatment
of high-risk individuals was highly cost effective,
such that it was the dominant strategy in the
oldest age group, and resulted in incremental
costs per QALY ranging from £34 to £265 in
younger age groups.

Relevant study
Some quality considerations including:
differential discount rates applied to
costs and benefits, no adverse events
were included, the treatment intervention
was not described in detail, only strokes
and myocardial infarctions considered,
Framingham equations applied without
calibration to the population under study
Sponsored by UK Medical Research Council
Training fellowship and UK NHS Primary
Career Scientist Award
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Study
Murray et al 2003

Base
year/
Cost-effectiveness results
currency
2000
International
dollars using
purchasing
power parity
exchange
rates

Combination treatment for people whose risk of
a cardiovascular event over the next 10 years is
above 35% is cost effective leading to substantial
additional health benefits by averting an additional
63 million DALYs per year worldwide.
The absolute-risk approach at a threshold of
35% is always more cost effective than treatment
based on either the measured systolic BP or the
measured cholesterol concentration.

Relevance/quality/comments

Relevant study
Some quality considerations including:
Comparator was no intervention, no cost
offsets were included for cardiac events
prevented
Sponsorship not stated

From the perspective of how best to achieve the
best population health for the available resources,
the optimum overall strategy is a combination
of the population-wide and individual-based
interventions.
Newman et al 2008

2003/04
US$

Under baseline assumptions, combination
polypharmacy was less expensive and more
effective than the current standard, namely,
no treatment. Thus, the use of combination
polypharmacy was a dominant strategy

Relevant study
Some quality considerations including: limited
to males ≥55 years, the analytic time horizon
and perspective not stated
Sponsorship not stated

Neyt et al 2009

2007
Euros

The results showed that smoking cessation is an
intervention that should be encouraged. Lowdose aspirin was more cost-effective ranging
from €3.854/LYG to €29.509/LYG compared to
smoking cessation for smokers and ranging from
€401/LYG to €13.451/LYG compared to notreatment for non-smokers. The results for statin
treatment are less cost effective. Only for the
high risk group aged 60, the cost-effectiveness
was about €30,000/LYG under the assumption
that the cheapest alternative statin would be
prescribed. For other subgroups the ICER for
statin treatment was about €50,000/LYG

Limited relevance
Some quality considerations including: limited
to males, aged 50 and 60, the analytic
time horizon was only 10 years, differential
discounting applied to costs and benefits,
the comparator interventions are less relevant
than current practice

The cost-effectiveness ratios are unattractively
high: US$200,000 per QALY gained for the
echocardiography strategy (compared with ECG),
and US$700,000 for the ‘ACE inhibitor for all’
strategy (compared with ECG). The incremental
cost effectiveness of prescribing ACE inhibitor
therapy to everybody was never less than
US$100,000/QALY in the sensitivity analysis.

Relevant study

For 45-year-old men who do not smoke, are not
hypertensive and have a 10-year risk for CHD of
7.5%, aspirin was more effective and less costly
than no treatment. The addition of a statin to
aspirin therapy produced an incremental costutility ratio of US$56,200 per quality-adjusted
life-year gained compared with aspirin alone. The
addition of a statin is more cost-effective as risk
increases.

Relevant study

Aspirin use cost US$13,300 per additional QALY
gained in the base case. Results were sensitive
to age, CVD risk, relative risk reductions with
aspirin for ischaemic strokes and MI, excess
risk of haemorrhagic stroke and gastrointestinal
bleeding, and the disutility of taking medication.
Probabilistic sensitivity analysis for 65-year-old
women at moderate CVD risk found a 27%
chance that aspirin produces fewer QALYs than
no treatment, a 35% chance that the cost-utility
ratio was less than US$50,000 per QALY gained,
and a 37% probability that it was greater than
US$50,000 per QALY gained.

Not relevant

Nordmann et al 2003 1999
US$

Pignone et al 2006

Pignone et al 2007

2003
US$

2005
US$

Sponsorship stated as ‘no external funding’

Some quality considerations including:
40-year-old males only.
Sponsorship not stated

Some quality considerations including: limited
analysis of 45 year old males, the comparator
is
aspirin and no therapy
Sponsorship from Bayer

Aspirin not relevant to the guidelines
Sponsorship from Bayer
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Base
year/
Cost-effectiveness results
currency

Relevance/quality/comments

Pilote et al 2005

1996
Canadian$

Among the surveyed individuals with a TC
level higher than 6.2mmol/L the proportions of
individuals for which lipid-lowering therapy was
cost-effective (at a threshold level of CA$50,000/
year of life saved) were 85.6% of men and 28.7%
of women for primary prevention.

Limited relevance.
Average cost effectiveness only. Not a costutility study.
Sponsorship provided by a grant from the
Fonds de la Recherché en Santé de Quebec.

Pletcher et al 2009

2006
US$

Full adherence to ATP III primary prevention
guidelines would require starting (9.7 million)
or intensifying (1.4 million) statin therapy for
11.1 million adults and would prevent 20 000
myocardial infarctions and 10 000 CHD deaths
per year at an annual net cost of US$3.6 billion
(US$42 000/QALY) if low-intensity statins cost
US$2.11 per pill. The ATP III guidelines would be
preferred over alternative strategies if society is
willing to pay US$50,000/QALY and statins cost
US$1.54 to US$2.21 per pill. At higher statin
costs, ATP III is not cost-effective; at lower costs,
more liberal statin-prescribing strategies would be
preferred; and at costs less than US$0.10 per pill,
treating all persons with low-density lipoprotein
cholesterol levels greater than 3.4 mmol/L (130
mg/dL) would yield net cost savings.

Relevant study

Within the time horizon of the trial (5 years),
the cost effectiveness of atorvastatin was
US$137,276 per QALY. At 10 years, the
incremental cost per QALY improved to US$
3,640 per QALY. At 25 years, the overall costs
were lower and QALYs higher in the atorvastatin
arm. Costs of managing CV events were
lower after five years for patients treated with
atorvastatin. For patients with type 2 diabetes
and one additional risk factor for CV disease,
normal LDL-cholesterol and no history of a
CV event, primary prevention with atorvastatin
appears to be cost saving and improve outcomes
over 25 years although it is costly from a shortterm US-payer perspective.

Relevant study

Study

Ramsey et al 2008

2005
US$

Some quality considerations including: Study
included unrelated health care costs. Shorter
than lifetime horizon analysed
Sponsorship from Flight Attendants Medical
Research Institute and Swanson Family Fund

Some quality considerations including: Cost
of adverse events not included
No statement on compliance
Sponsored by Pfizer

Schwander et al
2009

2007
Euros

Comparing eprosartan to enalapril in a primary
prevention setting the mean costs per quality
adjusted life year (QALY) gained were highest
in Germany (€24,036) followed by Belgium
(€17,863), the UK (€16,364), Norway (€ 13,834),
Sweden (€ 11,691) and Spain (€ 7,918).

Relevant study
Some quality considerations including: no
adverse events included, utility weights
applied may not be appropriate, Framingham
equations applied without calibration to the
population under study, effectiveness data
taken from one small trial (n=59)
Sponsored by Solvay Pharmaceuticals

Ward et al 2007

2004
British
Pounds

The cost-effectiveness of statins depends on
the CHD risk in the population treated and
the age and gender of the population under
consideration. In primary prevention the
discounted cost per QALY estimates for primary
prevention at the age of 45 range between
£9,500 and £30,500 for men and women as
annual CHD risk levels fall from 3% to 0.5%. By
the age of 85 years the corresponding values are
£36,800 and £110,600

Relevant study
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High-quality study except for differential
discount rates applied to costs and benefits
National Institute for Health Research HTA
Programme sponsored

Appendix 4: Assessment and Management summary

Risk Assessment and Management Algorithm: Adults aged 45 years and over
without known history of CVD
Already known to be at increased risk?
Adults with any of the following conditions do not require absolute CVD risk
assessment using the Framingham Risk Equation because they are already
known to be at clinically determined high risk of CVD: (EBR: Grade D)
• Diabetes and age >60 years
• Diabetes with microalbuminuria (>20 mcg/min or urinary
albumin:creatinine ratio >2.5 mg/mmol for males, >3.5 mg/mmol 		
for females)
• Moderate or severe CKD (persistent proteinuria or estimated
glomerular filtration rate (eGFR) <45 mL/min/1.73 m2)
• A previous diagnosis of familial hypercholesterolaemia
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure
≥110 mmHg
• Serum total cholesterol >7.5 mmol/L

NO

Conduct formal absolute
risk assessment

Calculate risk level using Framingham Risk
Equation (EBR: Grade B):
• Australian cardiovascular risk charts
• Web calculator (www.cvdcheck.org.au)
• Enter age 74 for adults aged 74+ (CBR)

YES

High: greater than 15%
risk of CVD within the next
5 years (includes clinically
determined high risk) (PP)

• Provide frequent and
sustained lifestyle advice,
support and 		
follow-up (CBR)
• Commence BP + lipidlowering therapy unless
contraindicated or 		
clinically inappropriate
(EBR: Grade B)

Moderate: 10-15% risk of CVD within the next
5 years (PP)
Provide lifestyle advice and support (CBR)
Is one of the following present?
• BP persistently ≥160/100 mmHg
• Family history of premature CVD
• South Asian, Middle Eastern, Maori or Pacific
Islander peoples

YES
• Identify all other risk
factors
• Continue with lifestyle
intervention (CBR)
• Treat for BP and/or
lipid lowering (CBR)

Monitor response (PP)

Provide lifestyle advice (CBR)

Is BP persistently ≥160/100 mmHg?

YES

NO
Monitor and review
risk at 3-6 months
(CBR)
Has risk improved?

YES

Monitor individual risk factor
response to treatment (PP)

Low: less than 10% risk of CVD
within the next 5 years (PP)

NO

• Treat BP
(CBR)
• Continue		
with 			
lifestyle 		
advice (CBR)

NO

Consider
Continue
with lifestyle treating for BP
intervention
and/or lipid
(CBR)
lowering (CBR)

Monitor
response
(PP)

Monitor
response (PP)

Review absolute risk
according to clinical
context (PP)

Review absolute risk in
6-12 months (PP)

Review absolute risk in
6-12 months (PP)

Review absolute risk in
2 years (PP)

EBR: Evidence-based recommendation (Graded A-D) CBR: Consensus-based recommendation PP: Practice point
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Risk Assessment and Management Algorithm:

Aboriginal and Torres Straight Islander adults aged 35 and over without known
history of CVD
Already known to be at increased risk?
Adults with any of the following conditions do not require absolute CVD risk
assessment using the Framingham Risk Equation because they are already
known to be at clinically determined high risk of CVD: (EBR: Grade D)
• Diabetes and age >60 years
• Diabetes with microalbuminuria (>20 mcg/min or urinary
albumin:creatinine ratio >2.5 mg/mmol for males, >3.5 mg/			
mmol for females)
• Moderate or severe CKD (persistent proteinuria or estimated
glomerular filtration rate (eGFR) <45 mL/min/1.73 m2)
• A previous diagnosis of familial hypercholesterolaemia
• Systolic blood pressure ≥180 mmHg or diastolic blood pressure
≥110 mmHg
• Serum total cholesterol >7.5 mmol/L

NO

Conduct formal absolute
risk assessment

• Aboriginal and Torres Strait Islander adults aged over 74 (CBR)
Calculate risk level using Framingham
Risk Equation (EBR: Grade B):
• Australian cardiovascular risk charts
• Web calculator www.cvdcheck.org.au

YES

High: greater than 15%
risk of CVD within the next
5 years (includes clinically
determined high risk) (PP)

Moderate: 10-15% risk of CVD within the next 5
years (PP)

Provide lifestyle advice (CBR)
Provide lifestyle advice and support (CBR)

• Provide frequent and
sustained lifestyle advice,
support and follow-up (CBR)
• Commence BP + lipid
lowering therapy
unless contraindicated or
clinically inappropriate 		
(EBR: Grade B)

Monitor individual risk factor
response to treatment (PP)

Review absolute risk
according to clinical
context (PP)

Low: less than 10% risk of CVD
within the next 5 years (PP)

• Identify all other risk factors
• Continue with lifestyle intervention (CBR)
• Treat for BP and/or lipid-lowering (CBR)

Monitor individual risk
factor response to treatment
(PP)

Review absolute risk in
6-12 months (PP)

Is BP persistently ≥160/100mmHg?

YES

• Treat BP
(CBR)
• Continue		
with lifestyle 		
advice (CBR)

Monitor
response
(PP)

Review absolute risk in
2 years (PP)

EBR: Evidence-based recommendation (Graded A-D), CBR: Consensus-based recommendation, PP: Practice Point
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NO

Risk Management Summary - High Risk

CVD risk

High risk
Clinically
determined
Diabetes and age
>60 years
Diabetes with
microalbuminuria
(>20 mcg/min or
UACR >2.5 mg/
mmol for males,
>3.5 mg/mmol for
females)
Moderate or
severe CKD
(persistent
proteinuria or
eGFR <45 mL/
min/1.73 m2)
A previous
diagnosis of FH
SBP ≥180 mmHg
or DPB ≥110
mmHg
Serum TC >7.5
mmol/L
A&TSI adults aged
>74 years
or calculated
using FRE as
>15% AR of CVD
events over 5
years

Lifestyle
Frequent and
sustained specific
advice and
support regarding
diet and physical
activity.
Appropriate
advice,
support and
pharmacotherapy
for smoking
cessation.
Advice given
simultaneously
with blood
pressure and
lipid lowering
pharmacotherapy

Pharmacotherapy
BP
lowering

Lipid
lowering

Treat
simultaneously
with lipid
lowering unless
contraindicated
or clinically
inappropriate.

Treat
simultaneously
with BP
lowering unless
contraindicated
or clinically
inappropriate.

Consider other
treatable causes
for raised BP
before starting
therapy.

Consider other
treatable causes
for dyslipidaemia
before starting
therapy.

Commence with
ACE inhibitor
OR angiotensin
receptor blocker
OR CCB OR Low
dose thiazide
or thiazide-like
diuretic.

Commence with
a statin.

For diabetes or
CKD commence
with ACE inhibitor
or angiotensin
receptor blocker.
Add second or
third agent from
different class as
needed towards
target.
Consider
withdrawal of
therapy for
people who make
profound lifestyle
changes.

Add ezetimibe,
bile acid
binding resin or
nicotinic acid
if LDL-C levels
not sufficiently
reduced or
required dose
of statin not
tolerated. Use
these agents as
monotherapy
if statins not
tolerated at all.
Add fenofibrate,
nicotinic acid or
fish oil to statin
if TG levels
not sufficiently
reduced.
Consider
withdrawal of
therapy for
people who
make profound
lifestyle
changes.

Antiplatelet
Not routinely
recommended

Targets

Monitoring

BP and lipids
monitored
at approx 6
weekly intervals
until sufficient
improvement
≤130/80 mmHg achieved or
maximum tolerated
in all people
dose reached.
with diabetes;
BP: ≤140/90
mmHg in
general or
people with
CKD;

≤130/80
mmHg if micro
or macro
albuminuria
(UACR > 2.5
mg/mmol in
men and >3.5
mg/mmol in
women

Adjust medication
as required.
Review of AR
according to
clinical context.

Lipids: TC <4.0
mmol/L; HDL-C
≥ 1.0 mmol/L;
LDL-C <2.0
mmol/L;
Non HDL-C
<2.5 mmol/L;
TG < 2.0
mmol/L
Lifestyle:
Smoking
cessation
(if smoker);
consume
diet rich in
vegetables and
fruit, low in salt
and saturated
and trans fats;
at least 30
mins moderate
intensity
physical activity
on most or
preferably
every day of
the week; limit
alcohol intake.

105

Risk Management Summary - Moderate Risk

CVD risk

Lifestyle

Moderate
risk

Appropriate,
specific advice
and support
regarding diet and
physical activity.

Calculated using
FRE as 10–15%
Appropriate
AR of CVD
advice,
events over 5
support and
years
pharmacotherapy
for smoking
cessation.

Lifestyle
advice given in
preference to
pharmacotherapy.

Pharmacotherapy
BP
lowering

Antiplatelet

Not routinely
recommended
Consider BP
lowering if 3–6
months of lifestyle
does not reduce
risk.

Not routinely
Not routinely
recommended
recommended
Consider lipid
lowering if 3–6
months of
lifestyle does not
reduce risk.

Consider BPlowering therapy
in addition to
lifestyle advice if:
• BP persistently
≥160/100 mmHg
• Family history
of premature CVD
• Specific
population
where the FRE
underestimates
risk e.g. A&TSI
peoples, South
Asian, Maori and
Pacific Islander,
Middle Eastern.

Consider lipidlowering therapy
in addition to
lifestyle advice if:
• Family history
of premature
CVD
• Specific
population
where the FRE
underestimates
risk e.g. A&TSI
peoples, South
Asian, Maori and
Pacific Islander,
Middle Eastern.

Consider other
treatable causes
for raised BP
before starting
therapy.
Commence any
agent as for high
risk. Add second
or third agent
from different
class as needed
to reach target.
Consider
withdrawal of
therapy for
people who make
profound lifestyle
changes.
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Lipid
lowering

Consider other
treatable causes
for dyslipidaemia
before starting
therapy.
Commence
statin as for high
risk.
Consider
additional
treatment as
for high risk if
indicated.
Consider
withdrawal of
therapy for
people who
make profound
lifestyle
changes.

Targets

Monitoring

BP and lipids
monitored
at approx 6
weekly intervals
until sufficient
improvement
≤130/80 mmHg achieved or
maximum tolerated
in all people
dose reached.
with diabetes;
BP: ≤140/90
mmHg in
general or
people with
CKD;

≤130/80
mmHg if micro
or macro
albuminuria
(UACR > 2.5
mg/mmol in
men and >3.5
mg/mmol in
women
Lipids: TC <4.0
mmol/L; HDL-C
≥1.0 mmol/L;
LDL-C <2.0
mmol/L;
Non HDL-C
<2.5 mmol/L;
TG <2.0
mmol/L
Lifestyle:
Smoking
cessation
(if smoker);
consume
diet rich in
vegetables and
fruit, low in salt
and saturated
and trans fats;
at least 30
mins moderate
intensity
physical activity
on most or
preferably
every day of
the week; limit
alcohol intake.

Adjust medication
as required.
Review of AR every
6-12 months

Risk Management Summary - Low Risk

CVD risk

Lifestyle

Low risk

Brief, general
lifestyle advice
regarding diet and
Calculated using physical activity.
FRE as <10%
AR of CVD
Appropriate
events over 5
advice,
years
support and
pharmacotherapy
for smoking
cessation

Pharmacotherapy
BP
lowering

Lipid
lowering

Not routinely
recommended.

Not routinely
recommended

Consider BPlowering therapy
in addition to
specific lifestyle
advice if BP
persistently
≥160/100 mmHg.
Consider other
treatable causes
for raised BP
before starting
therapy.
Commence any
agent as for high
risk. Add second
or third agent
from different
class as needed
to reach target.
Consider
withdrawal of
therapy for
people who make
profound lifestyle
changes.

Antiplatelet
Not routinely
recommended

Targets

Monitoring

BP monitored
at approx 6
weekly intervals
until sufficient
improvement
achieved or
≤130/80 mmHg maximum tolerated
dose reached.
in all people
with diabetes;
Adjust medication
as required.
≤130/80
BP: ≤140/90
mmHg in
general or
people with
CKD;

mmHg if micro
or macro
albuminuria
(UACR >2.5
mg/mmol in
men and >3.5
mg/mmol in
women

Review AR every 2
years.
Blood test results
within 5 years can
be used.

Lipids: TC <4.0
mmol/L; HDL-C
≥1.0 mmol/L;
LDL-C <2.0
mmol/L;
Non HDL-C
<2.5 mmol/L;
TG <2.0
mmol/L
Lifestyle:
Smoking
cessation
(if smoker);
consume
diet rich in
vegetables and
fruit, low in salt
and saturated
and trans fats;
at least 30
mins moderate
intensity
physical activity
on most or
preferably
every day of
the week; limit
alcohol intake.

A&TSI: Aboriginal and Torres Strait Islander peoples; BP: Blood Pressure; CKD: Chronic Kidney Disease; DBP: Diastolic Blood Pressure; FH: Familial
Hypercholesterolaemia; FRE: Framingham Risk Equation; HDL-C: High Desity Lipoprotein Cholesterol; LDL-C: Low Density Lipoprotein Cholesterol;
SBP: Systolic Blood Pressure; TC: Total Cholesterol; TG: Triglycerides.
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Appendix 5:

Recommendations for future research
The recommendations in these guidelines have been
developed from the current evidence base, using
methodology from NHMRC Levels of Evidence and
Grades for Recommendations for Developers of
Guidelines (2009) to appraise and evaluate the quality of
the evidence. However, these guidelines are based on an
AR approach rather than assessing individual risk factors.
Almost all of the research reviewed during the development
process selected study participants based on one or more
factors (but not on a formal comprehensive risk assessment
considering a number of factors together). This has meant
a larger number of practice points are provided compared
with previous guidelines which have used a single risk factor
approach. This difference in single verses AR highlights
major gaps in evidence for this approach. Hence a list of
future research priorities has been included here. Research
priorities should be based on consideration of the burden of
disease, the potential to conduct high quality research in the
area and the potential impact on health outcomes.

Assessment tools
• Validation of the FRE or other tools in populations
including the aged and adults aged 18- 30 years and
determination of the optimum age for risk assessment.
• Investigation of the extra predictive value of significant
risk factors that are not currently included in the FRE
such as obesity, physical inactivity, family history of CVD,
socioeconomic status and psychosocial factors.
• Comparison of the predictive value of emerging
biomarkers with current risk assessment tools.
• Development of a risk assessment equation for people
already on pharmacotherapy for blood pressure or lipid
lowering.

Absolute risk prediction in specific subpopulations
• Investigation of new or modified tools for absolute CVD
risk assessment based on risk equations specific to
the Australian population, especially the indigenous
population.
• Determination of the best predictive tool for people with
diabetes and/or CKD.

Treatment
• Clinical trials for pharmacotherapy to lower blood
pressure or lipids to be conducted and analysed using
AR selection criteria.
• Clinical trials of the value of including aspirin for
management of CVD risk using an AR approach in
combination with blood pressure and/or lipid lowering
therapy.
• New combination therapies such as various versions of
the Polypill to be investigated for effect on population AR
reduction.
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• Studies of lifestyle measures to be conducted with more
methodological rigour, such as statistically significant
sample sizes, exclusion of people with CVD at baseline,
and appropriate time for follow-up.

Cost effectiveness of absolute risk
• Detailed local study of the cost effectiveness of various
AR assessment tools compared to current practice to
determine whether AR improves outcomes and reduces
health care costs;
• Study of the cost effectiveness of various health system
models for identification and management of chronic
diseases.

Patient adherence
• High quality study comparing different interventions for
improvement of patient adherence to medication.
• Communication of risk information to consumers
• Development of an effective method for communication
to consumers of AR status and the potential impact of
management strategies.
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Glossary and abbreviations
Glossary of terms
Abdominal obesity
Excess body fat predominantly around the waist.
Absolute risk (global risk, total risk)

Body mass index (BMI)
A calculated number used to identify and measure
underweight, overweight or obesity, calculated from a
person’s height and weight. BMI = weight (in kg) divided by
height (in m) squared.

The numerical probability of an event occurring
within a specified period, usually expressed as a
percentage. (e.g. 5-year AR of 15% means there is a
15% probability that the individual will experience a
cardiovascular event within five years).

Cardiovascular disease (CVD)

Absolute risk reduction

Cardiovascular events

The arithmetic difference between event rates
in two groups (e.g. the rates of CVD in a lipidlowering treatment group subtracted from the rate
in the untreated group). For any given relative risk
reduction, the AR reduction decreases when event
rates are low in the given population.

Group of outcomes which may vary between trials but
normally includes myocardial infarction, stroke, death from
a vascular cause (including coronary, pulmonary embolism,
haemorrhage) or any arterial revascularisation procedure.

Albuminuria
The presence of excessive amounts of a protein called
albumin in the urine.
Anti-platelet agents
Medicines that reduce the risk of abnormal blood clotting
(e.g. aspirin, clopidogrel).
Atrial fibrillation (AF)
Rapid, irregular beating of the heart which can mean that
the heart is not pumping efficiently.
Blood pressure (BP)
The pressure of the blood against the inner walls of the
arteries as it is pumped around the body by the heart.
Blood pressure varies from moment to moment and is
affected by factors such as body position, breathing,
emotional state, physical activity and sleep.
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Group term for all medical conditions affecting the heart
or blood vessels (e.g. coronary heart disease, stroke,
peripheral arterial disease, some types of kidney disease).

Cholesterol
See lipids.
Chronic heart failure (CHF)
A condition in which the heart does not pump blood
effectively, typically resulting in breathlessness and
fatigue.
Chronic kidney disease (CKD)
Long-term inability of the kidney/s to function normally,
most commonly caused by diabetes, inflammation of the
kidneys or high blood pressure.
Cochrane review
A comprehensive systematic review and meta-analysis
(where possible).
Cohort studies
A type of medical research in which a selected group of
people is studied over time, often over a period of several
years.

Coronary heart disease (CHD)

Non HDL-C

A disease in which arteries that surround the heart and
supply blood to the heart muscle become partly blocked.

The cholesterol in low density lipoprotein, intermediate
density lipoprotein and very low density lipoprotein.

Diabetes mellitus (diabetes)

Numbers needed to treat (NNT)

A long-term disease that affects the way body cells take
up and use glucose (sugar) from the blood, resulting in
abnormally high levels of glucose in the blood.
Dyslipidaemia
An abnormal amount of lipids (e.g. cholesterol or
triglycerides) in the blood, usually abnormally high levels.
Family history of CVD
A family history of premature cardiovascular disease refers
to an event that occurs in relatives including parents,
grandparents, uncles and/or aunts before the age of 55
years.
Familial hypercholesterolaemia
An inherited condition in which removal of cholesterol from
the blood is reduced, causing high blood cholesterol levels
and early heart disease in some families.

Average number of patients who need to be treated to
prevent one additional bad outcome. The number is the
inverse of the absolute risk reduction.
Peripheral arterial disease (PAD)
Disease affecting the arteries other than those of the
heart or brain.
Proteinuria
The presence of excessive amounts of protein
(>150 mg per day) in the urine. These proteins are
typically albumin, but also consist of low molecular
weight immunoglobulin, lysozyme, insulin and beta-2
microglobulin.
Relative risk (RR)

A statistical method of predicting an individual’s likelihood
of developing CVD within the next five or 10 years, based
on risk factors such as age, sex and blood pressure.

The ratio of the rate of events (e.g. CVD) in the
population exposed to a risk factor to the rate among
the unexposed population (e.g. the risk of someone
developing a CVD event who has a given set of risk
factors, compared with the risk in someone of the
same age and sex who does not have those risk
factors).

Hypertension

Relative risk reduction (RRR)

Framingham Risk Equation

Raised blood pressure.
Lipids
Fatty substances naturally occurring in the blood
(cholesterol and triglycerides).
Macroalbuminuria
A raised level of albumin in the urine (more than 300mg of
albumin in the urine per day).

The difference in event rates between two groups (e.g.
treatment group versus control group), expressed as
a proportion of the event rate in the untreated group.
Often remains constant whether event rates are high or
low within the population.
Renovascular disease
Cardiovascular disease affecting the blood vessels
supplying the kidney.

Microalbuminuria

Risk factor

A slightly raised level of albumin in the urine (between 30
mg and 300 mg per day).

A characteristic of a person (or people) that is positively
associated with a particular disease or condition.

Myocardial infarction (heart attack)

Stroke

Temporary loss of blood supply to the heart muscle,
typically caused by a blood clot that suddenly blocks a
narrowed artery. This can result in heart muscle damage.

Sudden loss of blood supply to the brain (e.g. due to
blockage of an artery by a blood clot, or because the artery
breaks or bursts).
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TC: HDL ratio

EWG: Expert working group

Total cholesterol divided by high density lipoprotein. Used in
the Framingham Risk Equation.

FRE: Framingham Risk Equation

Transient ischaemic attack (TIA)
Transient episode of neurologic dysfunction caused by
loss of blood flow. TIAs share the same underlying cause
as stroke and the same symptoms but symptoms resolve
within a few minutes or less than 24 hours.
Triglycerides
See Lipids.

GFR: Glomerular filtration rate
GP: General practitioner
HDL: High-density lipoprotein cholesterol (also HDL-C)
HMG-CoA: 3-hydroxy-3-methylglutaryl-coenzyme A (statin)
ICER: Incremental cost-effectiveness ratio
LDL: Low-density lipoprotein cholesterol (also LDL-C)
LVH: Left ventricular hypertrophy

Abbreviations

MBS: Medicare Benefits Schedule
MI: Myocardial infarction

ACE: Angiotensin-converting enzyme

NHMRC: National Health and Medical Research Council

AF: Atrial fibrillation

NNT: Numbers needed to treat

APCC: Australian Primary Care Collaboratives

NVDPA: National Vascular Disease Prevention Alliance

AR: Absolute risk

OGTT: Oral Glucose Tolerance Test

ARB: Angiotensin receptor blocker

OR: Odds ratio

A&TSI: Aboriginal and Torres Strait Islander Peoples

PBAC: Pharmaceutical Benefits Advisory Committee

AUC: Area Under the ROC curve

PBS: Pharmaceutical Benefits Scheme

BP: Blood pressure

QALY: Quality adjusted life year

BMI: Body mass index

RACGP: Royal Australian College of General Practitioners

CAD: Coronary artery disease

RCT: Randomised controlled trial

CCB: Calcium channel blocker

RR: Relative risk

CHD: Coronary heart disease

RRR: Relative risk reduction

CKD: Chronic kidney disease

SBP: Systolic blood pressure

CI: Confidence interval

SCORE: Systematic Coronary Risk Evaluation project

CVD: Cardiovascular disease

SR: Systematic review

DALY: Disability adjusted life years

TC: Total cholesterol

DBP: Diastolic blood pressure

TG: Triglyceride

DoHA: Department of Health and Ageing

TIA: Transient ischaemic attack

ECG: Electrocardiography

UACR: Urinary albumin:creatinine ratio

EGFR: Estimated glomerular filtration rate

UKPDS: United Kingdom Prospective Diabetes Study
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